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Chapter 1:
General introducti on
Guus AMS van Dongen
Maria JWD Vosjan
Adapted from:
Cancer Biotherapy and Radiopharmeuti cals. (2010) 25:375-85
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1.	 Monoclonal	antibodies	and	antibody	imaging:	Immuno-PET
1.1	 Characteristics	of	monoclonal	antibodies
One hundred years ago, Paul Ehrlich, the founder of chemotherapy, received the Nobel 
Prize for Physiology or Medicine1,2. His postulate of creating ‘magic bullets’ for use in 
the fight against human diseases inspired generations of scientists to develop powerful 
molecular cancer therapeutics. Magic bullets being drugs that go straight to their disease-
specific targets and not being harmful to healthy tissues. Researchers who followed in 
his footsteps indeed succeeded to identify specific receptors on the surface of tumor 
cells. One key achievement in realizing Ehrlich’s vision was the development of the 
hybridoma technology for the production of monoclonal antibodies (mAbs) by Georges 
Köhler and César Milstein3. With this technology an unlimited range of murine mAbs can 
be obtained against any particular cellular antigen. During their initial use in the 1980s, 
therapeutic successes with murine mAbs were limited due to their immunogenicity and 
their restricted ability to induce immune effector mechanisms4,5. This prompted the 
development of chimeric and humanized antibodies that use a plethora of mechanisms 
to attack cancer cells, such as antibody-dependent cellular toxicity (ADCC), complement-
dependent cytotoxicity (CDC), blockade of signal transduction, induction of apoptosis, 
and immunomodulation. Besides intact mAb molecules (molecular weight ~150 kDa), 
also mAb fragments and variants were engineered like F(ab’)
2
, F(ab’), Fab, single chain 
Fv (scFv), and the covalent dimers scFv
2
, diabodies and minibodies (molecular weights 
ranging from 25-100 kDa), as well as several types of protein therapeutics based on 
nontraditional scaffolds such as domain antibodies6, Affibodies7, Nanobodies8, and 
Anticalins9. 
Presently, 30 mAbs, have been approved by the U.S. Food and Drug Administration 
(FDA) for therapy, most of them for systemic treatment of cancer10-13. The yearly sales of 
mAbs have been estimated at $20 billion in 200614,15. Moreover, despite the economic 
downturn the  mAb market has grown till $48 billion in 201016. The top 5 mAbs had sales 
over $5 billion each in 2010. The clinical phase for FDA approved anticancer mAbs took 
on average 90.8 months10. Over 200 new mAb candidates for treatment of cancer and 
immunological diseases are under clinical development by biotech and pharmaceutical 
firms worldwide, and also here most of them are full-size humanized and human IgG 
antibodies rather than antibody fragments or antibody-like scaffolds17. 
Despite these commercial successes, it is fair to state that the efficacy of current 
mAbs is still quite limited, with benefit for just a portion of patients, while approval of new 
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mAbs directed against novel targets is stagnati ng. Moreover, the costs of mAb therapy are 
excessive, and this issue has become subject of nati onal discussions regarding the rights 
of cancer care18,19. The questi on is how to improve the effi  ciency of mAb development and 
the effi  cacy of mAb-based therapy and how to identi fy pati ents with the highest chance 
of benefi t. In other words: when, how and for whom should anti body-based therapy be 
reserved? Stakeholders in this arena are physicians (who want to have pati ents treated 
in an opti mal way), pharmaceuti cal companies (who want to have rapid and cheap 
drug development, and applicati on of mAbs in appropriate pati ent groups), insurance 
companies and health care authoriti es (who want to have opti mal effi  cacy of medicines, 
at minimum price) and fi rst of all pati ents groups (who want to have highest probability 
for cure, at minimum morbidity). To answer these questi ons, bett er insight in the in vivo 
behavior of therapeuti c mAbs and their interacti on with criti cal disease targets in individual 
pati ents should be obtained. For this, Positron Emission Tomography (PET) imaging with 
radiolabeled mAbs (immuno-PET) is parti cularly att racti ve and bett er qualifi ed than Single 
Photon Emission Computerized Tomography (SPECT) imaging, because it enables sensiti ve 
non-invasive whole body imaging of mAbs at superior spati al and temporal resoluti on20.  
Figure	1.	Number of approved mAbs for cancer treatment by the FDA. The fi rst approved mAb was rituximab. Up to now 12 
mAbs have been approved for cancer treatment.
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1.2	 Monoclonal	antibodies	and	their	targets
While intact mAbs typically achieve optimal tumor-to-non-tumor ratios 2-4 days after 
injection, for the smaller fragments this is mostly 1-6 hours after injection. Currently, 
twelve mAbs have been approved by the US Food and Drug Administration (FDA) for 
cancer therapy, all being intact mAbs (Table 1 and Figure 1). Seven of the mAbs have 
been approved for treatment of hematological malignancies: rituximab, gemtuzumab 
ozogamicin, alemtuzumab, ibritumomab tiuxetan, tositumomab, ofatumumab and 
brentuximab vedotin. Five mAbs have been approved for therapy of solid tumors: 
trastuzumab is used for treatment of metastatic breast cancer; cetuximab, bevacizumab 
and panitumumab have been approved for treatment of metastatic colorectal cancer; 
while cetuximab and bevacizumab have also been approved for the treatment of head 
and neck cancer and non-small cell lung cancer, respectively. Finally, ipilimumab was most 
recently approved for treatment of advanced melanoma. These “solid tumor mAbs” are 
most effective when combined with chemo- or radiotherapy. They interfere with signal 
transduction pathways by targeting growth factors or their receptors, the key drivers of 
Table	1. Approved mAbs for cancer treatment
FDA 
Approved 
Generic name 
(trade name) 
Target Type Indication 
1997 Rituximab 
(Rituxan) 
CD20 Chimeric IgG1 Non-Hodgkin’s 
lymphoma 
1998 Trastuzumab 
(Herceptin) 
HER2/neu Humanized IgG1 Breast cancer 
2000 Gemtuzumab ozogamicin (Myelotarg) 
a 
CD33 Humanized IgG4 
conjugated 
to calicheamicin 
Acute myeloid leukemia 
2001 Alemtuzumab 
(Campath-1H) 
CD52 Humanized IgG1 Chronic lymphatic leukemia 
2002 90Y-Ibritumomab tiuxetan (Zevalin) a CD20 90Y-radiolabeled murine 
IgG1 
Non-Hodgkin’s lymphoma 
2003 131I-Tositumomab 
(Bexxar) a 
CD20 131I-radiolabeled murine 
IgG2a 
Non-Hodgkin’s lymphoma 
2004 
2006 
Bevacizumab 
(Avastin) 
VEGF Humanized IgG1 Colorectal cancer 
Non-small cell lung cancer 
2004 
2006 
Cetuximab 
(Erbitux) 
EGFR Chimeric IgG1 Colorectal cancer 
Head and neck cancer 
2006 Panitumomab 
(Vectibix) 
EGFR Human IgG1 Colorectal cancer 
2009 Ofatumumab 
(Arzerra) 
CD20 Human IgG1 Chronic lymphocytic leukemia 
2011 Ipilimumab 
(Yervoy) 
CTLA-4 Human IgG1 Melanoma 
2011 Brentuximab vedotin 
(Adcetris)a 
CD30 Chimeric IgG1,  
conjugated to MMAE drug 
Anaplastic large cell 
lymphoma, Hodgkin 
lymphoma 
 
aConjugated antibodies. 
Abbreviations: FDA, U.S. Food and Drug Administration; CD, cluster of differentiation; HER2/neu, human epidermal 
growth factor receptor 2; VEGF, vascular endothelial growth factor, EGFR, epidermal growth factor receptor; CTLA, 
Cytotoxic T-Lymphocyte Antigen; MMAE, monomethyl auristatin E.
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tumor growth and survival. In additi on, most of the naked therapeuti c mAbs can also act 
by other eff ector mechanisms like ADCC, CDC, or inducti on of apoptosis. To enhance its 
therapeuti c potency, gemtuzumab has been armed with the supertoxic drug ozogamicin, 
brentuximab with monomethyl auristati n E (MMAE), while ibritumomab ti uxetan 
(Zevalin™) and tositumomab (Bexxar™) are radiolabeled mAbs containing the β--emitt ers 
ytt rium-90 (90Y) and iodine-131 (131I), respecti vely. Due to a ‘cross-fi re’ eff ect, radionuclides 
are especially att racti ve as warheads to be used in radioimmunotherapy (RIT), since in 
order to be eff ecti ve not all tumor cells have to be targeted by radiolabeled mAbs. Next to 
aforementi oned mAbs, one naked mAb (Nimotuzumab) and one radioimmunoconjugate 
(131I-ch-TNT) have been approved in China11. Clinical successes with aforementi oned 
therapeuti c mAbs have boosted research and development on new mAbs directed against 
validated and novel targets enormously21. 
In 2007 Reichert and Valge-Archer11 reported on 206 unique therapeuti c mAbs in 
clinical trials during the ti me period 1980 to 2005 by commercial companies worldwide for 
a variety of cancer indicati ons. The 206 anti -cancer mAbs were specifi c for 76 targets. Of 
these 76, 43 were targets for only one mAb. Remarkably, 91 mAbs were specifi c for only 10 
targets, and for most of these targets approved mAbs have become available in the mean 
ti me. Targets of highest interest included: epithelial cell adhesion molecule (EpCAM) (17 
mAbs), epidermal growth factor receptor (EGFR) (12 mAbs), mucin-1 (MUC1/CanAg) (10 
mAbs), cluster of diff erenti ati on 20 (CD20) (10 mAbs), carcino-embryonic anti gen (CEA) 
and human epithelial receptor 2 (HER2) (9 mAbs each), and CD22, CD33, Lewis Y and 
prostate-specifi c membrane anti gen (PSMA) (6 mAbs each). Taking into account the large 
number of mAbs directed against novel as well as validated targets under development, 
this raises the questi on about how to select the best mAbs in an effi  cient way.
1.3	 Anti	body	imaging	in	a	therapeuti	c	setti		ng
Two diff erent approaches of immuno-PET imaging are followed to guide therapy with 
mAbs, being mostly slow kineti c intact mAbs designed to give durable blockade of growth 
factors or their receptors (see secti on 1.2). In a fi rst approach, fast kineti c anti body-based 
PET probes are used for same-day imaging at low radiati on burden for pati ents, to confi rm 
target expression, as recently described by Wu et al22,23. This approach is potenti ally 
helpful for diagnosti c purposes and as a scouti ng procedure for the selecti on of pati ents 
for therapy with intact mAbs. In a second approach, the therapeuti c intact mAbs are 
radiolabeled themselves and imaged in a pretherapy scouti ng setti  ng or early during the 
course of therapy to get a bett er insight in the in vivo behavior and effi  cacy of the mAbs 
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in individual patients.
For the first approach mAb fragments or small mAb-like molecules can be used. 
Since for immuno-PET the physical half-life (t
½
) of the radionuclide should be matched to 
the biological half-life of the protein to which it is being conjugated, for this application 
gallium-68 (68Ga,  t
½ 
= 1.13 h), fluorine-18 (18F, t
½ 
= 1.83 h), copper-64 (64Cu, t
½ 
= 12.7 h), 
niobium-90 (90Nb, t
½
 = 14.6 h), yttrium-86 (86Y, t
½ 
= 14.7 h) and bromine-76 (76Br, t
½ 
= 16.2 
h) are the positron emitters of choice. The short-lived positron emitter 68Ga is of particular 
clinical interest, because it can be obtained from a commercially available long life-span 
68Ge/68Ga generator (t
½
 = 271 d), making it continuously available even for centers without 
a cyclotron, and at reasonable costs. Procedures for coupling these positron emitters to 
mAbs and preclinical results with short-lived positron emitters coupled to mAb fragments 
have been extensively examined20,22-29. Although excellent imaging results have been 
obtained with antibody-based PET probes in tumor-bearing mice, caution is needed when 
aiming the translation of these results to clinical applications. While mAb reactivity with 
human tumors is considered to be similar for xenografted nude mice and cancer patients, 
cross-reactivity with normal organs can be totally different. This was demonstrated in 
PET imaging studies with anti-EGFR mAbs in nude mice bearing EGFR (HER1)-positive 
human cancer xenografts. Most mAbs, cetuximab and panitumumab included, only bind 
to human EGFR and not to murine EGFR, and therefore showed predominantly high and 
selective tumor uptake30-32. However, Tolmachev et al33, evaluated an 8 kDa Affibody 
recognizing human as well as murine EGFR, and observed a relatively high liver uptake 
and low tumor uptake. Liver uptake was particularly high at low Affibody dose and could 
be explained by the abundant EGFR expression in this organ, which is consistent with 
abundant EGFR expression in human livers. Indeed, initial clinical imaging studies with 
111In-labeled anti-EGFR mAb 225 also showed high liver uptake, while for imaging of 
EGFR expression in tumors relatively high mAb doses were required34. Also recent clinical 
immuno-PET studies with 89Zr-trastuzumab demonstrated that a relatively high mAb dose 
of at least 50 mg is required to allow reliable HER2 imaging in breast cancer patients. 
At low mAb dosis rapid hepatic clearance of the probe was observed, most probably 
due to high levels of shed extracellular domain (ECD) of HER2 in the plasma (Figure 2)35. 
Aforementioned data indicate that tumor imaging with a low dose of fast kinetic mAb 
fragment or intact mAb will be difficult if not impossible, when there is a high level of 
target antigen present in well accessible normal organs (mAb sink). 
In the second approach, therapeutic intact mAbs are radiolabeled with long-lived 
positron emitters like zirconium-89 (89Zr, t
½ 
= 78.4 h) or iodine-124 (124I, t
½ 
= 100.3 h) and 
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imaged prior or during the course of mAb therapy. For the latt er purpose, a small part of 
the therapeuti c dose of intact mAb can be radiolabeled, while cold and radiolabeled mAb 
can be administered simultaneously or immediately aft er each other. With this approach, 
the relati on between targeti ng effi  ciency and therapeuti c response can be studied.
We foresee that quanti tati ve PET imaging of therapeuti c intact mAbs can be of 
value at several stages of mAb development and applicati on. Preclinical immuno-PET 
studies in xenograft  bearing nude mice can learn about the effi  ciency of tumor targeti ng 
with a parti cular mAb and about regulati on of target expression, while immuno-PET 
studies in non-human primates can be parti cularly att racti ve to assess cross-reacti vity 
with normal ti ssues in relati on to toxicity. From fi rst-in-human clinical trials with new 
mAbs it is important to learn about the ideal mAb dosing for opti mal tumor targeti ng 
(e.g. saturati on of receptors), the uptake in criti cal normal organs to anti cipate toxicity, 
and the interpati ent variati ons in pharmacokineti cs and tumor targeti ng. mAb imaging 
might provide this informati on in an effi  cient and safe way, with fewer pati ents treated at 
subopti mal dose. This approach is especially att racti ve when a novel type of anti body-like 
scaff old is evaluated or when the mAb of interest is directed against a novel tumor target 
that has not been validated in clinical trials before. As will be illustrated in a later secti on, 
quanti tati ve mAb imaging might also be of value to guide opti mal use of FDA approved 
mAbs, also when used in combinati on therapy. 
1.4	 Quality	aspects	of	clinical	immuno-PET
To translate immuno-PET from preclinical investi gati ons to a phase I clinical trial, it 
is necessary to create a pharmaceuti cal quality formulati on, manufactured under 
current good manufacturing practi ce (cGMP). In most cases the radionuclides used for 
radiolabeling are to be considered as acti ve pharmaceuti cal ingredients (APIs), especially 
when the fi nal preparati on is released for use without further purifi cati on. Also chelates 
used for binding of radionuclides are to be considered as APIs. Quality aspects that must 
be documented for radionuclides and radiopharmaceuti cals are: identi fi cati on (e.g., half-
life, gamma emission spectrum); (radio)chemical purity; stability data; storage conditi ons; 
expiry; batch identi fi cati on, and impurity profi le. During the last years procedures have 
been developed for the producti on of large batches of highly pure 89Zr and 124I in a cGMP 
compliant way, and both positron emitt ers are nowadays commercially available36-38.
 While 89Zr is coupled via a chelate to the lysine residues of a mAb, 124I can be 
coupled directly via tyrosine residues. With respect to the latt er, procedures have been 
established for effi  cient coupling of carrier-added 124I 38, while many preclinical proof 
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 Aforementi oned achievements indicate that almost all reagents and procedures 
are in place to allow broad scale clinical applicati on of immuno-PET with 89Zr- and 
124I-labeled slow kineti c mAbs. However, improvement might be achieved when a more 
effi  cient and rapid method of coupling of 89Zr to proteins would be developed.
 While 89Zr is parti cularly suitable for PET imaging of internalizing mAbs, 124I is the 
radionuclide of choice in combinati on with non-internalizing mAbs. In contrast to directly 
labeled 124I, 89Zr is trapped inside the cell aft er internalizati on of the mAb (residualizati on) 
Figure	2.	Dose-dependent biodistributi on and blood clearance of 89Zr-trastuzumab with 10 mg trastuzumab (A), 50 mg 
trastuzumab (B), or 10 mg trastuzumab (C) during trastuzumab therapy. Blood pool acti vity and intesti nal excreti on are 
indicated by arrows. (from Dijkers EC, et al,35).
of concept 124I-immuno-PET studies have been performed as described in some recent 
reviews20,23. For stable coupling of 89Zr to mAbs, a multi step procedure has been developed 
by Verel et al. using a succinylated derivati ve of desferrioxamine B (N-sucDf) as bifuncti onal 
chelate36. The choice of desferrioxamine B is att racti ve because it is used clinically in a 
safe way for many years. In the mean ti me, several preclinical immuno-PET studies have 
been performed with 89Zr-N-sucDf-mAb conjugates as prelude to clinical trials, e.g. with 
cmAb U3636, DN30 (anti -c-Met)39, G250 (anti -carbonic anhydrase IX)40,41, cetuximab30,32, 
ibritumomab ti uxetan42, rituximab43, bevacizumab44, and trastuzumab45. A shortcoming of 
the N-sucDf-based labeling procedure, however, is that it is relati vely ti me consuming and 
complicated, and therefore challenging with respect to cGMP compliancy. 
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30,46. Residualizati on also occurs to some extent in organs of mAb catabolism like liver, 
kidney and spleen. For mAb fragments 68Ga can be the radionuclide of choice, since the 
half-life of the mAb fragments matches with the half life of this positron emitt er. 68Ga is 
also a residualizing PET isotope and might be coupled to a mAb fragment in the same way 
as 89Zr.
Quality analyses to be performed aft er radiolabeling include tests to assess 
the chelate-to-mAb substi tuti on rati o, radiochemical purity, mAb integrity and 
immunoreacti vity, and apyrogenicity. When labeled according to aforementi oned 
procedures, 124I-mAbs can also be used as PET surrogates for scouti ng the biodistributi on 
of therapeuti c 131I-mAb conjugates, while 89Zr-mAbs can be used for scouti ng therapeuti c 
90Y- and 177Lu-mAb conjugates30,38,42,46-48. 
1.5	 Potenti	al	of	89Zr-trastuzumab	PET:	an	example
In current practi ce, pathological analyses are oft en performed to confi rm target 
expression and to select pati ents for mAb therapy. For example, pati ents with metastati c 
breast cancer are only eligible for therapy with the anti -HER2 mAb trastuzumab, when 
protein overexpression and gene amplifi cati on has been confi rmed on a biopsy of the 
tumor by immunohistochemistry or fl uorescence in situ hybridizati on (in 20-30% of 
pati ents). It is questi onable, however, whether a representati ve overview of in vivo HER2 
expression status can be obtained by analysis of just one single biopsy. It is possible that 
HER2 expression in primary tumor and metastati c lesions is heterogeneous, or does not 
remain stable during the course of the disease for example upon chemo- and/or hormonal 
therapy49-52.
Taking multi ple or repeated biopsies is not a soluti on, especially because lesions 
are oft en heterogeneous (resulti ng in non-representati ve biopsies) and diffi  cult to access. 
It is of note that HER2 has also a functi onal role in normal ti ssues like the heart. This is 
probably the explanati on for the cardiotoxicity induced by trastuzumab, especially when 
combined with anthracyclines. Interesti ngly, shortly aft er completi on of anthracycline 
treatment, myocardial HER2 over-expression has been demonstrated in 50% of the 
pati ents53. Therefore, it seems worthwhile to evaluate the value of trastuzumab imaging 
for predicti on of cardiotoxicity, especially when next generati on anti -HER2 therapeuti cs 
like trastuzumab-DM1 (trastuzumab coupled to the supertoxic drug mertansine) are 
considered for therapy53-55. Cross-reacti vity of such supertoxic conjugates with normal 
ti ssues might result in unacceptable toxicity, as was recently demonstrated for the anti -
CD44v6 conjugate bivatuzumab-DM156.
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Anti body imaging might have added value for pati ent selecti on, because it can be 
used to assess target expression and mAb accumulati on in all tumor lesions and normal 
ti ssues, non-invasively, quanti tati vely, and even over ti me (4D). This informati on might 
be parti cularly relevant when mAb therapy is combined with other treatment modaliti es 
like chemo- and radiotherapy, to fi nd routes to maximum synergism. Ideally, topographic 
informati on on tumor extension is obtained to enable assessment of homogeneity of mAb 
tumor accumulati on.
Preclinical proof of concept studies have been performed using 89Zr-trastuzumab 
as the PET imaging probe. 89Zr-trastuzumab immuno-PET appeared capable of visualizati on 
of HER2-positi ve xenograft s, primary tumors as well as small metastati c lesions, while 
HER2-negati ve lesions present in the same animals were not detected (Figure 3)45.  Using 
the same 89Zr-trastuzumab probe, downregulati on of HER2 expression was visualized and 
quanti fi ed upon treatment of tumors with HSP90 inhibitors57,58. Since also EGFR and VEGF 
expression are downregulated by these HSP90 inhibitors, similar results can be obtained 
by imaging with radiolabeled cetuximab or bevacizumab59,60. These studies showed that 
immuno-PET probes like 89Zr-trastuzumab have the potenti al to be used to measure the 
effi  cacy of treatment with HSP90 inhibitors, and that due to the longer half life of 89Zr this 
probe is bett er qualifi ed for HER2 expression imaging than previously described 68Ga- and 
64Cu-trastuzumab probes57,61-63.
Figure	3. Examples of noninvasive small-animal PET images (dorsal presentati on). 89Zr-trastuzumab uptake in human SKOV-3 
xenograft s in 3 mice at 6 h (A), day 1 (B), and day 6 (C, metastasized tumor) aft er injecti on is shown. Primary tumors are 
indicated by arrows (from Dijkers EC, et al45).
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1.6	 Experience	with	clinical	immuno-PET
124I-labeled mAbs already have been used for clinical immuno-PET years ago, but the 
number of pati ents included in these studies was small64,65. Diagnosti c results were far 
from opti mal, among others because of the poor quality of the murine mAbs used, which 
were lacking the specifi city of nowadays mAbs66. Currently, interest in 124I-labeled mAbs has 
been renewed, partly due to the improved methods for producti on of 124I and its coupling 
to mAbs. Two clinical applicati ons att racted att enti on. Jayson et al.67 used various doses of 
124I-HuMV833, a mAb binding to VEGF
121
 and VEGF
165
, to perform PET-imaging studies in 12 
pati ents with various progressive solid tumors. Anti body distributi on and clearance were 
markedly heterogeneous between and within pati ents and between and within individual 
Figure	4. Immuno-PET images with 89Zr-cmAb U36 of head and neck cancer pati ent with a tumor on the right side of the soft  
palate and a lymph node metastasis at the left  side of the neck (level III). Images were obtained 72 hours post injecti on. A, 
coronal image of primary tumor; B, coronal image of lymph node metastasis in the neck; C, sagitt al image of primary tumor; 
D, sagitt al image of lymph node metastasis in the neck (from Börjesson PKE, et al.70).
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tumors. These differences may represent the variation in available targets for the mAb, 
which could have implications for anti-VEGF therapy. In the mean time similar studies 
have been started using 89Zr-bevacizumab as the imaging probe44,60.
In the other clinical application 124I-immuno-PET was used for in vivo profiling of 
renal cancer. Divgi et al.68 used 124I-cmAb G250 to predict the presence of clear cell renal 
carcinomas in 25 patients scheduled for surgical tumor resection. G250 is directed against 
carbonic anhydrase-IX, which is over-expressed in clear-cell renal carcinoma. It might be 
informative to know whom of the renal cancer patients have this aggressive tumor type 
because of treatment decisions, although opinions on this point deviate69. 15 of 16 clear-
cell carcinomas were identified accurately by immuno-PET, and all nine non-clear-cell renal 
masses were negative for the tracer. This study illustrates how molecular imaging with 
specific probes can contribute to personalized medicine. Also here, 89Zr-G250 conjugates 
are under development as alternative immuno-PET probes40,41.
Since the introduction of 89Zr-immuno-PET technology, several clinical trials have 
been started, for example using 89Zr-labeled trastuzumab, bevacizumab, cetuximab, 
rituximab or ibritumumab tiuxetan as the PET probe, and a few have been reported in 
literature. A first-in-human 89Zr-immuno-PET trial has been conducted with 89Zr-cmAb 
U36, to see whether this imaging probe is safe and capable for imaging of CD44v6-positive 
tumors70,71. The aim was to determine the diagnostic value of immuno-PET with 89Zr-cmAb 
U36 in patients with head and neck squamous cell carcinoma (HNSCC), who were at high 
risk of having neck lymph node metastases. Twenty HNSCC patients, scheduled to undergo 
resection of the primary tumor and uni- or bilateral neck dissection, underwent CT and/or 
MRI and 89Zr-cmAb U36 immuno-PET prior to surgery. Immuno-PET detected all primary 
tumors (n = 17) as well as lymph node metastases in 18 of 25 positive neck levels. Missed 
lymph nodes were relatively small and contained just a small proportion of tumor tissue. 
Representative images are shown by Figure 4. It was concluded that immuno-PET with 
89Zr-cmAb U36 performs at least as good for detection of HNSCC lymph node metastases 
(and probably distant metastases) as CT/MRI, and that use of PET-CT might further support 
image interpretation.   
In these studies also radiation dose estimates were made, while the potential for 
89Zr-cmAb U36 quantification was assessed72.  PET quantification of blood-activity in the 
left ventricle of the heart showed good agreement with sampled blood activity (difference 
equals 0.2% ± 16.9%), except for heavy weight patients (> 100 kg). A good agreement 
was also found for assessment of mAb uptake in primary tumors (mean deviation: 
-8.4% ± 34.5%), indicating the potential of 89Zr-immuno-PET for accurate non-invasive 
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quanti fi cati on of mAb biodistributi on. The mean radiati on doses for pati ents receiving 74 
MBq 89Zr in this study was about 40 mSv, which is high and will limit repeated applicati on 
of 89Zr-immuno-PET. However, the introducti on of the new-generati on PET/CT scanners 
will allow bett er-quality immuno-PET images to be obtained with a lower 89Zr acti vity dose. 
Indeed, recent PET/CT studies in which 37 MBq of 89Zr-trastuzumab were used, showed 
excellent quality images at an eff ecti ve dose of about 20 mSv35.
Figure	5. Examples of 89Zr-trastuzumab uptake 5 days p.i. in a pati ent with liver and bone metastases (A) and two pati ents 
with multi ple bone metastases (B+C). A number of lesions have been specifi cally indicated by the arrows (from Dijkers EC, 
et al.35). 
The Groningen group determined the best conditi ons for PET imaging of HER2 
expression with 89Zr-trastuzumab35. For this purpose HER2-positi ve metastati c breast 
cancer pati ents received 37 MBq 89Zr-trastuzumab at three trastuzumab protein doses, 10 
or 50 mg or 100 mg while pati ents were on trastuzumab treatment. Fourteen pati ents were 
included. Several conclusions were drawn from these studies: at least 50 mg trastuzumab 
is needed to allow reliable visualizati on of mAb uptake in HER2-positi ve lesions; the best 
moment to assess 89Zr-trastuzumab tumor uptake is 4-5 days post-injecti on; PET images 
showed a high spati al resoluti on, and a good signal-to-noise rati o, which resulted in an 
image quality unapproachable by previous 111In-trastuzumab SPECT scans73. Excellent 
tumor uptake and visualizati on of metastati c liver, lung, bone and even brain HER2-
positi ve lesions were obtained (Figure 5). 89Zr-trastuzumab PET allowed quanti fi cati on of 
conjugate uptake in HER2 positi ve lesions, and it became clear that for some pati ents 
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Figure	6. Schemetic representation of conventional antibodies and heavy-chain only antibodies present in camelid serum.
2	 Nanobody,	next	generation	antibody	technology
2.1	 Improvement	of	antibody	therapy:	multi-specificity
All approved antibodies for cancer treatment are intact mAbs, and most of them are 
directed against a growth factor or growth factor receptor. As mentioned in section 1.1, 
notwithstanding several clinical successes the efficacy of current mAbs is quite limited. 
This conclusion comes with very recent insights that selective targeting of just one single 
tumor target might be insufficient for optimal efficacy. Cancer cells have the inherent 
ability to use several growth factor (receptor) systems for growth advantage and survival, 
which means that other receptor systems can take over the signaling and therefore tumors 
are still able to survive after blockade of just one growth factor (receptor) system. The 
potential of dual-specificity antibody therapy has already been demonstrated in several 
studies in which mAbs or tyrosine kinase inhibitors affecting different anti-cancer targets, 
with extensive tumor load no HER2 saturation occurred during trastuzumab therapy74. 
This latter observation indicates that some breast cancer patients might be underdosed 
with current trastuzumab therapy regimens, and it therefore could be considered to use 
HER2-PET for applying a more patient tailored trastuzumab dosing schedule.
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e.g., EGFR, HER2, IGF-IR or VEGF-R2 were combined 75-82. For example, Barnes et al.83 
demonstrated in a preclinical study that simultaneous administrati on of the human anti -
IGF-IR anti body IMC-A12 and cetuximab (anti -EGFR) showed signifi cant growth inhibiti on 
in head and neck cancer xenograft s, while single agent therapies only showed minimal 
reducti on. Moreover, in 2009 Tonra et al.84 showed that targeti ng VEGF-R2 and EGFR was 
prioriti zed over other treatment strategies uti lizing EGFR, IGF-1R and VEGF-R2 anti bodies 
in nude mice bearing diff erent xenograft s. Several clinical trials have been started aiming 
at the simultaneous inhibiti on of EGFR and VEGF-2R, using tyrosine kinase inhibitors or 
mAbs 85.
A disadvantage of using combinati ons of traditi onal intact mAbs for cancer 
therapy, however, is the high costs. Moreover, due to their large size (~150 kDa) tumor 
penetrati on of intact mAbs is not opti mal and therefore it is challenging to reach all tumor 
cells for eff ecti ve growth inhibiti on. Besides mixtures of mAbs, also single molecule mAb-
fragments that aff ect more than one target have been evaluated. Such mAb-formats 
would lead most easily to drug registrati on once anti -tumor acti vity has been proved. Lu 
et al.86 developed an IgG-like bispecifi c anti body (bi-diabody) directed against the EGFR as 
well as IGF-1R and demonstrated that inhibiti on of both receptors, either by a mixture of 
monospecifi c anti bodies or by the bispecifi c bi-diabody, resulted in broader and enhanced 
anti -tumor acti vity in tumor bearing mice. Although these results were fascinati ng, the 
questi on remained if bispecifi c versions of conventi onal mAbs are the most favorable 
format for dual-specifi city targeti ng. In the studies of Lu et al.86, in vivo instability was 
observed; while the producti on of the bi-diabody was rather complicated. In 2011, Dong 
and coworkers87 described another IgG-like bispecifi c anti body that targets EGFR as well as 
IGF-1R. Improvement was made in the stability, whereas PEGylati on was used to enhance 
the solubility and serum half-life. In vitro assays showed that this bispecifi c anti body 
improved inhibiti on of cell growth compared to the monospecifi c combinati on of mAbs. 
In animal studies in mice bearing diff erent tumor xenograft s, best tumor growth delays 
were seen in the group that received the bispecifi c mAb. 
In an analysis in Nature Reviews Drug Discovery in 2011, Holmes88 discussed the 
potency of bispecifi c anti bodies based on immunoglobulin G (IgG) and it was stated that 
the development of bispecifi c anti bodies is ‘hot’ at this moment. The clinical knowledge 
of monospecifi c mAbs has matured, and many pharmaceuti cal companies are keen on 
developing bispecifi c anti bodies that have the potenti al to simultaneously aff ect two 
targets. Some bispecifi c anti bodies are in phase II clinical trials like; MM-111, targeti ng 
HER2 and HER3; FBTA05, which targets CD20 and CD3; and blinatumomab which is used 
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for acute lymphoblastic leukemia. It uses a retargeting mode of action to bring CD3+ T cells 
into close contact with B cells that express CD19.
2.2	 Novel	antibody	formats
Nanobody technology might be better suited for blockade of growth factor (receptor) 
systems. Nanobodies are smaller than intact traditional IgG mAbs and can therefore better 
penetrate into a tumor. Besides this, Nanobody technology enables easy construction 
of so called “dual specific” or “multiple specific” Nanobodies (targeting more than one 
tumor target) in search for more effective cancer treatment. For preclinical and clinical 
evaluation of the targeting potential of such new antibody fragments immuno-PET can be 
of great help.
2.2.1	 Nanobodies	
Nanobodies are a novel class of antibody-based fragments which were initially discovered 
in 1993 in members of the Camelidae family (e.g., llama, camel and dromedary)89. Since 
these naturally occurring antibodies are devoid of light chains, the antigen-binding region 
is composed of only a single immuno globulin (Ig) fold, the VH, termed ‘VHH‘ (variable 
part of the heavy chain or heavy–chain antibodies). These Ig’s consists of two disulfide-
linked heavy chains, each composed of one variable domain (VHH or Nanobody) linked to 
two constant domains (CH2 and CH3) via a hinge region (Figure 6). Similar types of heavy 
chain only antibodies have also been found in nurse sharks and spotted ratfish90. 
The small molecular size of Nanobodies offers several advantages and some 
potential disadvantages in comparison to the larger conventional antibodies. Major 
advantages are high solubility, intrinsic stability, easy cloning, modular nature, binding 
to cavities and difficult-to-access antigens, and easy production in bacteria or yeast. 
A drawback can be the small size of a Nanobody (~15 kDa) which is below the renal 
threshold, causing rapid excretion via the kidneys. To elongate the half-life of a Nanobody 
an albumin-specific Nanobody unit can be fused to the existing Nanobody91,92. The 
elongated life time Nanobodies have a life time comparable to conventional IgGs and can 
be used as therapeutics. 
Nanobodies can easily be formatted into multiple-targeting molecules by fusing 
different Nanobody units within one molecule directed against different epitopes on 
the same growth factor or the same receptor (called; bi-paratopic Nanobodies) as such 
increasing the potency and enhancing therapeutic efficacy. Alternatively, Nanobody units 
can be combined within one molecule targeting different receptors or ligands (called; bi-
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specifi c Nanobodies). These latt er Nanobodies are able to block more than one receptor 
pathway, and therefore potenti ally improve therapeuti c eff ecti veness.  
2.3	 Receptor	tyrosine	kinases
Cell membrane receptors can be classifi ed into disti nct families based on the ligands they 
recognize, the biological responses they induce and, more recently, according to their 
primary structure93. One large family of cell surface receptors provides intrinsic protein 
tyrosine kinase acti vity. These receptor tyrosine kinases (RTKs) play an important role in 
the control of most fundamental cellular processes like the cell cycle, cell migrati on, cell 
metabolism and survival, as well as cell proliferati on and diff erenti ati on. In the following 
paragraphs the commonly upregulated, overexpressed and/or acti vated RTKs will be 
discussed in more detail. Moreover, their suitability for drug targeti ng in cancer therapy 
will be discussed.
Figure	7.	The MAPK and PI3K/AKT pathways are acti vated by various receptor kinases (EGFR, VEGF, c-Met, IGFR and 
others) by their cognate ligands (e.g., EGF, VEGF, HGF, and IGF) leading to proliferati on of tumor cells.
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2.3.1	 Epidermal	Growth	Factor	Receptor
The epidermal growth factor receptor (EGFR, also known as HER-1 or ErbB1) consists of 
four family members of related receptor tyrosine kinases (ErbB1-4; HER1-4)94. EGFR and 
its family members are implicated in the development and progression of different human 
cancers like head and neck, breast, lung, prostate, and colorectal cancer. When EGFR is 
overexpressed this frequently results in poor prognosis for patients.
Members of this receptor class have a common structural architecture (see 
Figure 7): an ecto-domain were different ligands can bind, a transmembrane region, 
and an intracellular domain containing the RTK, and the different tyrosine residues that 
are phosphorylated upon receptor activation95. The HER receptors can be stimulated 
by more than 20  different natural  ligands. EGF or TGFα bind to EGFR and induces 
receptor dimerization. This can either be homodimerization (two of the same receptors) 
or heterodimerization (two different receptors), which leads to kinase activation and 
downstream signaling, with ultimately cell proliferation. No ligand is known for HER2, 
whereas HER3 contains an inactive tyrosine kinase. So, for the functioning of these two 
receptors heterodimerization is essential. Finally, Heregulin, Neuregulin and Betacellulin 
are known ligands for HER4.
Upon tyrosine kinase activation, 1-10 different tyrosine residues in the cytoplasmatic 
intracellular domain become phosphorylated. These phosphorylated tyrosine residues 
form binding sites for different signaling molecules. The ligand identity, as well as the 
dimer partner determines which tyrosines are phosphorylated, and hence which proteins 
are recruited and which (tumor-promoting) processes are initiated (e.g. proliferation, 
migration, metastasis, angiogenesis etc). As these processes are the hallmarks of cancer, 
HER receptors are considered to be the tumor ‘Achilles heels’ in therapeutic approaches, 
with EGFR and HER2 being most broadly exploited as targets for blocking of dimerization.
Several approaches are currently being undertaken to inhibit HER-signaling: 1) 
blocking of ligand binding to EGFR by monoclonal antibodies; 2) blocking of EGFR and 
HER2 dimerization by monoclonal antibodies; 3) blocking kinase activation by small 
molecule drugs like tyrosine kinase inhibitors; and 4) modulation of EGFR expression, 
either by inhibition of EGFR synthesis by siRNA or by stimulation of EGFR degradation95. 
As mentioned in section 1.1 mAbs Erbitux® (cetuximab) and Vectibix® 
(panitumumab) directed against HER1, and Herceptin® (trastuzumab) against HER2 have 
been approved as cancer therapeutics. Also the tyrosine kinase inhibitors (TKIs) Iressa® 
(gefitinib), Tarceva® (erlotinib) have been approved for HER1-cancer therapy, whereas 
Tykerb® (lapatinib) and Caprelsa® (vandetanib) have been approved for both EGFR and 
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HER2 therapy. Furthermore, many new mAbs and TKIs are under development.
2.3.2	 Hepatocyte	Growth	Factor	and	c-Met	Receptor
Hepatocycte Growth Factor (HGF), also known as scatt er factor, is secreted as a single-chain, 
inacti ve polypepti de by mesenchymal cells, and is cleaved by serine proteases into a 69-
kDa α-chain and 34-kDa β-chain. HGF is the only known ligand for the c-Met receptor96-98. 
The c-Met receptor is expressed during embryogenesis and adulthood in epithelial 
cells of many organs like liver, prostate, pancreas, muscle, kidney, and bone marrow. 
In tumor cells, c-Met acti vati on triggers diverse series of signaling cascades resulti ng, 
like the HER receptor, in cell growth, proliferati on, invasion, metastasis formati on and 
escape from apoptosis98. Overexpression of HGF and c-Met is associated with increased 
aggressiveness of tumors and poor prognosti c outcome of cancer pati ents (www.vai.org/
vari/metandcancer and ref 99). HGF and c-Met expression have been observed in most 
solid tumors. Blocking HGF might be a more benefi cial strategy over blocking the c-Met 
receptor, as HGF is expected to be highly expressed in the tumor only 82. 
The last decades, several pharmaceuti cal companies have been acti vely involved in 
the development of therapeuti c mAbs and TKIs that antagonize c-Met acti vati on. At least 
16 agents have been or are being evaluated in the clinic at the moment, as reviewed by Liu 
et al.100.  To their and our knowledge, three anti -HGF mAbs are under clinical development 
at the moment, including AMG102 (rilotumumab), a humanized anti -human HGF IgG2 
mAb from Amgen, AV-299 from Schering/Aveo, and TAK-701 from Milennium.
Furthermore, the HGF/c-Met pathway has been found to have a relati onship 
with other important pathways, like EGFR, HER2, RON, CD44 and FAS100. Resistance to 
EGFR targeted therapy is e.g. known to include acti vati on of a parallel pathway like c-Met. 
c-Met amplifi cati on has shown to be responsible for acquired resistance to the EGFR-TKI 
gefi ti nib in non-small-cell lung cancer (NSCLC). Resistance there was mediated by c-Met-
ErbB3 transacti vati on, leading to restored signaling via the PI3K/AKT pathway 101. 
2.3.3	 Insulin-like	Growth	Factor	Receptor	type	1	(IGF-1R)
The receptor tyrosine kinases (RTK) from the insulin-like growth factor (IGF) signaling 
system also play a prominent role in tumor growth102. The IGF system consists of the 
ligands insulin, IGF-I and IGF-II, and the cell-surface receptors that mediate their biological 
eff ects. The latt er include the insulin receptor (IR), the IGF-I receptor (IGF-IR) and the IGF-
II receptor (IGF-IIR). The IGF receptors belong, like EGFR, to the family of receptor tyrosine 
kinases, and are present in the plasma membrane as heterotetramers containing two α 
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and two β-subunits. Ligand binding involves the simultaneous interaction of the ligand 
with both α-subunits and this cross-linking triggers receptor activation. Phosphorylation 
of the intracellular domain of the receptor results in molecular signaling leading to cell 
proliferation. Insulin is essential for glucose homeostasis, whereas both IGF ligands are 
involved in normal growth and development. 
Comparable to the EGFR system, overexpression of receptors from the IGF 
system has been frequently observed in different tumors. Therefore, this receptor class 
is considered to be a promising anti-cancer target for mAbs and small molecules. Similar 
to what has been performed for the ErbB family of receptors; antagonistic mAbs that 
inhibit both ligand binding and receptor activation have been generated against the IGF 
receptor system. Because of the shared signaling pathways (Figure 7), it can be expected 
that EGFR and IGF-1(R) signaling affect each other (“cross-talk”); (1) stimulation of the 
IGF system enhanced signaling of other growth factor systems such as EGF, (2) IGF caused 
resistance against growth inhibition and cell death induced by anti-EGFR mAb cetuximab, 
and (3) IGF-1R/EGFR heterodimerization counteracted the anti-tumor action of the TKI 
erlotinib. These data provide a strong rationale for combined EGFR and IGF-1(R) targeting 
and inhibition81.
2.3.4	 Vascular	Endothelial	Growth	Factor	(VEGF)
Angiogenesis is a process by which new blood vessels are formed from existing capillaries. 
The newly formed blood vessels supply the blood and oxygen that is essential for a solid 
tumor to grow beyond a certain size (1-2 mm3). The angiogenic process is induced by 
the activation of vascular endothelial cells through binding of vascular endothelial growth 
factors (VEGFs) to different cell surface receptors. These growth factors are produced by 
macrophages, but also by tumor cells themselves. 
There are seven VEGF members, among which VEGF-A plays a major role in tumor 
blood vessel formation103. The receptor family for the VEGFs comprises three tyrosine 
kinase receptors (VEGFR1-3) and two co-receptors (neuropilin-1 and 2) of which VEGF-R1 
and R2 are primarily involved in tumor angiogenesis103.
By now, many compounds with anti-angiogenic activity have been described, 
however, with exception of drugs targeting VEGF ligands or receptors, the vast majority 
have failed to confirm the encouraging preclinical results when tested in clinical trials104,105. 
Furthermore, the initial concept to radically ‘‘starve’’ the tumor by stripping the blood 
supply had to be modified as aggressive angiogenesis inhibition may aggravate tumor 
metabolism and promote metastatic spread.
29
1
2.4	 The	potenti	al	of	Nanobodies	for	dual-specifi	city	therapy
Up ti ll now, only two formats of single domain anti body fragments are known: domain 
anti bodies based on human VH
 
segments and the naturally occurring camelid VHH 
fragments, called Nanobodies (Figure 6). The domain anti bodies based on human VH 
segments have the disadvantage that geneti c engineering is needed to compensate for 
the absence of – and therefore loss of - contact to the VL domain. This part of VH segments 
naturally contains a hydrophobic interface, which needs to be mutated to ensure the 
stability of the single domain8,110. In contrast, Nanobodies are naturally occurring as single 
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Figure	8. Flexibility of the Nanobody technology toolbox for generati on of multi -valent and/or multi -specifi c single molecule 
formats. Theoreti cal design showing the size relati onship between Nanobodies and classical intact mAbs. It has to be as-
sessed how many “beads in the chain” can be exploited. For practi cal reasons, this will most probably be between 3 and 5 
units.
 Many of the mechanisms responsible for increased tumor growth related to 
EGF(R), c-Met, IGF-I(R), and VEGF(R) are disti nct. For this reason, simultaneous blockade 
of receptor systems would probably result in improved effi  cacy of tumor therapy. While 
several anti -VEGF-R2 mAbs are under development, anti bodies that bind (neutralize) the 
VEGF-R2 ligand (VEGF) also show tumor inhibitory eff ects (e.g. bevacizumab)106. High VEGF 
expression was found to be strongly correlated with high VEGF-R2 expression, and this 
co-expression was associated with higher tumor proliferati on and worse survival. These 
results suggest the existence of an autocrine VEGF-loop and provide a strong rati onale for 
anti -VEGF therapy. Also for the HER family and VEGF-R2, signaling cross-talk has become 
apparent (Figure 7): while EGFR induces the expression of VEGF, EGFR/HER2 hetero-dimers 
induce VEGF expression and promote angiogenesis even more potently107. Inhibiti on of 
EGFR with cetuximab was shown to result in anti -angiogenic eff ects like a decrease in 
VEGF synthesis108. Moreover, VEGF expression was elevated in anti -EGFR-resistant colon 
cancer109. Therefore, it seems logical to combine anti -EGFR and anti -VEGF therapy.
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domain structures and are therefore inherently more stable as monomer. More important, 
Nanobody technology allows for immunization of Camelidae with the antigen of interest 
and the subsequent cloning of the full repertoire of affinity matured Nanobody genes. For 
domain antibodies based on human VH gene segment, only (semi) synthetic “single pot” 
libraries can be made, usually leading to low affinity lead molecules, which subsequently 
need affinity maturation.
Due to the single domain character of Nanobody fragments, standard molecular 
biology techniques such as polymerase chain reaction (PCR) allow for the facile purification 
and selection of appropriate Nanobody candidates from the full antibody repertoire of 
immunized camelids. Unique features of the Nanobody platform compared to conventional 
mAb technology are: (1) easy and rapid drug development, (2) adjustable serum half life 
time, by using half-life extension technology; combining targeting Nanobodies with anti-
albumin Nanobody units (3) easy and cheap production in bacteria and yeast, and (4) 
high flexibility of drug format. The relatively small size of the gene (360-400 nt) permits 
Nanobody genes to be fused as separate building blocks into proteins as dimers (~35 kDa), 
trimers (~50 kDa) or multimers (Figure 8). Nanobody studies in cynomolgous monkeys 
point to low immunogenicity. Because of their small size they are well capable of tumor 
penetration. The aforementioned Nanobody technology seems very promising for 
development of next generation dual-specificity mAbs91,111. 
First clinical trials with Nanobodies were performed with Nanobody ALX-0081, 
against the von Willebrand factor (vWF). vWF acts at a very early stage in the blood 
clotting cascade by controlling the platelet adhesion and aggregation, and it represents a 
potential novel anti-thrombotic target in cardiovascular disease. In 2009, a phase II clinical 
trial with Nanobody ALX-0081 in high risk patients with Acute Coronary Syndrome (ACS) 
undergoing a percutaneous coronary intervention (PCI) was started. In this study ALX-
0081 is compared with ReoPro® (abciximab) as adjunctive therapy to a PCI procedure. 
Results of this study are expected soon. Before this clinical trial a study was performed to 
assess the in vitro efficacy of ALX-0081 in human blood112. In this study, nine patients who 
were scheduled for a PCI procedure and 11 healthy volunteers were included.  Blood was 
drawn 24 h before and 1 h after start of the PCI procedure, and was subsequently spiked 
with different concentrations of ALX-0081 or buffer. In all in vitro experiments, ALX-0081 
led to complete inhibition of platelet adhesion and aggregation.
Other Nanobodies are entering phase I clinical trials (e.g., anti-TNFα, anti-RANKL, 
anti-IL-6R, anti-CXCR4).
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3.	 Aim	and	outline	of	the	thesis
In this thesis, novel anti body technology to improve imaging and blockade of growth 
factors and their receptors in cancer is described. For this purpose, PET and Nanobody 
technology were explored using binding units directed against EGFR, HGF and serum 
albumin as an example. Next to these, also Nanobodies directed against IGF-1R, HER2 
and VEGF were developed within the framework of the STW-project and the collaborati on 
with Ablynx, but not evaluated during the course of this promoti on period.
For stable coupling of 89Zr to mAbs, a multi step procedure was developed by 
Verel et al. using a succinylated derivati ve of desferrioxamine B (N-sucDf) as bifuncti onal 
chelate. This multi step procedure is used in clinical setti  ngs in a safe way for many years; 
however, a more rapid and less laborious procedure is desirable. In chapter 2 the newly 
developed chelate p-isothiocyanotobenzyl-desferrioxamine is described. This novel 
chelate was developed to enable rapid coupling of the long-lived positron emitt er 89Zr 
to slow kineti c mAbs and anti body-like scaff olds, opening avenues towards accurate 
quanti tati ve assessment of biodistributi on and PET imaging of these molecules. In 
chapter 3 a convenient protocol is provided for conjugati on of 89Zr to slow kineti c mAbs 
or anti body-like scaff olds (like Nanobodies). In chapter 4 the newly developed desferal-
chelate was also investi gated for its suitability to couple the short-lived positron emitt er 
68Ga to fast kineti c Nanobodies. As an example the monovalent anti -EGFR Nanobody 
7D12 was used. Chapter 5 presents the results with a trivalent anti -EGFR-Nanobody in 
a preclinical therapy study using mice bearing EGFR-positi ve human xenograft s. In this 
study, the effi  cacy of the trivalent Nanobody 7D12-9G8-Alb1 was compared with the 
already registered mAb cetuximab. Nanobody 7D12-9G8-Alb1 is a biparatopic Nanobody 
targeti ng two diff erent epitopes on EGFR fused with an anti -albumin unit (Alb1) that 
causes half-life extension in blood. In chapter 6 we present the fi rst preclinical data with 
two bivalent anti -HGF-Nanobodies 1E2-Alb8 and 6E10-Alb8. To this end, biodistributi on 
studies using 89Zr-labeled anti -HGF-Nanobodies and therapy studies with anti -HGF-
Nanobodies were performed. The eff ecti veness of these Nanobodies in comparison to 
other mAbs under clinical development is discussed. In chapter 7, a general discussion of 
the results presented in this thesis is provided.
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Abstract
Purpose Immuno-PET is an emerging imaging tool for the selection of high potential 
antibodies (mAbs) for imaging and therapy. The positron emitter zirconium-89 (89Zr) has 
attractive characteristics for immuno-PET with intact mAbs. Previously, we have described 
a multi-step procedure for stable coupling of 89Zr to mAbs via the bifunctional chelate (BFC) 
tetrafluorophenol-N-succinyldesferal (TFP-N-sucDf). To enable widespread use of 89Zr-
immuno-PET, we now introduce the novel BFC p-isothiocyanatobenzyl-desferrioxamine B 
(Df-Bz-NCS) and compare its performance in 89Zr-immuno-PET with the reference BFC TFP-
N-sucDf. Methods Three mAbs were premodified with Df-Bz-NCS and labeled with 89Zr at 
different pHs to assess the reaction kinetics and robustness of the radiolabeling. Stability 
of both 89Zr-Df-Bz-NCS- and 89Zr-N-sucDf-conjugates was evaluated in different buffers 
and human serum. Comparative biodistribution and PET studies in tumor bearing mice 
were undertaken. Results The selected conjugation conditions resulted in a chelate:mAb 
substitution ratio of about 1.5:1. Under optimal radiolabelling conditions (pH between 
6.8–7.2), the radiochemical yield was >85% after 60 min incubation at room temperature, 
resulting in radioimmunoconjugates with preserved integrity and immunoreactivity. The 
new radioimmunoconjugate was very stable in serum for up to 7 days at 37°C, with <5% 
89Zr release, and was equally stable compared to the reference conjugate when stored in 
the appropriate buffer at 4°C. In biodistribution and imaging experiments the novel and 
the reference radioimmunoconjugates showed high and similar accumulation in tumours 
in nude mice. Conclusions The novel Df-Bz-NCS BFC allows efficient and easy preparation 
of optimally performing 89Zr-labelled mAbs, facilitating further exploration of 89Zr-immuno-
PET as an imaging tool.
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Introduction
Presently, hundreds of monoclonal antibodies (mAbs) and mAb fragments are under 
clinical development because of their excellent potential for diagnosis and systemic 
treatment of cancer and other pathological conditions [1]. Positron emission tomography 
(PET) offers an attractive imaging option to confirm and quantify selective tumor uptake 
of such targeting molecules [2-4].
To enable PET imaging of intact mAbs and mAb-fragments (immuno-PET), an 
appropriate positron emitter, with a half-life (t
1/2
) that is compatible with the time needed 
to achieve optimal tumor-to-nontumor ratios (typically 2-4 days for intact mAbs, and 2-4 
hours for mAb-fragments), has to be securely coupled to the targeting molecule. Among 
others, the following positron emitters for immuno-PET are under investigation at the 
moment: gallium-68 (68Ga; t
½
: 1.13 h), fluorine-18 (18F; t
½
: 1.83 h), copper-64 (64Cu; t
½
: 12.7 
h), yttrium-86 (86Y; t
½
: 14.7 h), bromine-76 (76Br; t
½
: 16.2 h), zirconium-89 (89Zr; t
½
: 78.4 
h), and iodine-124 (124I; t
½
: 100.3 h). Another important consideration in the choice of a 
positron emitter is whether the mAb or mAb fragment becomes internalized after binding 
to the target antigen. In that case, a positron emitter is needed that residualizes in the 
target cell after internalization, like 68Ga, 64Cu, 86Y, and 89Zr, to enable imaging at optimal 
contrast. These radionuclides have to be attached via chelating agents to mAbs and mAb-
fragments. 
For the imaging of intact mAbs with PET, we recently described the large scale 
production of 89Zr and a strategy for labeling mAbs with 89Zr via a multi-step synthesis 
using a succinylated-derivative of desferrioxamine B (N-sucDf ) as bifunctional chelate [5]. 
The utility of this approach was clearly demonstrated through high-quality 89Zr-mAb-PET 
images reported in preclinical and clinical studies [6-13]. The choice of desferrioxamine 
B is attractive because it is used clinically in a safe way for many years. The upcoming 
commercialization of 89Zr will make this radionuclide broadly available for research and 
clinical applications.A shortcoming of the aforementioned labeling approach is that 
the multi-step procedure is relatively complicated and time-consuming, and therefore 
challenging with respect to Good Manufacturing Practice (GMP) compliancy. We now 
introduce a newly developed p-isothiocyanatobenzyl-derivative of desferrioxamine B (Df-
Bz-NCS; Macrocyclics, TX) that enables an efficient and rapid preparation of 89Zr-labeled 
mAbs. 
 The chemical characterization of Df-Bz-NCS, its subsequent coupling to mAbs, 
and the radiolabeling of Df-Bz-NCS conjugated mAbs with 89Zr, are described. The in vitro 
stability of 89Zr-Df-Bz-NCS-mAb conjugates is compared with the corresponding 89Zr-N-
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sucDf-mAb conjugates. In addition, comparative biodistribution and animal-PET studies 
are presented.
Materials and methods
Materials, monoclonal antibodies, cell lines, and radioactivity
All reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. 
No special measures were taken regarding working under strict metal-free conditions. 
Deionized water (18 MΩ) was used in all reactions. Df-Bz-NCS was obtained from 
Macrocyclics (cat. no. B-705 world patent application WO 2008/124467 A1 for the 
synthetic details). MAb cetuximab (Erbitux; 2.0 mg/mL) directed against the epidermal 
growth factor receptor (EGFR) was purchased from Merck (Darmstadt, Germany) [14]. 
Selection, production, and characterization of chimeric mAb U36 (cU36; 11.53 mg/mL) 
directed against CD44v6 has been described elsewhere [15]. MAb rituximab (MabThera; 
10 mg/mL) directed against CD20 was purchased from Roche Nederland BV (Woerden, 
The Netherlands). 
The human epidermoid cervical carcinoma cell line A431 and the CD20+ B-cell 
lymphoma cell line Ramos were both obtained from the American Type Culture Collection 
(www.atcc.com, ATCC number: CRL-1555 and CRL-1596, respectively). The head and neck 
squamous cell carcinoma (HNSCC) cell line FaDu was obtained from Karl-Heinz Heider 
(Boehringer Ingelheim, Vienna, Austria)[16], and the HNSCC cell line UM-SCC-11B was 
obtained from Dr. T.E. Carey (Ann Arbor, MI)[17]. 
  89Zr (T
1/2
 = 78.4 h, β+ = 22.6%; ~2.7 GBq/mL in 1 M oxalic acid) was produced by BV 
Cyclotron VU (Amsterdam, The Netherlands) by a (p,n) reaction on natural yttrium-89 (89Y) 
and isolated with a hydroxamate column [5]. 
Characterization of p-Isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS)
Synthesis of the new ligand 1-(4-isothiocyanatophenyl)-3-[6,17-dihydroxy-7,10,18,21-
tetroxo-27-[N-acetylhydroxyamino)-6,11,17,22-tetraazaheptaeicosane)thiourea 
(p-isothiocyanato-benzyl desferrioxamine; Df-Bz-NCS) was performed by Macrocyclics 
(Dallas, TX). In short, Desferrioxamine B mesylate (Df; Desferal, Novartis, Basel) 
was dissolved in isopropanol/water while gently stirring. A chloroform solution of 
1,4-phenylendiisothiocyanate and triethyl amine was then added and the reaction 
progress was monitored by reverse phase HPLC. Upon completion, the reaction mixture 
was extracted with 0.1 M HCl. The lower organic layer was concentrated in vacuo to 
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remove the chloroform but not the isopropanol. The remaining organic solution was 
purified by reverse-phase preparative HPLC using a water/acetonitrile gradient [Detector: 
UV/VIS at 275 nm. Column: Phenomenex Luna C18(2) (250x50 mm, 10 μm). Sample prep: 
Direct injection of the isopropanol solution. Mobile phase: 0-10 min 40/60 A/B; 10–15 min 
ramp 40/60 to 90/10 A/B; 15-25 min 90/10 A/B; A = CH
3
CN, B = H
2
O. Flow rate = 100ml/
min. Retention time of product was ~10min. Desired fractions were placed at -20°C to 
precipitate the product. The final product was isolated by filtration as a white solid (41% 
yield).  
Figure 1. Schematic representation of mAb modification with the new bifunctional chelate Df-Bz-NCS (1) and subsequent 
labeling with 89Zr (2) (a). The multi-step reference procedure using desferrioxamine B as starting ligand (b).
Analytical data final product: 1H NMR (D
6
-DMSO): δ 1.21 (m, -CH
2
, 6H), 1.38 (m, -CH
2
, 4H), 
1.95 (s, -CH
3
, 3H), 2.27 (m, -CH
2
, 4H), 2.99 (m, CH
2
, 4H), 3.45 (m, CH
2
, 8H), 7.35 (d, 2,6-ArH, 
J = 8.9 Hz, 2H), 7.75 (d, 3,5=ArH, J=8.9 Hz, 2H), 7.75 (m, N-H, 2H), 7.88 (bs, N-H, 1H), 9.59 
(m, N-OH, 4H). 13C NMR: δ 19.18 (CH
3
), 22.34, 22.35, 22.44, 24.88, 24.90, 24.94, 24.96, 
24.98, 26.42, 26.88, 27.66, 28.78, 28.79, 28.83, 37.28, 37.92, 42.57, 42.60, 42.63, 45.67, 
45.97, 121.92, 123.50, 124.98, 131.58, 138.17 (N=C=S), 169.00 (C=O), 170.20 (C=O), 
170.84 (C=O), 179.02 (C=S). Elemental analysis calculated (%) for C
33
H
52
N
8
O
8
S
2
: C 52.64, 
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H 6.96, N 14.88, S 8.52, found C 52.43, H 7.08, N 14.81, S 8.59. m/z: (ESI+); 775 (100% 
[M + Na]+), (ESI-); 751 (100% [M-H]-). Chromatographic purity: > 98% Detector: UV/VIS at 
225 nm. Column: Restek Ultra IBD (100x4.6 mm, 3 μm, 100 A). Sample prep: a 1.0 mg/ml 
solution prepared in DMSO. Mobile phase: 0-10 min ramp 5/95 to 95/5 A/B; 10-15 min 
95/5 A/B; A = 0.1% TFA in CH
3
CN, B = 0.1% TFA in H
2
O.
Preparation of 89Zr-labeled Df-Bz-NCS-mAb
cU36, cetuximab, or rituximab were premodified with Df-Bz-NCS (Fig. 1a). In short, while 
gently shaking, a three-fold molar excess of Df-Bz-NCS (in 20 µL DMSO) was added to the 
mAb (2 – 10 mg in 1 mL 0.1 M NaHCO
3
 buffer, pH 9.0), and incubated for 30 min at 37°C. 
Nonconjugated chelate was removed by size exclusion chromatography using a PD10 
column (GE Healthcare Life Sciences) and 0.9% sodium chloride/gentisic acid 5 mg/ml (pH 
5.0) as eluent. Subsequently, Df-Bz-NCS-mAb was labeled with 89Zr at room temperature 
in a volume of 2 mL for 60 min; to 200 µl 89Zr (37-250 MBq) solution 90 µl 2 M Na
2
CO
3
 
were added, after 3 min 300 µl 0.5 M HEPES buffer (pH 7.0), 710 µl Df-Bz-NCS-mAb (1 - 
2 mg) and 700 µl 0.5 M HEPES (pH 7.0) were added. Other pH values were obtained by 
adjusting the HEPES buffer to chosen pH values. Finally, 89Zr-Df-Bz-NCS-mAb was purified 
by size exclusion chromatography (PD10 column) using 0.25 M sodium acetate/gentisic 
acid 5 mg/ml buffer (pH 5.5) or 0.9% sodium chloride/gentisic acid 5 mg/ml (pH 5.0) as 
the mobile phase.
Preparation of 89Zr-labeled N-sucDf-mAb
As reference to the new method for 89Zr labeling, Df was also coupled to mAbs via the multi-
step procedure as previously described by Verel et al. [5] (Figure 1b). In short, the chelate 
Df was succinylated (N-sucDf), temporarily filled with stable iron [Fe(III)], and coupled to 
the lysine residues of the mAb (cU36 or cetuximab) by means of a tetrafluorophenol-N-
sucDf ester. After removal of Fe(III) by transchelation to EDTA at 35°C, the premodified 
mAb was purified on a PD10 column. Approximately 1 N-sucDf moiety was coupled per 
mAb molecule. Subsequently, N-sucDf-mAb was labeled with 89Zr in 0.25 M HEPES buffer 
at pH 7.0; to 200 µl 89Zr (37-185 MBq) solution 90 µl 2 M Na
2
CO
3
 were added, after 3 min 
300 µl 0.5 M HEPES buffer (pH 7.0), 710 µl N-SucDf-mAb (1 - 2 mg) and 700 µl 0.5 M HEPES 
(pH 7.0) were added. Finally, 89Zr-N-sucDf-mAb was purified on a PD10 column using 0.9% 
sodium chloride/gentisic acid 5 mg/ml (pH 5.0) or 0.25 M sodium acetate/gentisic acid 5 
mg/ml buffer (pH 5.5) as the mobile phase.
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Analyses
After each preparation of 89Zr-labeled Df-Bz-NCS-mAb or N-sucDf-mAb, the conjugates 
were analyzed by instant thin-layer chromatography (ITLC) for radiolabeling efficiency and 
radiochemical purity, and by high performance liquid chromatography (HPLC) and sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by phosphor 
imager analyses for integrity, and by a cell-binding assay for immunoreactivity. 
 ITLC analyses of 89Zr-labelled N-sucDf-mAb or Df-Bz-NCS-mAb was performed on 
silica gel impregnated glass fiber sheets (Pall Corp., East Hills, NY). As the mobile phase, 
0.02 M citrate buffer (pH 5.0) was used. 
HPLC monitoring of the final products was performed on a Jasco HPLC system 
using a SuperdexTM 200 10/300 GL size exclusion column (GE Healthcare Life Sciences). As 
eluent, a mixture of 0.05 M sodium phosphate and 0.15 M sodium chloride (pH 6.8) was 
used
 
at a flow rate of 0.5 ml/min. Electrophoresis was performed on a Phastgel System 
(GE Healthcare Life Sciences) using preformed 7.5% SDS-PAGE gels under non-reducing 
conditions.
The immunoreactivity was determined by measuring binding of 89Zr-cU36, 89Zr-
cetuximab, or 89Zr-rituximab (10.000 cpm/ml) to a serial dilution of 0.2% glutaraldehyde-
fixed UM-SCC-11B cells or 2% paraformaldehyde-fixed A431, or Ramos cells, respectively, 
essentially as described by Lindmo et al. [18].
Determination of chelate-to-mAb ratio
The Df-Bz-NCS to mAb molar ratio was determined following a general method as described 
by Meares et al. [19]. In short, conjugates were labeled according to the aforementioned 
procedure with a known nanomolar excess of zirconium oxalate solution spiked with 89Zr.
 
In vitro stability
For assessment of the in vitro stability of 89Zr-Df-Bz-NCS-mAb in comparison with the 
reference conjugate 89Zr-N-sucDf-mAb, two sets of experiments were performed. In a first 
set, labeled mAbs were stored at 4°C (storage and transportation conditions) and room 
temperature in 0.9% NaCl/gentisic acid 5 mg/ml or 0.25 M sodium acetate/gentisic acid 
5 mg/ml. Final activity concentration was between 30 – 40 MBq/ml, specific activity was 
between 67 - 86 MBq/mg mAb. At various time points, aliquots were taken and analyzed 
by ITLC, SDS-PAGE and HPLC.
 In a second set, purified radiolabeled mAbs were added to freshly prepared human 
serum (1:4 v/v dilution; sodium azide added to 0.02%) at a final concentration of the 
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radiolabeled conjugates of ~1.3 nmol/ml and ~45 MBq/ml. The samples were incubated at 
37°C in a CO
2
-enriched atmosphere (5% CO
2
). At various time points, aliquots were taken 
and analyzed by ITLC, SDS-PAGE, and HPLC.
Evaluation of in vivo biodistribution
For assessment of biodistribution and the in vivo stability of the new 89Zr-Df-Bz-NCS-mAb 
conjugate in comparison with the established 89Zr-N-sucDf–mAb conjugate, two sets of 
experiments were performed with nude mice bearing subcutaneously implanted human 
xenografts of the HNSCC line FaDu or the vulvar tumor line A431 at two lateral sides. 
In one experiment, the moderately internalizing cU36 mAb was tested, in the other the 
extensively internalizing mAb cetuximab [20]. Female mice (HSD:Athymic Nude-Foxn1nu, 
21-31 g; Harlan) were 8 to 10 weeks old at the time of the experiments. All animal 
experiments were done according to NIH Principles of Laboratory Animal Care and Dutch 
national law (“Wet op de dierproeven”, Stb 1985, 336).
 In a first experiment, mice bearing FaDu xenografts (two groups of n=8) were 
injected intravenously (i.v.) with either 89Zr-Df-Bz-NCS-cU36 (0.38 ± 0.01 MBq) or the 
reference compound 89Zr-N-sucDf-cU36 (0.38 ± 0.01 MBq). Unlabeled mAb cU36 was 
added to the injection mixture to bring the total mAb dose to 100 µg per mouse. At 72 
and 144 h post injection, four mice of each group were anesthetized, bled, killed, and 
dissected. After blood, tumor, and normal tissues had been weighed, the amount of 
radioactivity in each sample was measured in a gamma counter. Radioactivity uptake was 
calculated as the percentage of the injected dose per gram of tissue (%ID/g).
In a second experiment, mice bearing A431 xenografts (two groups of n=16) were 
injected i.v. with either 89Zr-Df-Bz-NCS-cetuximab (0.24 ± 0.01 MBq) or the reference 
compound 89Zr-N-sucDf-cetuximab (0.24 ± 0.01 MBq). Unlabelled cetuximab was added 
to the injection mixture to bring the total mAb dose to 500 µg per mouse. At 24, 48, 72, 
and 120 h post injection, four mice of each group were anesthetized, bled, killed, and 
dissected, with further processing according to the above procedure.
PET study
PET imaging was performed on a double-crystal-layer HRRT PET scanner (Siemens/CTI), 
a dedicated small animal and human brain scanner, as described earlier [7,21]. FaDu 
xenograft-bearing nude mice (two groups of n=3) were anesthetized by inhalation of 2% 
isoflurane, injected with either 4.12 ± 0.04 MBq 89Zr-Df-Bz-NCS-cU36 (~200 µg mAb) or 
4.03 ± 0.09 MBq 89Zr-N-sucDf-cU36 (~200 µg mAb) via the retroorbital plexus, and scanned 
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at 72h post-injection. 
Transmission scans for attenuation and scatter correction were routinely 
obtained with each scan in two-dimensional mode using a single point 137Cs source. 
Three-dimensional emission scans were acquired in 64-bit list mode during 60 min using 
a 400-650 keV window. The 64-bit list mode file was first converted into a single-frame 
histogram using a span of 9, and subsequently reconstructed using a 3D ANW-OSEM 
reconstruction algorithm with 2 iterations and 16 subsets and a matrix size of 256x256, 
including corrections for normalization, decay and dead time. For visualization of the 
images, Amide’s A Medical Imaging Data Examiner (AMIDE) was used, freely available 
for download online [22]. Immediately after the PET scan the animals were killed, blood, 
tumors, major organs and tissues were collected, weighed, and counted in a gamma-
counter. 
Statistical analyses
Differences in tissue uptake between injected conjugates were statistically analyzed for 
each time point with SPSS 15.0 software using Student t-test for unpaired data. Two-sided 
significance levels were calculated and P <0.01 was considered statistically significant.
Results
Preparation of 89Zr-Df-Bz-NCS-mAb
89Zr-Df-Bz-NCS-mAb was prepared according to the chemical route as shown in Figure 1a. 
First, Df-Bz-NCS is coupled to the lysine groups of a mAb. Conjugation conditions selected 
for this step comprised the addition of a three-fold molar excess of Df-Bz-NCS to the mAb 
solution (13 - 66 nmol mAb), a reaction pH of 9.0, and incubation for 30 min at 37°C. 
These conditions resulted in a reproducible chelate:mAb substitution ratio of about 1.5:1, 
irrespective cU36, cetuximab or rituximab was used, as assessed by trace labeling with 89Zr 
in a standard solution of Zr-oxalate.
 In the next step, Df-Bz-NCS-mAbs were labeled with 89Zr in HEPES buffer (final 
concentration 0.25 M). After 60 min incubation at room temperature at pH 6.8 – 7.2, the 
amount of 89Zr trans-chelated from oxalate to Df-Bz-NCS-mAb was always more than 85% 
(mean, 91.9±4.6%). The time courses of 89Zr-complexation of mAb cU36 conjugated with 
Df-Bz-NCS at different pHs are shown in Figure 2. Labeling efficiency was distinctly higher 
at pH 6.8 and 7.2 than at pH 6.0, 6.2 and 7.4.
 Labeling of mAb cU36, cetuximab or rituximab modified with Df-Bz-NCS resulted 
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in overall yields after purification of always >80% (mean, 87.0±4.6%). The radiochemical 
purity was always >95% (mean, 97.5±0.7%; determined with ITLC and confirmed by HPLC). 
The immunoreactive fraction of the different 89Zr-Df-Bz-NCS-mAb preparations ranged 
from 84.1% to 96.8% at the highest cell concentration, and was similar to those of their 
131I-labelled counterparts (data not shown). HPLC and SDS-PAGE analyses revealed optimal 
integrity of the different mAbs after modification and labeling with 89Zr (data not shown). 
Evaluation of in vitro stability
89Zr-labeled Df-Bz-NCS-mAb and N-sucDf-mAb conjugates were both stored in 0.9% NaCl/
gentisic acid 5 mg/ml and in 0.25 M sodium acetate/gentisic acid 5 mg/ml at 4°C over 
several days to evaluate the in vitro stability. To anticipate effects of insufficient cooling, 
the conjugates were also analyzed after storage at room temperature (21°C). Storing the 
89Zr-Df-Bz-NCS-mAb conjugates in 0.25 M sodium acetate/gentisic acid 5 mg/ml buffer (pH 
5.5) at 4°C gave the best results; only 0.9±0.4% of the initially bound 89Zr was dissociated 
from the mAb after 48 h, and 4.1±1.3% after 144 h. Upon storage in the same buffer 
at room temperature (21°C), 6.1±1.4% and 10.5 ± 2.1% was dissociated after 48 h and 
144 h, respectively. Also upon storage in 0.9% NaCl/gentisic acid 5 mg/ml (pH 5.0) at 4°C 
the radioimmunoconjugates remained reasonably stable, showing 13.2±2.8% dissociation 
after 144 h. However, storage in the same buffer at room temperature resulted in rapid 
release of radioactivity from the conjugate, 48.4±5.7%. The corresponding 89Zr-N-SucDf-
mAb conjugates remained very stable, showing less than 5% release after 144 h under all 
conditions investigated.
The in vitro stability data for the 89Zr-Df-Bz-NCS-cU36 and 89Zr-N-sucDf-cU36 
conjugates, when incubated in freshly prepared human serum at 37°C, showed that 
loss of 89Zr from both conjugates over a 7 day period was very small. The percentages 
dissociated at day 3 were 2.3±0.1% for the Df-Bz-NCS conjugate and 3.4±0.6% for the 
N-sucDf conjugate, and at day 7 were 4.0±0.6% for the Df-Bz-NCS conjugate and 4.7±0.5% 
for the N-sucDf conjugate, respectively.
Evaluation of the in vivo biodistribution
Two sets of biodistribution studies were performed. In the first experiment, 89Zr-Df-Bz-NCS-
cU36 and the reference compound 89Zr-N-sucDf-cU36 were injected into FaDu-bearing 
nude mice. At 72 and 144 h after injection, the average %ID/g of tumor, blood, normal 
tissue, and gastrointestinal contents was determined (Figure 3). No significant differences 
in the biodistribution of both conjugates were found.
 Only a minor proportion of mAb cU36 internalizes after binding to its target 
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Figure 2. Time course of 89Zr complexation of mAb cU36 conjugated with Df-Bz-NCS at different pH and at room tempera-
ture.
antigen, therefore in the second biodistribution study the anti-EGFR mAb cetuximab was 
chosen because of the high rate of internalization. 89Zr-Df-Bz-NCS-cetuximab and the 
reference compound 89Zr-N-sucDf-cetuximab were injected into A431-bearing nude mice. 
At 24, 48, 72, and 120 h after injection, the average %ID/g of tumor, blood, normal tissue, 
and gastrointestinal contents was determined (Figure 4). The overall biodistribution of the 
two radioimmunoconjugates was very similar, showing no significant differences except 
for blood levels at 24 and 120 h after injection (Figure 4; significant differences (P<0.01) 
are indicated with an asterisk). The 89Zr-Df-Bz-NCS-cetuximab tumor accumulation ranged 
from 15.6±4.4 %ID/g to 23.1±7.1 %ID/g and the 89Zr-N-sucDf-cetuximab accumulation 
from 12.3±3.2 %ID/g to 25.3±6.1 %ID/g, in the time period between 24 and 120 h post 
injection.
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Figure 3. Biodistribution of 89Zr-Df-Bz-NCS-cU36 (black bars) amd 89Zr-N-sucDf-cU36 (white bars) in FaDu tumor-bearing 
nude mice at 72 h (a) and 114 h (b) after injection. Total administered mAb dose: 100 µg. Mean (%ID/g) ±SD at each time 
point after injection (n=4 animals per time point for each conjugate)
PET study
To exclude 89Zr uptake in tissues not evaluated in the biodistribution experiments, a PET 
imaging study was performed. Representative PET images of FaDu xenograft-bearing nude 
mice at 72 h after injection with 89Zr-Df-Bz-NCS-cU36 or 89Zr-N-sucDf-cU36 are shown in 
Figure 5a and 5b, respectively. Immuno-PET with both radioimmunoconjugates revealed 
clear delineation of the tumors (arrows), whereas no prominent uptake of radioactivity 
was observed in other tissues, except for the liver in which 89Zr residualizes after catabolism 
of the conjugates.
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Figure 4. Biodistribution of 89Zr-Df-Bz-NCS-cetuximab (black bars) and 89Zr-N-sucDe-cetuximab (white bars) in A431 
tumor-bearing nude mice at 24 h (a), 48 h (b), 72 h (c), and 120 h (d) after injection. Total administered mAb dose: 500 µg. 
Mean (%ID/g) ±SD at each time point after injection (n=4 animals per time point for each conjugate). Significant differnces 
(P<0.01) in biodistribuition between both radrioimmunoconjugates are marked with an asterisk.
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Discussion
Immuno-PET, the tracking and quantification of mAbs and mAb-fragments with PET 
in vivo, is an emerging novel option to improve diagnostics and to guide mAb-based 
therapy [2-4]. Availability of positron emitters with a proper half-life, simple and robust 
radiochemistry, and advanced animal as well as clinical PET and PET-CT scanners, is crucial 
in these developments.
 In the present report, we have described a method for labeling mAbs with the 
long-lived positron emitter 89Zr using the novel bifunctional chelate Df-Bz-NCS. 89Zr has 
attractive characteristics for immuno-PET with intact mAbs, especially when these mAbs 
become internalized upon binding to their cellular target. Radioimmunoconjugates 
produced by this method were stable in storage buffer as well as in human serum in vitro. 
Biodistribution and imaging experiments showed high and selective accumulation in 
tumors in nude mice.
 The chelate Df has frequently been used for radiolabeling of mAbs in the past, 
but these conjugates have never been evaluated clinically [23-26]. More recently, Verel 
et al. [5] developed a sophisticated method for stable coupling of 89Zr to mAbs using a 
succinylated-derivative of Df, which was used as the reference method in the present study 
(Figure 1b). 89Zr-labelled mAbs prepared according to this method have been successfully 
tested preclinically and clinically [6-13]. In the past and ongoing clinical studies, neither 
adverse reactions nor significant changes in blood and urine values were observed after 
injection of these conjugates. Moreover, no antibody responses directed against the Df 
chelate were observed indicating that its immunogenicity is low [8]. These data illustrate 
that 89Zr-labeled Df-mAbs can be used safely in patients. However, a shortcoming of the 
aforementioned method is that the multi-step procedure is relatively complicated and 
time consuming, and therefore challenging with respect to GMP compliance. 
 Now we introduce p-isothiocyanatobenzyl-derivative of Df (Df-Bz-NCS) that might 
provide an efficient and rapid preparation of 89Zr-labelled mAbs. Bifunctional chelates 
bearing isothiocyanate as the reactive group for conjugation to mAbs or other biologicals 
are frequently used [27]. The isothiocyanate group of the bifunctional chelate forms a 
thiourea bond with a primary amine of the protein or mAb. 
Coupling of Df-Bz-NCS to mAbs was very efficient. A reproducible chelate:mAb 
substitution ratio of 1.5:1 was obtained in a typical conjugation reaction with several 
different mAbs using only a three-fold molar excess of Df-Bz-NCS. The chelate:mAb 
substitution ratio was chosen to be kept below 2, to avoid alteration of the pharmacokinetics 
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and immunoreactivity of the mAb [28, 29].
 The rate of complexation of 89Zr into the Df-Bz-NCS conjugate was very similar 
as compared to the reference N-sucDf conjugate reported by Verel et al. [5], indicating 
that the different chemical linkages (e.g. =S instead of =O group in the side chain which 
might be involved in 89Zr4+ coordination) have no influence on the complexation rate. 
At the pH-optimum, almost quantitative complexation was reached after 30 minutes 
at room temperature. The resulting radioimmunoconjugates showed no impairment of 
immunoreactivity and integrity of the mAbs.
 Radioimmunoconjugates were stored in various media to find the optimal 
conditions for storage and transportation over several days. The 89Zr-Df-Bz-NCS-mAb can 
best be stored at 4°C in sodium acetate buffer in presence of the antioxidant gentisic acid. 
Under these conditions, only a minor portion of the initially bound 89Zr was dissociated 
from the mAb after 144 h. The need for protection of the radioimmunoconjugate against 
radiation damage during storage has been shown in previous studies [5, 30]. The presence 
Figure 5. HRRT PET images (coronal slices) of two different FaDu xenograft-bearing nude mice at 72 h after injection with 
89Zr-Df-Bz-NCS-cU36 (a) or with 89Zr-N-sucDf-cU36 (b). Slices from ventral (left) to dorsal (right). Images demonstrate high 
level of radiolabeled antibody accumulating in the tumor (arrows point to flank tumors) and low levels of tracer uptake in 
nontarget tissues
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of the antioxidant ascorbic acid during storage of high-dose 90Y- or 131I-labelled mAbs 
proved to be beneficial, however, ascorbic acid cannot be used during storage of 89Zr-
labelled Df-mAbs, because this reagent causes detachment of 89Zr from Df by reducing Zr4+ 
to Zr2+ [5].
Under certain storage conditions, the new 89Zr-Df-Bz-NCS conjugate is slightly 
less stable than the reference radioimmunoconjugate, and it is important to be aware of 
this. Especially, the presence of Cl--ions in the storage buffer impaired the integrity of the 
radioimmunoconjugates, most likely due to the radiation-induced formation of OCl--ions 
reacting with the SH-group of the enolised thiourea-unit. The thus formed intermediary 
sulphenyl chloride bonds, and sulphonyl chloride bonds arising upon further oxidation, are 
known to undergo a series of reactions, among which are coupling reactions and cleavage 
of methionyl peptide bonds. ITLC data also indicated that most of the deterioration is not 
detachment of 89Zr from the Df-chelate itself, but disruption of the Zr-Df unit. 
 The in vitro stability of the 89Zr-Df-Bz-NCS conjugate and the 89Zr-N-sucDf 
conjugate was also compared in freshly prepared human serum at 37°C. The stability 
of both conjugates under these conditions was very comparable and high, showing less 
than 4.7% release after a 7 days incubation period. Serum acts as an oxidisable scavenger 
and protects against directs hits to the mAb molecule, minimizing the radiation-induced 
deterioration of the mAb. Comparable in vitro stability data of 89Zr-N-sucDf conjugates 
were previously reported by our group [20].
 To investigate whether the new linker used for coupling of Df to the mAbs 
affects the biodistribution properties in mice, two sets of biodistribution experiments 
were performed. In the first experiment, the biodistribution of 89Zr-Df-Bz-NCS-cU36 and 
the reference compound 89Zr-N-sucDf-cU36 was compared in FaDu-bearing nude mice. 
In this model, no significant differences in the biodistribution between both conjugates 
were found. However, only a minor proportion of mAb cU36 internalizes after binding 
to its target antigen, therefore in the second biodistribution study the anti-EGFR mAb 
cetuximab was chosen because of the high rate of internalization [20]. Also in this model, a 
very similar biodistribution was found. Although, some significant differences were found, 
e.g. blood levels at 24 and 120 h after injection. Overall, both studies indicate that the 
different linkers used do not affect the biodistribution properties in nude mice. Moreover, 
none of the normal organs showed an adverse high uptake. The aforementioned results 
were confirmed in comparative immuno-PET studies with both chelates. PET images did 
not show accumulation of radioactivity in bone, which would have been indicative of free 
89Zr.
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Conclusions
In the present study we evaluated the newly developed bifunctional chelate Df-Bz-NCS for 
radiolabeling of mAbs with 89Zr for PET-imaging. The two-step procedure allows efficient 
and rapid preparation of 89Zr-labeled mAbs. Resulting 89Zr-Df-Bz-NCS-mAb conjugates 
appeared optimal with respect to radiochemical purity, integrity, and immunoreactivity. 
Furthermore, the radioimmunoconjugates were stable in serum in vitro and comparative 
biodistribution and imaging experiments showed high and selective accumulation in 
tumors in nude mice. Special emphasis should be given to the storage conditions. The 
recent commercialization of 89Zr and the availability of an easy-to-use radiolabeling 
strategy using Df-Bz-NCS allow further exploration of 89Zr-immuno-PET as an imaging tool 
for the selection of high potential candidate mAbs for therapy as well as for the selection 
of patients with the highest chance of benefit from mAb-based therapy [2].
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Abstract
The positron emitter zirconium-89 (89Zr) has very attractive properties for positron emission 
tomography (PET) imaging of intact monoclonal antibodies (mAbs) using immuno-PET. 
This protocol describes the step-by-step procedure for the facile radiolabeling of mAbs 
or other proteins with 89Zr using p-isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS). 
First, Df-Bz-NCS is coupled to the lysine–NH
2
 groups of a mAb at pH9.0 (pre-modification), 
followed by purification using gel filtration. Next, the premodified mAb is labeled at room 
temperature by addition of a [89Zr]Zr-oxalic acid solution followed by purification using gel 
filtration. The entire process of premodification, radiolabeling and purification steps will 
take about 2.5 h.
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Introduction
At present, hundreds of monoclonal antibodies (mAbs) and mAb fragments are under 
clinical development because of their excellent potential for the systemic treatment of 
cancer and other pathological conditions1,2. Positron emission tomography (PET) offers 
an attractive imaging option: (1) to confirm and quantify tumor uptake of such targeting 
molecules; (2) to learn about uptake in critical normal organs to anticipate toxicity; and (3) 
to elucidate the inter-patient variations in pharmacokinetics and tumor targeting3-6.
For PET imaging of mAbs (immuno-PET), an appropriate positron emitter, with 
a half-life (t
½
) that is compatible with the time needed to achieve optimal tumor-to-
non tumor ratios (typically 2-4 days for intact mAbs), has to be securely coupled to the 
targeting molecule. Therefore, zirconium-89 (89Zr; t
½
: 78.4 h) was selected. Other positron 
emitters for immuno-PET are under investigation at the moment: gallium-68 (68Ga; t
½
:1.13 
h), fluorine-18 (18F; t
½
:1.83 h), copper-64 (64Cu; t
½
:12.7 h), yttrium-86 (86Y; t
½
:14.7 h), 
bromine-76 (76Br; t
½
:16.2 h), and iodine-124 (124I; t
½
:100.3 h)3-6
.
We recently described the large scale production of radionuclidic pure 89Zr 
(specific activity ≥0.15 GBq nmol-1) with a small cyclotron (89Y-target; E
p
 14 MeV), and 
a strategy for labeling mAbs with 89Zr via a multi-step synthesis using a succinylated-
derivative of desferrioxamine B (Df) as bifunctional chelate7. The utility of this approach 
was demonstrated through high quality 89Zr-mAb-PET images and quantification results 
reported in preclinical8-12 and clinical studies5-11. In these studies, typically 370 kBq and 
37-74 MBq 89Zr-mAb was used for immuno-PET in mice and humans, respectively. In both 
preclinical and clinical studies neither pharmacokinetic changes nor aspecific accumulation 
in non-target organs were observed, except for uptake in catabolic organs like liver and 
kidneys. The only concern is the high radiation dose to the patient, which is inherent to the 
use of long-lived positron emitters like 89Zr and 124I, and might limit repeated application of 
89Zr-immuno-PET15. Df is an attractive chelate because it is used clinically in a safe way for 
many years13,15-17. The recent commercialization of 89Zr makes this radionuclide generally 
available for research and clinical development. (see Materials).
A shortcoming of the aforementioned approach is that the multi-step procedure, 
extensively described by Verel et al.7, is relatively complicated and time consuming.  In this 
protocol we present an efficient and more rapid preparation of 89Zr-labeled mAbs using 
the newly developed p-isothiocyanatobenzyl-derivative of Df (Df-Bz-NCS; Macrocyclics)18. 
First, Df-Bz-NCS is coupled to the lysine-NH
2
 groups of a protein at pH 9.0, followed by 
purification using gel filtration. Next, the pre-modified mAb is labeled at room temperature 
by addition of a [89Zr]Zr-oxalic acid solution followed by purification using gel filtration. For 
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this preparation there is no need to work under strict metal-free conditions and neither is 
it necessary to remove trace metal ions from the solutions like in other chelate chemistry 
(e.g., DOTA and DTPA). When mAb fragments instead of complete antibodies are used, 
this protocol can still be used, maintaining the same molar ratios of reagents as described 
herein.
There is an earlier version of this protocol (ref number, http://www.
natureprotocols.com/2008/01/24/facile_radiolabeling_of_monocl.php) present in the 
community generated section of our site (http://protocols.nature.com/user/login). Since 
then, this method has been used in published primary research (Perk et al.18), and this 
version has been peer-reviewed.
 Df-Bz-NCS is also a very convenient bifunctional chelate for labeling of proteins 
at room temperature with gallium-68 (68Ga; t
½
: 1.13 h) (M.J.W.D.V. and G.A.M.S.v.D., 
unpublished observations). 68Ga is especially attractive for PET imaging of fast kinetic 
targeting proteins like mAb fragments, but this is not part of the present protocol.
The procedure described is for mAbs and mAb fragments like Nanobodies19 
(www.ablynx.com) but can also be used for other proteins in the mass range 2-10 mg, 
provided the same molar ratios of reagents are applied. A schematic representation of the 
procedure is shown in Figure 1.
Figure 1. Schematic representation 
of monoclonal antibody (mAb) 
modification with Df-Bz-NCS (1) and 
subsequent labeling with 89Zr (2).
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Materials
REAGENTS
CRITICIAL Special actions need not to be taken regarding working under metal-free conditions. Trace metal ions need not to 
be removed from the solutions. 
	 Antibody or protein to be conjugated (typically 2-10 mg)
	 Df-Bz-NCS (molecular weight=752.9 g mol-1; Macrocyclics, cat. no. B-705)
	 Distilled, deionized water (Milli-Q; greater than 18 MΩ*cm  resistance)
	 DMSO (Aldrich, cat. no. 494429)
	 Sodium carbonate; 0.1 M and 2.0 M solutions in water (Aldrich, cat. no. 204420)
	 Normal (0.9%) saline (B.Braun, cat. no. 5/12251178/1197)
	 Gentisic acid (Fluka, cat. no. 37550)
	 Oxalic acid; 1.0 M solution in water (Fluka, cat. no. 75688)
	 HEPES buffer solution (Invitrogen, cat. no. 15630-049; see REAGENT SETUP)
	 Sodium hydroxide (NaOH); 1.0 M solution in water (Riedel-de Haën, cat. no. 30620) 
	 Sulfuric acid solution (Merck, cat. no. 1.00714.1000) 
	 Citric acid monohydrate (Fluka, cat. no. 27491)
	 Sodium acetate trihydrate (Fluka, cat. no. 71190) 
	 Gentisic acid 5 mg ml-1 in 0.25 M sodium acetate (pH5.4-5.6) 
(see REAGENT SETUP) CRITICAL: prepare fresh on the day of use
	 Sodium dihydrogen phosphate monohydrate (Merck, cat. no. 1.06346.0500)
	 Disodium hydrogen phosphate anhydrous (Merck, cat. no. 1.06566.0100)
	 Sodium chloride (Merck, cat. no. 1.06404.0500)
	 Sodium azide (Merck, cat. no. 1.06688.0100) CAUTION Highly toxic
	 Instant Thin Layer Chromatography strips (ITLC) eluent (see REAGENT SETUP)
	 High-Performance Liquid Chromatograph (HPLC) eluent (see REAGENT SETUP)
	 [89Zr]Zr-oxalate in 1.0 M oxalic acid (≥ 0.15 GBq nmol-1) (IBA Molecular)
CAUTION: 89Zr emits positrons and gamma rays. It is imperative that researchers follow the guidelines set forth by their 
institution and the Nuclear Regulatory Commission, and ALARA (As Low As Reasonably Achievable) protocols to minimize 
exposure to emitted radiation. Proper protective equipment, shielding, ring and body dosimetry badges and a contamination 
monitor are required when handling any radioactive materials.
EQUIPMENT
	 Calibrated pH meter, with Biotrode (Hamilton, cat. no. 238140)
	 Eppendorf tubes, Protein LoBind Tubes, 1.5 ml (Eppendorf, cat. no. 0030 108.116)
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	 Shaker
	 Disposable PD-10 desalting columns (GE Healthcare Life Sciences, cat. no. 17-0851-01)
	 Thermomixer comfort (Eppendorf, cat. no. 5355 000.011)
	 Sterile/clean glass reaction vials, 20 ml
	 ITLC strips (Biodex, cat. no. 150-771) 
	 HPLC with a UV and a g-detector connected in series
	 HPLC column: size exclusion Superdex™ 200 10/300 GL (GE Healthcare Life Sciences, cat. no. 17-5175-01)
	 0.45 µm filter for HPLC eluent (Millipore, cat. no. HVLP04700)
	 SDS-PAGE system, Phastgel system; (GE Healthcare Life Sciences,  cat. no 18-1200-10)
REAGENT SETUP
Gentisic acid 5 mg ml-1 in 0.25 M sodium acetate buffer (pH 5.4-5.6) Dissolve 3.4 g sodium acetate trihydrate and 0.5 g 
gentisic acid in 100 ml Milli-Q. Mix well and check the pH. Acceptance range: pH 5.4-5.6.
0.5 M HEPES buffer (pH 7.1-7.3) Add 18 ml of Milli-Q to 20 ml 1 M HEPES solution. Check pH. If pH < 7.1 adjust pH with 1 M 
NaOH, if pH > 7.3 adjust pH with 1 M H
2
SO
4
. Adjust volume to 40 ml with Milli-Q.
ITLC eluent (pH 4.9-5.1) Dissolve 420 mg citric acid monohydrate in 100 ml Milli-Q water, add 0.98 ml 2.0 M sodium 
carbonate. Mix well and check the pH. Acceptance range: pH 4.9-5.1.
HPLC eluent (pH 6.2-7.0) Dissolve 13.8 g of sodium dihydrogen phosphate monohydrate, 14.2 g of disodium hydrogen 
phosphate, 17.4 g of sodium chloride, and 1.3 g of sodium azide in 2 l of water. Mix well and check the pH. Acceptance 
range: pH 6.2-7.0. Pass the eluent through a Millipore filter and degas before use.
EQUIPMENT SETUP
HPLC method for quality control Turn the UV detector on and equilibrate the HPLC-column using the described HPLC eluent, 
flow 0.5 ml min-1 for at least 30 min prior to injection of the sample. The blank run is an injection with PD-10 column eluent 
(5 mg ml-1 gentisic acid in 0.25 M sodium acetate pH  5.4 -5.6). 
A typical quality control run for a labeled 89Zr-mAb is 20 µl injection on Superdex™ 200 10/300 GL column, flow 0.5 ml min-1; 
R
t
 mAb =~25 min; R
t
 unbound 89Zr =~45min.
Procedure
Coupling of the bifunctional chelate  (TIMING 50 min)
1. Pipette the required amount of mAb solution (max. 1 ml; by preference between 2 and 
10 mg ml-1 mAb) into an Eppendorf tube. Adjust the reaction mixture to a total volume of 
1 ml by adding a sufficient amount of normal saline into the tube.
CRITICAL STEP Concentrations lower than 2 mg ml-1 will decrease the efficiency of the 
conjugation reaction, resulting in lower Df-mAb molar ratio.
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2. Adjust pH of the mAb solution to pH 8.9 – 9.1 with 0.1 M Na
2
CO
3
 (max. 0.1 ml).
CRITICAL STEP Alternatively, the desired pH for the reaction can be obtained by performing 
a buffer exchange of the mAb stock solution against 0.1 M sodium bicarbonate buffer 
(pH9.0).
3. Dissolve Df-Bz-NCS in DMSO at a concentration between 2 and 5 mM (1.5-3.8 mg ml-1) 
depending on the amount of mAb used. Add this to the protein solution to give a three-
fold molar excess of the chelator over the molar amount of mAb and mix immediately. 
Keep the DMSO concentration below 2% in the reaction mixture.
CRITICAL STEP Typically, 20 µl (in steps of 5 µl) 2-10 mM Df-Bz-NCS (40-200 nmol) in DMSO 
is added to 2-10 mg intact antibody (13.2-66 nmol). In those cases, between 0.3-0.9 Df 
moieties will be coupled per antibody molecule18.
4. Incubate the reaction for 30 min at 37°C using a Thermomixer at 550 rpm.
5. In the mean time rinse a PD-10 column with 20 ml 5 mg ml-1 gentisic acid in 0.25 M 
sodium acetate (pH 5.4-5.6).
6. Pipette the conjugation reaction mixture onto the PD-10 column and discard the flow-
through.
7. Pipette 1.5 ml 5 mg ml-1 gentisic acid in 0.25 M sodium acetate (pH 5.4-5.6) onto the 
PD-10 column and discard the flow-through. 
8. Pipette 2 ml 5 mg ml-1 gentisic acid in 0.25 M sodium acetate (pH 5.4-5.6) onto the PD-
10 column and collect the Df-protein.
PAUSE POINT The Df-Bz-NCS-mAb can be stored at -20 °C until the day of radiolabeling for 
at least 2 weeks.
Radiolabeling (TIMING 1 h 45 min)
9. Pipette the required volume (=a) of [89Zr]Zr-oxalic acid solution (max. 200 µl, typically 37 
-185 MBq) into a glass ‘reaction vial’. 
CAUTION Follow appropriate radiation safety measures for Steps 9 – 17.
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10. While gently shaking, add 200 µl – a µl (see Step 9) 1 M oxalic acid into the reaction 
vial. Subsequently, pipette 90 µl 2 M Na
2
CO
3
 into the reaction vial and incubate for 3 
minutes at room temperature.
11. While gently shaking, pipette successively 0.30 ml 0.5 M HEPES (pH7.1-7.3), 0.71 ml 
of premodified mAb (typically 0.7-3.0 mg), and 0.70 ml 0.5 M HEPES (pH7.1-7.3) into the 
reaction vial.
CRITICAL STEP The pH of the labeling reaction should be in the range of 6.8-7.2 for optimal 
labeling efficiency.  
Radiolabeling efficiency =  CPM R
f  
0.0 - 0.1 (CPM radiolabeled mAb)
    CPM R
f
 0.0 - 1.0 (CPM total)   
x 100%
12.  Incubate for 1 h at room temperature while gently shaking the reaction vial. 
Radiolabeling efficiency (typically >85%) can be determined by instant thin-layer 
chromatography (ITLC) using chromatography strips and 20 mM citric acid (pH 4.9-5.1)
(ITLC eluent) as solvent. A 0.5-2.0 µl aliquot of the reaction solution can be directly applied 
to the ITLC strip. Radiolabeled mAb (R
f
 = 0.0 - 0.1). Any radioactivity R
f
 >0.1 represents 
radioactivity not bound to the mAb.
13. Meanwhile, rinse a PD-10 column with 20 ml 5 mg ml-1 gentisic acid in 0.25 M sodium 
acetate (pH 5.4-5.6). 
14. After 1 h incubation, pipette the reaction mixture onto the PD-10 column and discard 
the flow-through.
15. Pipette 1.5 ml 5 mg ml-1 gentisic acid in 0.25 M sodium acetate (pH 5.4-5.6) onto the 
PD-10 column and discard the flow-through. 
MBq 89Zr product vial (see Step 16)
MBq 89Zr starting activity (see Step 9)
x 100%
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16. Pipette 2 ml 5 mg ml-1 gentisic acid in 0.25 M sodium acetate (pH 5.4-5.6) onto the PD-
10 column and collect the purified radiolabeled mAb.
17. Calculate the overall labeling yield:     
and analyze the purified radiolabeled mAb by ITLC, HPLC and SDS-PAGE (EQUIPMENT 
SETUP). When the radiochemical purity is greater than 95% it is ready for storage at 4 °C 
or dilution in 5 mg ml-1 gentisic acid in 0.25 M sodium acetate (pH 5.4-5.6) for in vitro or in 
vivo studies.  When the purity is <95% the PD-10 column purification should be repeated. 
The radiolabeled mAb is stable upon storage for 48 h (0.9% ± 0.4 % dissociation of the 
initial bound 89Zr in a 37 MBq ml -1 89Zr-mAb solution at t = 48 h, but presence of chloride 
ions should be avoided).
PROBLEM	   POSSIBLE	  REASONS	   SOLUTION	  
Low	  labeling	  yield	   Low	  premodification	  efficiency;	  insufficient	  
removal	  of	  unreacted	  hydrolysed	  Df-­‐Bz-­‐
NCS;	  incorrect	  pH	  during	  labeling	  
A	  higher	  molar	  excess	  of	  Df-­‐Bz-­‐
NCS	  can	  be	  chosen	  in	  the	  
conjugation	  reaction;	  repeat	  the	  
PD-­‐10	  purification,	  or	  apply	  the	  
alternative	  given	  below	  
mAb	  aggregation	   Inhomogenic	  Df/mAb	  ratio	  due	  to	  high	  local	  
DMSO	  concentration	  resulting	  in	  excessive	  
local	  reaction	  (deviating	  from	  Poisson	  
distribution);	  radiolysis	  
Ensure	  efficient	  shaking	  of	  the	  
reaction	  mixture	  upon	  adding	  the	  
chelate;	  pre-­‐modification	  can	  be	  
performed	  at	  room	  temperature;	  
ensure	  that	  gentisic	  acid	  is	  added	  
to	  the	  reaction	  buffers	  when	  
indicated	  
Low	  radiochemical	  purity	   Insufficient	  purification	   Repeat	  PD-­‐10	  purification	  or,	  
alternatively	  ultrafiltration	  or	  
dialysis	  can	  be	  applied	  in	  the	  
purification	  steps	  
 
Table 1 Troubleshooting table
CRITICAL STEP Gentisic acid is introduced during labeling and storage to minimize 
deterioration of the mAb integrity by radiation. The use of Cl- ions should be avoided 
since radiation and subsequent radiolysis of water molecules form OCl- ions which very 
specifically react with the SH-group of the enolized thiourea unit. The thus formed 
intermediary sulphenyl chloride bonds, and the sulphonyl chloride bonds arising upon 
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Figure 2. Representative HPLC chromatograms and SDS-PAGE gels. a and b show zirconium-89 (89Zr)-labeled cmAb U36, 
and c and d show 89Zr-labeled anti-EGFR nanobody (www.ablynx.com). SDS-PAGE was performed on a Phastgel System (GE 
Healthcare Life Sciences) using preformed 7.5% (b) or high density (d) SDS-PAGE gels under non-reducing conditions. 
further oxidation, are known to undertake a series of reactions, among which are coupling 
reactions and cleavage of methionyl peptide bonds. Therefore, the use of a 0.25 M sodium 
acetate buffer is strongly recommended.
Timing
Steps 1-8, Coupling of the bifunctional chelate: 50 min
Steps 9-17: Radiolabeling: 1 h 45 min
Troubleshooting
Troubleshooting advice can be found in Table 1.
Anticipated results
Typically, 0.3-0.9 Df moieties are coupled per antibody molecule18. Labeling of the Df-
conjugated mAb with 89Zr will result in overall radiolabeling yields of >85%. Resulting 89Zr-
mAb conjugates are optimal with respect to radiochemical purity (>95% according to ITLC, 
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analytical HPLC and SDS-PAGE), immunoreactivity, and in vivo stability. Representative 
HPLC chromatograms and SDS-PAGE gels of 89Zr-labeled cmAb U36 (150 kDa), and of a 
89Zr-labeled anti-EGFR nanobody19 (15 kDa),  are shown in Figure 2. 
The positron emitter 89Zr can be applied to assess normal biodistribution, and 
confirm and quantify selective tumor uptake of mAbs, mAb-fragments, non-traditional 
antibody-like scaffolds or other proteins of interest in animal and clinical studies using PET-
imaging. A representative 89Zr-immuno-PET image is shown in Figure 3.
Figure 3. Positron emission tomography (PET) images of a nude mouse bearing two head and neck cancer FaDu xenografts, 
obtained at 72 h after i.v. injection of the anti-CD44v6 conjugate 89Zr-Df-Bz-NCS-cmAb U36 (3.7 MBq, 200 µg mAb) with a 
double-crystal-layer high resolution research tomograph PET scanner (HRRT PET scanner, Siemens/CTI). Coronal slices from 
ventral (left) to dorsal (right). Tumors are indicated by arrows.
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Abstract
Purpose  The ~15 kDa variable domains of camelid heavy-chain-only antibodies 
(called Nanobodies®) have the flexibility to be formatted as monovalent, monospecific, 
multivalent or multispecific single chain proteins with either fast or slow pharmacokinetics. 
We report the evaluation of the fast kinetic anti-epidermal growth factor receptor 
(EGFR) Nanobody 7D12, labelled with 68Ga via the novel bifunctional chelate (BFC) 
p-isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS). Df-Bz-NCS has recently been 
introduced as the chelate of choice for 89Zr-immuno-positron emission tomography (PET). 
Methods Nanobody 7D12 was premodified with Df-Bz-NCS at pH 9. 
Radiolabelling with purified 68Ga was performed at pH 5.0 – 6.5 for 5 min at room 
temperature. For in vitro stability measurements in storage buffer (0.25 M NaOAc 
with 5 mg ml-1 gentisic acid, pH 5.5) at 4°C or in human serum at 37°C, a mixture 
of 67Ga and 68Ga was used. Biodistribution and immuno-PET studies of 68Ga-Df-Bz-
NCS-7D12 were performed in nude mice bearing A431 xenografts using 89Zr-Df-Bz-
NCS-7D12 as the reference conjugate.
Results    The Df-Bz-NCS chelate was conjugated to Nanobody 7D12 with a chelate-
to-Nanobody molar substitution ratio of 0.2:1. The overall 68Ga radiochemical yield was 
55-70% (not corrected for decay); specific activity 100-500 MBq/mg. Radiochemical purity 
of the conjugate was >96%, while the integrity and immunoreactivity were preserved. 
68/67Ga-Df-Bz-NCS-7D12 was stable in storage buffer as well as in human serum during a 
5-h incubation period (< 2% radioactivity loss). In biodistribution studies the 68Ga-labelled 
Nanobody 7D12 showed high uptake in A431 tumours (ranging from 6.1±1.3 to 7.2±1.5 
%ID/g at 1-3 h after injection) and high tumour to blood ratios, which increased from 
8.2 to 14.4 and 25.7 at 1, 2 and 3 h after injection, respectively. High uptake was also 
observed in the kidneys. Biodistribution was similar to that of the reference conjugate 
89Zr-Df-Bz-NCS-7D12. Tumours were clearly visualized in a PET imaging study.
Conclusions  Via a rapid procedure under mild conditions a 68Ga-Nanobody was 
obtained that exhibited high tumour uptake and tumour to normal tissue ratios 
in nude mice bearing A431 xenografts. Fast kinetic 68Ga-Nanobody conjugates can 
be promising tools for tumour detection and imaging of target expression.
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Introduction
The epidermal growth factor receptor (EGFR, HER1, ERb1) is a transmembrane protein 
of the tyrosine kinase receptor family. Activation of EGFR causes signalling that may lead 
to cell division, increased motility, angiogenesis, and suppression of apoptosis [1]. EGFR 
over-expression or constitutive activation has been shown to be associated with poor 
survival and recurrences in many human malignancies [2]. Detection of EGFR expression 
via nuclear medicine visualization may provide advantages over immunohistochemical 
staining of tumour biopsies, since evaluation of both the primary tumour as well as the 
metastases can be achieved. In addition, such confirmation of EGFR expression can be 
of value as a scouting procedure to select patients for anti-EGFR therapy with approved 
monoclonal antibodies (mAbs) like cetuximab or panitumumab or small molecular tyrosine 
kinase inhibitors. On this latter topic several studies with intact anti-EGFR (αEGFR) mAbs 
or mAb fragments labelled with single photon emission computed tomography (SPECT) 
(111In, 99mTc) or positron emission tomography (PET) (64Cu, 89Zr) radionuclides have been 
reported [3-9].
 Nanobody technology provides new perspectives for mono- as well as multitarget 
tumour detection and therapy [10-12]. Nanobodies are derived from a unique antibody 
format that is present in species from the family of Camelidae, including llama, camel 
and dromedary. These animals contain, besides their conventional antibody repertoire, 
an antibody class consisting of heavy chains only [10, 13]. The variable region of the 
heavy chain only antibodies (VHH) represents the complete binding unit of the antibody. 
Because of the small size of these VHH fragments (~15 kDa), this binding unit is also called 
Nanobody®. Although being smaller than a scFv fragment, a Nanobody has full antigen-
binding potential and does not show aggregation problems, because of hydrophilic instead 
of hydrophobic patches in the V
H
 and V
L
 domains. Due to their single domain character, 
standard molecular biology techniques such as polymerase chain reaction (PCR) allow 
for the facile purification and selection of appropriate Nanobody candidates from the 
full antibody repertoire of immunized animals [14]. Unique features of the Nanobody 
technology platform in comparison to conventional mAb technology are easy and rapid 
drug development, and the easy and cheap production in bacteria and yeast [10, 15].
For a proof of concept we used the Nanobody technology platform to construct 
two αEGFR Nanobodies [11]. The biodistribution of a 177Lu-labeled bivalent αEGFR 
Nanobody (αEGFR-αEGFR) in A431 tumor bearing nude mice showed a tumor uptake of 
5.0±1.4 percentage of the injected dose per gram of tissue (%ID/g) at 6 h after injection 
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and high tumour to normal tissue ratios (e.g. tumour to blood ratio >80) due to rapid 
blood clearance. Simple fusion of an anti-albumin Nanobody building block gave a 50-
kDa single-chain construct (αEGFR-αEGFR-αAlb) that showed pharmacokinetics and 
tumour uptake (up to 35.2±7.5 %ID/g) comparable to cetuximab, but faster and deeper 
tumour penetration. Therefore, such Nanobody formats might be ideal for imaging and 
therapeutic purposes, respectively. 
 In the present study we evaluated the in vivo diagnostic potential of fast kinetic 
αEGFR Nanobody 7D12 within the immuno-PET approach. For this purpose the short-lived 
positron emitter gallium-68 (68Ga, t
½
 = 68 min, E
β+max
 1.92 MeV) was chosen. 68Ga is an 
attractive positron emitting radionuclide since it is cyclotron-independently available via 
the 68Ge/68Ga generator system.
In aqueous solutions the three-valent gallium forms a complex with many 
bifunctional chelates (BFC’s) containing oxygen and nitrogen as donor atoms. The only 
clinically used BFC for 68Ga is 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid 
(DOTA), but fast complex formation requires high temperature [16-19]. More recently, 
several new chelates have been described for labelling of 68Ga to heat-labile proteins at 
ambient temperature including 1.4.7-triazacyclononane-1,4,7-triacetic acid (NOTA) and 
N,N’-bis [2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N´-diacetic acid HBED-CC) 
[19-21]. However, this new generation BFCs is not yet available for clinical immuno-PET 
applications. 
For coupling of the long-lived positron emitter zirconium-89 (89Zr; t
½
 = 78.4 
h, E
β+max
 0.9 MeV) (23%) to intact mAbs, we recently introduced the novel BFC 
p-isothiocyanatobenzyl derivative of desferrioxamine B (Df-Bz-NCS) [22, 23]. The choice 
of desferrioxamine B is attractive because it has been used safely in the clinical setting 
for many years. Since the hydroxamate function in desferrioxamine B has also been used 
for coupling of gallium-67 (67Ga) in the past [24-27], we investigated whether this same 
Df-Bz-NCS can be used for labelling of 68Ga under mild conditions. If so, a similar kind of 
GMP-compliant radiochemistry can be used for labelling of slow kinetic mAbs with 89Zr, 
and fast kinetic mAb fragments with 68Ga. 
In this study, after establishing optimal 68Ga labelling procedures by using a control 
intact IgG mAb, the bifunctional chelate Df-Bz-NCS was conjugated to αEGFR Nanobody 
7D12 and subsequently radiolabelled with 68Ga. The resulting 68Ga-Df-Bz-NCS-7D12 
conjugate was analysed for stability at 4°C in storage buffer and at 37°C in serum, whereas 
its in vivo behaviour was investigated via biodistribution and animal PET studies, using 
89Zr-Df-Bz-NCS-7D12 as the reference.
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Materials and Methods
Figure 1. Two step synthesis of 68Ga-Df-Bz-NCS-mAb with the bifuncti onal chelate Df-Bz-NCS.
Materials
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. 
Deionised water (18 MΩ*cm) and ultra pure HCl (Ga content 0.02 ng natGa/g) was used. No 
other special measures were taken regarding working under strict metal-free conditi ons. 
Df-Bz-NCS was purchased from Macrocyclics (catalog No. B705). Nanobody 7D12 was 
generated by Ablynx NV (Ghent, Belgium) as described previously [14] and kindly provided 
to us. The selecti on, producti on, and characterizati on of chimeric mAb U36 (cmAb U36 
11.53 mg/ml) directed against CD44v6 has been described elsewhere [28]. The human 
epidermoid cervical carcinoma cell line A431 was obtained from the American Type Culture 
Collecti on (www.atcc.com), ATCC number: CRL-1555. The head and neck squamous cell 
carcinoma (HNSCC) cell line UM-SCC-11B was obtained from Dr. T.E. Carey (Ann Arbor, MI) 
[29]. 68Ga was obtained from a commercial 68Ge/68Ga generator based on a TiO
2
 bedding 
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with 1.85 GBq 68Ge-loaded activity (IGG100; Eckert & Ziegler, Berlin, Germany). 67Ga was 
purchased as 67Ga-citrate (74 MBq/ml) from Covidien (Mansfield, MA). [89Zr]Zr-oxalate in 
1.0 M oxalic acid (≥ 0.15 GBq/nmol) was from IBA Molecular (www.iba.be/molecular).
Purification and concentration of 68Ga and 67Ga 
The 68Ga was eluted from the 68Ge/68Ga generator as described by Velikyan et al. [16]. 
In short, the generator was eluted according to the manufacturer’s protocol with 3.5 ml 
ultra pure 0.1 M HCl solution. To that solution 3.5 ml ultra pure 8 M HCl was added under 
stirring, to give a final concentration of ~ 4 M HCl. The solution was passed through a pre-
treated (1 ml 100% ethanol, 1 ml deionized water, 1 ml 4 M HCl) anion-exchange column 
[Chromafix, PS-HCO3 (s), Macherey-Nagel, Düren, Germany], the column was washed 
with 2 ml of 4 M HCl, flushed with air, and then the 68Ga was eluted from the chromafix 
column with 200 µl deionized water (elution efficiency >85%). The use of ultra pure HCl 
implies that this procedure attributes at most 1.1 pmol natGa to this eluate.
67GaCl
3
 was obtained from 67Ga-citrate. To this end, 67Ga-citrate was mixed with 
an equal volume of ultra pure 8 M HCl. This solution was passed through a pre-treated 
Chromafix column and eluted as described for 68Ga.
In all preparations for in vitro evaluation 68/67Ga was used, while for in vivo 
evaluation only 68Ga was applied.
Preparation of 68/67Ga-Df-Bz-NCS-cmAb U36
For development of labelling procedures, the 150-kDa intact cmAb U36 was used as the 
control mAb. cmAb U36 was premodified with Df-Bz-NCS as described by Perk et al. [22] 
(Fig. 1). In short, 5 mg cmAb U36 (33 nmol) reacted with 20 µl Df-Bz-NCS (100 nmol) in 
dimethyl sulphoxide (DMSO) for 30 min at 37°C at pH 9 in a shaker, in a total volume of 
1 ml. Nonconjugated chelate was removed by size exclusion chromatography using a PD-
10 column (GE Healthcare Life Science) with 0.25 M NaOAc pH 5.5 as eluant. The flow 
through and the first 1.5 ml were discarded. The next 2 ml containing the premodified 
mAb were stored. 
Ga-Df complex chelate formation conditions were selected by varying pH and 
protein concentration. As a result, the following procedure was developed; to 10 - 200 
µl (=a) 68Ga and/or 67Ga in deionized water, (3x a µl) 3 M NH
4
OAc buffer pH 7.2 were 
added and mixed for 5 min at room temperature. Subsequently, the premodified cmAb 
U36 (100–1000 µg) in 0.25 M NaOAc pH 5.5 was added; final reaction volume was 2 ml. 
The reaction was stopped after 5 min at room temperature by the addition of 50 µl 50 
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mM ethylenediaminetetraacetate acid (EDTA), followed by PD-10 column purification 
using 0.25 M NaOAc with 5 mg.ml-1 gentisic acid, pH 5.5, as eluant. The flow through and 
the first 1 ml were discarded. The next 2 ml containing the 68/67Ga-labelled cmAb U36 were 
collected and used for further experiments. 
Preparation of 68/67Ga-Df-Bz-NCS-7D12
The same protocol was applied for the modification and radiolabelling of the αEGFR 
Nanobody 7D12. In short, two mg 7D12 (125 nmol) was conjugated with 375 nmol Df-
Bz-NCS and after PD-10 column purification the premodified 7D12 (200-1000 µg) was 
labelled with 68/67Ga as described for cmAb U36. 
Preparation of 89Zr-Df-Bz-NCS-7D12
The 7D12 nanobody was premodified as described above with a threefold molar excess 
of Df-Bz-NCS chelate. After PD-10 column purification the premodified 7D12 was labelled 
with 89Zr as described by Perk et al. [22]. In short, Df-Bz-NCS-7D12 (100-1000 µg) was 
labelled with 89Zr (37 MBq) in 0.25 M HEPES buffer pH 7.0 at room temperature in a total 
volume of 2 ml. The 89Zr-Df-Bz-NCS-7D12 was purified by PD-10 column using 0.25 M 
NaOAc with 5 mg ml-1 gentisic acid, pH 5.5, as eluant. After discarding the flow through 
and the first 1 ml, the next 2 ml containing the 89Zr-labelled 7D12 was collected for further 
experiments.
Determination of Df to 7D12 molar ratio
The Df-Bz-NCS to 7D12 molar ratio was determined following a general method using a 
known nanomolar excess of GaCl
3
 spiked with 67Ga. In short, 250 nmol GaCl
3
 (in 4 M ultra 
pure HCl) was mixed with ~37 MBq 67Ga and purified according to aforementioned method 
using the anion Chromafix column. Thereafter, 500 µg of premodified Df-Bz-NCS-7D12 
was labelled according to the developed protocol with 20-60 nmol of the above prepared 
67Ga-GaCl
3
,
 
and the Df to 7D12 molar ratio was calculated. For comparison the Df to 7D12 
molar ratio was also determined with the use of zirconium oxalate spiked with 89Zr. 
Analysis
68Ga was measured using E
γ
 = 511 KeV and 67Ga with E
γ
 = 185 KeV. When dual isotope 
labelling products were produced, 67Ga radioactivity measurements were performed 
at least 20 h after production (after decay of 68Ga). Each 68/67Ga-labelled product was 
analysed by instant thin layer chromatography (ITLC) to determine the radiochemical 
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Figure 2. SDS-PAGE followed by phosphor imaging analysis (a) and HPLC chromatogram (b) of purified 68Ga-Df-Bz-NCS-7D12, 
where the upper panel represents the UV profile at 280 nm the lower panel the radioactivity profile.
labelling efficiency and radiochemical purity. The integrity of the Nanobody and mAb 
was analysed by high performance liquid chromatography (HPLC) and sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by phosphor imaging 
(Storm820, GE Healthcare). Immunoreactivity was determined by a cell-binding assay, 3 h 
at 37°C or overnight at 4°C. ITLC analysis of the 68/67Ga-labelled products was performed on 
chromatography strips (Biodex, Shirley, NY, USA); 2 µl were spotted on an ITLC strip with 50 
mM EDTA in Milli-Q as mobile phase. HPLC analysis was performed on a Jasco HPLC system 
using a SuperdexTM peptide size exclusion column (GE Healthcare Life Sciences) when a 
labelled Nanobody was injected, or a SuperdexTM 200 10/300 GL size exclusion column when 
labelled cmAb U36 was injected, with a mixture of 0.05 M sodium phosphate and 0.15 M 
sodium chloride (pH 6.8) as eluent at a flow rates of 1.0 and 0.5 ml min-1, respectively. Gel 
electrophoresis was performed on a Phastgel System (GE Healthcare Life Sciences) using 
high density SDS-PAGE gels when a labelled Nanobody was applied or 7.5% SDS-PAGE gels 
when labelled U36 was applied, under non-reducing conditions. Immunoreactivity was 
determined by measuring the binding of the 68/67Ga-7D12 or 68/67Ga-cmAb U36 to a serial 
dilution of 2% paraformaldehyde fixed A431 cells or 0.2% glutaraldehyde fixed UM-SCC-
11B cells, respectively, essentially as described by Lindmo et al. [30].
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In vitro stability
To determine the in vitro stability of the gallium-labelled Nanobodies, 500 µg 68/67Ga-
labelled 7D12 product was stored at 4°C up to 24 h in 0.25 M NaOAc pH 5.5, containing 5 
mg ml-1 gentisic acid as antioxidant, and compared with 89Zr-7D12. Amounts of activity at 
the start of storage were 120 MBq of 68Ga, 20 MBq of 67Ga and 20 MBq of 89Zr. After 5 and 
24 h storage aliquots were taken and analyzed by ITLC, HPLC and SDS-PAGE. 
 Stability of 68/67Ga-labeled 7D12 was also tested in freshly prepared human serum 
and compared with 89Zr-7D12. Activity amounts at the start of storage were 80 MBq 68Ga, 
18 MBq 67Ga and 18 MBq 89Zr. The labelled 7D12 (300 µg) was incubated at 37°C, in a CO
2
-
enriched atmosphere (5% CO
2
)
 
with freshly prepared human serum (1:4) in the presence 
of 0.02 % NaN
3
. Aliquots were taken after 5 and 24 h storage and analyzed by ITLC and 
HPLC.
 
Biodistribution study
The distribution of 68Ga-Df-Bz-NCS-7D12 was examined using nude mice (HSD:Athymic 
Nude-Foxn1nu, 20-30 g; Harlan) bearing subcutaneously implanted human xenografts of 
the vulvar tumour cell line A431 at two lateral sides. All animal experiments were done 
according to NIH Principles of Laboratory Animal Care and Dutch national law (“Wet op de 
dierproeven”, Stb 1985, 336).
In this experiment mice bearing A431 xenografts were injected with 0.35 MBq 
68Ga-Df-Bz-NCS-7D12 (6 µg) via the retro-orbital plexus. As reference compound, 0.35 MBq 
89Zr-Df-Bz-NCS-7D12 (6 µg) was used. Unlabelled 7D12 was added to the injection mixture 
to obtain a final dose of 50 µg per mouse. At 1, 2 and 3 h post injection (p.i.) four mice were 
anesthetized, bled, killed and dissected. Blood, tumour and normal tissues were weighed 
and radioactivity was measured in a gamma counter (Wallac, Turku, Finland). Radioactivity 
uptake for each sample was calculated as the %ID/g.
PET study
PET imaging was performed on a HRRT PET scanner (Siemens/CTI [31]), a dedicated human 
brain scanner. Three A431 xenograft-bearing mice were anaesthetized by inhalation of 2% 
isoflurane, injected with 5 MBq 68Ga-Df-Bz-NCS-7D12 (85 µg) via the retro-orbital plexus, 
and scanned for 3 h. In addition, three mice were injected with 2.5 MBq 89Zr-Df-Bz-NCS-
7D12 (85 µg). Unlabeled 7D12 was added to the injection mixture to obtain a final dose 
of 100 µg per mouse. Transmission scans for attenuation and scatter correction were 
routinely obtained with each emission scan. Three-dimensional emission scans were 
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acquired in list mode during 180 min. A single frame static image was reconstructed using 
ordinary Poisson ordered subsets expectation maximization (OP-OSEM).  For visualization 
of the images, the freely available Amide’s A Medical Imaging Data Examiner (AMIDE) 
program was used [32].
Statistical analysis
Differences in tissue uptake between injected conjugates were statistically analysed for 
each different time point with SPSS 15.0 software using Student’s t-test for unpaired data. 
Two-sided significance levels were calculated and p <0.01 was considered statistically 
significant.
Figure 4. Static PET image of A431 tumour-bearing mice obtained 2-3 h after injection of 68Ga-Df-Bz-NCS-7D12 (left mouse) 
or 89Zr-Df-Bz-NCS-7D12 (right mouse). Images demonstrate similar uptake of both tracers. Tumours are indicated by arrows.
Image planes have been chosen where both tumours were visible.
Results
Preparation of 68/67Ga-Df-Bz-NCS-cmAb U36 
The Ga-Df formation conditions were investigated by performing experiments with 
premodified Df-Bz-NCS-cmAb U36. The Df-Bz-NCS chelate was coupled at pH 9 to the 
lysine groups in a 3 fold molar excess via a 30-min incubation at 37°C. 
When a labelling was performed for 5 min in a 2 ml acetate solution at a pH in 
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the range 5.0 – 6.5 and an activity level of 200 MBq 68Ga (2 pmol) and 37 MBq 67Ga (25 
pmol), the labelling yield was consistently >90% provided the amount of mAb was >200 
µg (measured up to 1000 µg) i.e. >0.7 nmol bound Df-groups. For 100 µg (i.e. 0.35 nmol 
bound Df-groups) a labelling yield of 80% was obtained. When using a naked cmAb U36 
under these conditions, <1% of Ga was co-eluted with the PD-10 protein fraction. 
After PD-10 purification the labelled cmAb U36 was stored in 2 ml 0.25 M NaOAc 
with 5 mg ml-1 gentisic acid, pH 5.5, and analysed. The radiochemical purity was always 
96-99%, as determined with ITLC and HPLC. The immunoreactive fraction was determined 
by an overnight immunoreactivity assay (when using 67Ga) and was 81-86%.  The integrity 
of the labelled cmAb U36 was optimal as determined with SDS-PAGE and HPLC analysis 
(data not shown). The radiation dose derived from labelling with 200 MBq 68Ga and its 
subsequent full decay did not affect the integrity and immunoreactivity of the 68/67Ga 
product, which means that our chosen 0.25 M NaOAc with 5 mg ml-1 gentisic acid, pH 
5.5 buffer protected adequately against radiation damage. Dilution of the 68/67Ga-cmAb 
U36 product with human serum to a solution containing 70 pmol/ml Df showed <1% loss 
of label. Upon storage of this solution at 37°C, the radiochemical purity of  cmAb U36 
decreased during 5 h an additional 2% and during 24 h an additional 10%, as determined 
by ITLC and confirmed with HPLC.
Preparation of 68/67Ga-Df-Bz-NCS-7D12 and 89Zr-Df-Bz-NCS-7D12 
Aforementioned conditions applied to Nanobody 7D12 gave 0.2 desferal groups per 
Nanobody molecule. Labelling (200-1000 µg) of the Df-Bz-NCS-7D12 with 68/67Ga resulted 
in overall radioactivity yields of 55-70% (not corrected for decay). Radiochemical purity 
was always 96-99%, as determined by HPLC and ITLC. Immunoreactivity was 40-60% for 
the 3 h incubation assay at 37°C while the overnight assay at 4°C using 67Ga showed 80-
85%. The integrity of the Nanobody was preserved as determined with SDS-PAGE and 
HPLC analysis (see Figure 2). 
For the 89Zr-Df-Bz-NCS-7D12 the overall radioactivity yield was 59-73%, 
radiochemical purity was always 97-99%, and the immunoreactivity was 80-85% 
(determined with the overnight assay at 4°C). 
In vitro stability
In vitro stability of 68/67Ga-Df-Bz-NCS-7D12 was compared with 89Zr-Df-Bz-NCS-7D12. 
Radiochemical purity of 68/67Ga-Df-Bz-NCS-7D12 was 98±1% at the start and only slightly 
decreased during 5 h incubation in buffer at 4°C (1.5–2.0% release of 68/67Ga); after 24 h 
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Figure 3. Biodistribution of 7D12 labelled with 68Ga (black bars) or 89Zr (grey bars) in A431 tumour-bearing nude mice at 1 h 
(a), 2 h (b), and 3 h (c) p.i. Significant differences in uptake are marked with an asterisk. Data is presented as average of four 
mice and standard deviation.
the decrease was 6-7% as determined with ITLC and confirmed with HPLC. For 89Zr-Df-
Bz-NCS-7D12 the radiochemical purity was also 98±1% at the start, which decreased to 
97±1% after 24 h at 4°C. The integrity of both labelled 7D12 Nanobodies was not affected 
after 24 h at 4°C, as determined with SDS-PAGE and HPLC.
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In human serum at 37°C, radiochemical purity of both labelled 7D12 Nanobodies 
slightly decreased during 5 h in human serum (1-2% release of for both compounds) and 
after 24 h the percentage of 68/67Ga that was dissociated was 7–8%, and 1-2% for 89Zr as 
determined by ITLC and confirmed with HPLC.
Biodistribution study
For the biodistribution study nude mice bearing A431 xenografts were injected with either 
0.35±0.05 MBq 68Ga-Df-Bz-NCS-7D12 or 0.35±0.01 MBq 89Zr-Df-Bz-NCS-7D12 as control 
group. After 1 h high uptake was seen in tumour tissue for both radioisotopes (6.1±1.3 
%ID/g for 68Ga and 7.5±1.9 %ID/g for 89Zr), a level which remained constant up to 3 h 
post injection (6.1±0.9 and 7.6±1.9 %ID/g at 2 h, and 7.2±1.5 and 7.4±1.6 %ID/g at 3 h 
post injection for 68Ga and 89Zr, respectively). High radioactivity uptake was found in the 
kidneys, urine and bladder. Except for some liver uptake (2.1±0.1 and 0.7±0.1 %ID/g at 1 
h post injection for 68Ga and 89Zr, respectively) all other organs showed low uptake at all 
time points (< 0.5±0.2 %ID/g for 68Ga and < 0.3±0.1 %ID/g for 89Zr). For both radioisotopes 
tumour to blood ratios increased at later time points. At 1 h the tumour to blood ratio for 
68Ga was 8.2 and increased to 14.4 at 2 h and 25.7 at 3 h post injection, while the tumour 
to blood ratios for 89Zr were 14.8, 35.2 and 42.4 at 1, 2 and 3 h, respectively. In general, the 
overall biodistribution of both radioisotopes was very similar. For all time points significant 
differences between 68Ga and 89Zr were seen in liver and kidney, and at 1 h post injection 
significant difference was also observed for spleen (p<0.001).
PET study
To exclude possible radioactivity uptake in non-evaluated tissues in the biodistribution 
studies a PET imaging study was performed. In Figure 4 representative PET images are 
shown; a static PET image obtained 2-3 h after injection of 68Ga-Df-Bz-NCS-7D12 is seen in 
the left image while the right image represents a mouse 2-3 h after injection of 89Zr-Df-Bz-
NCS-Df. In both images the tumours are clearly visible, with good tumour to background 
contrast. High accumulation in the kidney and bladder was observed.
Discussion
In this present study, we describe a method for labelling of αEFGR Nanobody 7D12 with 68Ga 
using the novel bifuntional desferal chelate (Df-Bz-NCS) which was previously introduced 
for the coupling of 89Zr to intact mAbs [22, 23]. Using this method, stable 68Ga-7D12 
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radioimmunoconjugates were produced as demonstrated by stability testing in storage 
buffer as well as in human serum with only slightly less stability as compared with the 
reference compound 89Zr-Df-Bz-NCS-7D12. In addition, high and selective tumour uptake 
was observed in biodistribution and PET imaging experiments in nude mice bearing A431 
xenografts, which was similar for 68Ga-7D12 and the reference conjugate 89Zr-7D12. The 
latter indicates that Df-Bz-NCS is equally well suited for immuno-PET imaging, irrespective 
whether the short-lived positron emitter 68Ga or the long-lived positron emitter 89Zr is 
used. 89Zr-Df-antibodies have been extensively evaluated in clinical immuno-PET studies 
[33].
 Crucial in the labelling procedures described herein are (1) the use of ultra pure 
HCl, to keep the natGa concentrations as low as possible and also to minimize the amounts 
of Al, Fe and Zr, being strong competitors for complexation with Df, (2) the purification and 
concentration of 68Ga by use of an anion exchange column, to further minimize the amounts 
of Al, Fe and Zr, to get rid of contaminating metals originating from the generator and to 
keep [68GaCl
4
-] volumes for labelling small [16, 34], (3) the addition of a highly concentrated 
NH
4
OAc solution to the [68GaCl
4
-]-solution for efficient radiolabelling and stable complex 
formation (avoidance of the formation of gallium-oxo-chloro intermediates), (4) the use 
of a commercially available desferrioxamine B chelate that has been applied clinically in 
a safe way for many years [23], (5) radiolabelling at room temperature within a relatively 
wide pH range of 5.0–6.5, and (6) the use of 0.25 M NaOAc with 5 mg ml-1 gentisic acid, pH 
5.5 for protection during storage of the purified 68Ga-labelled conjugate. These procedures 
appeared efficient and mild, thus avoiding denaturation of protein, and resulted in 
optimal quality conjugates at an overall radiochemical yield of 55-70% (not corrected for 
decay). Therefore, these generic procedures seem suitable for GMP compliant labelling, 
irrespective the intrinsic stability of the biomolecule. 
 The only chelate that has been used for 68Ga-labelling of mAbs or mAb-like 
molecules for clinical purposes is DOTA [35]. With DOTA the best labelling kinetics were 
obtained in sodium acetate buffers at low pH [36]. Tolmachev et al. evaluated the 68Ga 
labelling kinetics of the DOTA containing anti-HER2 Affibody ABY-002. Labelling at room 
temperature for 5 minutes appeared inefficient (decay-corrected yield of less than 5%). 
Only after elevation of the temperature to 60°C or 90°C the yield increase to ~30 and 
~90%, respectively. The binding and pharmacokinetic characteristics of this particular 
Affibody did not become affected upon labelling, but it is open to question whether other 
proteins can resist the harsh labelling conditions of low pH and high temperature [35, 
37]. The same holds true for microwave heating that has been used for labelling of DOTA-
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bioconjugates with 68Ga [16, 38]. In our initial studies, using DOTA-Bz-NCS, less than 60% 
labelling was obtained after 20 min at 45°C, while the thus obtained labelled product 
was unstable. We postulate that at lower temperature no full N-coordination occurs. 
This means that the 68Ga-atom becomes ligated to the carboxyl functions of the DOTA 
molecule with still having water molecules in its coordination sphere instead of N, and 
that only concordant heating at elevated temperatures [37, 39] creates the additional 
N-coordination of the DOTA molecule leading to the 68Ga-DOTA-complex that is suitable 
for in vivo applications. This important aspect of complex formation is fully analogous to 
what has been shown by us for the synthesis of the 186Re-MAG3-complex [40]. 
NOTA and its derivatives as well as the recently introduced HBED-CC chelates 
might have advantages over DOTA, since labelling with these chelates can be performed 
at room temperature and modest pH [19-21, 41]. These chelates, however, have not been 
clinically evaluated yet, and for us this was the reason to evaluate the desferrioxamine B 
derivative.  Some controversy exists about the conditional stability constant of the Ga-Df 
complex at neutral pH. The in vitro stability we found corresponds well with the earlier 
findings of Smith-Jones et al. [25], Fani et al. [27], and Furukawa et al. [24], but seems to 
be rather in contrast with the findings of Caraco et al. [42] and Govindan et al. [26]. We 
feel that this is only an apparent controversy because the conditions under which Caraco 
et al. produced their Ga-Df-complex are completely different. We observed that a product 
formed at pH = 7.4 indeed suffered from instability indicating that at this pH a certain 
amount of weak complexes are formed containing partly hydrolyzed Ga ions and so being 
only mono- or bidentate bound to the three hydroxamate functions. With respect to the 
findings of Govindan et al. [26], they already suggested themselves that their findings 
are most probably mixed up by the fact that the linkages between their mAb and Df are 
intrinsically instable.
EGFR, a tyrosine kinase receptor, is highly expressed in many epithelial cancer 
cells and is a prime target for detection and therapeutic applications. Nuclear imaging 
techniques have a proven advantage over immunohistological techniques since nuclear 
imaging is noninvasive and whole-body scans can be obtained [43]. The use of Nanobodies 
as imaging moiety might have advantages over the use of intact mAbs, since a molecular 
weight of only 15 kDa allows for faster kinetics than intact mAbs in vivo. To our knowledge, 
Nanobodies have never been used for immuno-PET applications. In this study, 68Ga-
labelled Nanobody 7D12 showed high and selective uptake in A431 tumours, ranging from 
6.1 to 7.2 %ID/g at 1-3 h p.i., which was comparable to the reference compound  89Zr-7D12 
(7.5 to 7.4 %ID/g at 1-3 h). Significant differences in liver and kidney uptake were observed 
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between the 68Ga-7D12 and 89Zr-7D12 conjugates. These differences most probably reflect 
the slightly lower stability observed in the in vitro stability experiments. Maybe metabolite 
analyses might provide further insight. 
Huang et al. and Gainkam et al. [44, 45] studied the same (αEGFR) Nanobody 
7D12 in the same A431 xenograft model, but labelled with technetium-99m (99mTc) for 
SPECT applications. Tumour uptake of 99mTc-7D12 was 4.9 %ID/g at 1 h p.i. (assessed by 
quantitative analysis of SPECT images) and 6.1 %ID/g at 1.5 h p.i. (assessed by radioactivity 
counting of dissected tumours). Like 68Ga-7D12, 99mTc-7D12 showed high kidney uptake. 
However, uptake of 99mTc-7D12 in lung and spleen was higher than that of 68Ga-7D12: 2.1 
and 1.4 %ID/g versus 0.5 and 0.6 %ID/g, at 1 h p.i.. Given the superior properties of PET in 
comparison to SPECT for clinical quantitative imaging, these data suggests that 68Ga-7D12 
is the more attractive Nanobody-based probe for assessment of EGFR expression [46, 47].
  68Ga-7D12 allowed high contrast imaging at relatively early time points (1 h p.i.) in 
comparison with radiolabelled conventional intact mAbs used in other preclinical imaging 
studies. For example, in recent immuno-PET studies with 64Cu- and 89Zr-labelled anti-EGFR 
mAb cetuximab tumours could only be clearly delineated 16-24 h p.i. [7, 9, 48]. Another 
interesting small molecular protein was introduced for imaging of EGFR, namely the 8-kDa 
Affibody Z
EGFR:2377
 [49]. PET imaging studies in A431-bearing nude mice showed higher 
tumour contrast when 50 μg of 111In-labeled Z
EGFR:2377
 was injected in comparison to 5 μg, 
whereas for both doses high liver uptake was observed. For the 50 μg
 
111In-Z
EGFR:2377 
group, 
tumour and liver uptake at 4 h p.i. was 2.4 and 5.1 %ID/g, respectively. In comparison, 
tumour uptake of 68Ga-7D12 in the present study was substantially higher (7.2 %ID/g at 
3 h p.i.), while liver uptake was lower (2.0 %ID/g at 3 h p.i.). These interesting differences 
in uptake can be ascribed to differences in reactivity with murine EGFR. Both probes can 
bind to human EGFR expressed in human xenografts, but only 111In-Z
EGFR:2377 
can also bind 
to the murine EGFR in the liver. In accordance, initial clinical imaging studies with 111In-
labeled anti-EGFR mAb 225 showed high liver uptake, requiring relatively high mAb doses 
for imaging of EGFR expression [50]. 
Aforementioned data indicate 68Ga-7D12 Nanobody has potential for assessment 
of EGFR tumour expression; however, for clinical application thorough dose optimization 
might be needed to obtain optimal imaging results. The latter will be easier for 68Ga-
labelled Nanobodies directed against targets that show predominantly expression in the 
tumour, as was recently illustrated in PET imaging studies with 68Ga-labelled Affibody ABY-
002 directed against the HER2 receptor [35].
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Conclusion
The newly developed GMP-compliant two-step procedure for coupling desferal to a 
Nanobody allows efficient and rapid preparation of 68Ga-Nanobodies for clinical use with 
high labelling yields, high radiochemical purity and preservation of immunoreactivity. The 
anti-EGFR 68Ga-Df-Bz-NCS-7D12 Nanobody showed high accumulation in A431 xenografts 
in nude mice in biodistribution studies as well as in immuno-PET, which indicates that  this 
conjugate can be a promising fast kinetic noninvasive imaging probe for the detection of 
EGFR expression in tumours. 
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Abstract
The epidermal growth factor receptor (EGFR) has been shown to be a valid cancer target 
for antibody-based therapy. At present, several anti-EGFR monoclonal antibodies (mAbs) 
have been successfully used, such as cetuximab and matuzumab. X-ray crystallography 
data show that these antibodies bind to different epitopes on the ecto-domain of EGFR, 
providing a rationale for the combined use of these two antibody specificities. We have 
previously reported on the successful isolation of antagonistic anti-EGFR nanobodies. In 
our study, we aimed to improve the efficacy these molecules by combining nanobodies with 
specificities similar to both cetuximab and matuzumab into a single biparatopic molecule. 
Carefully designed phage nanobody selections resulted in two sets of nanobodies that 
specifically blocked the binding of either matuzumab or of cetuximab to EGFR and that did 
not compete for each others’ binding. A combination of nanobodies from both epitope 
groups into the biparatopic nanobody CONAN-1 was shown to block EGFR activation 
more efficiently than monovalent or bivalent (monospecific) nanobodies. In addition, this 
biparatopic nanobody potently inhibited EGF-dependent cell proliferation. Importantly, 
in an in vivo model of athymic mice bearing A431 xenografts, CONAN-1 inhibited tumour 
outgrowth with an almost similar potency as the whole mAb cetuximab, despite the fact 
that CONAN-1 is devoid of an Fc portion that could mediate immune effector functions. 
Compared to therapy using bivalent, monospecific nanobodies, CONAN-1 was clearly 
more potent in tumour growth inhibition. These results show that the rational design of 
biparatopic nanobody-based anti-cancer therapeutics may yield potent lead molecules 
for further development.
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Introduction
The epidermal growth factor receptor (EGFR) is a member of a family of four receptor 
tyrosine kinases (RTK), named Her- or cErbB1, -2, -3 and -4. The EGFR has an extra-cellular 
domain (ECD) which is composed of four sub-domains, two of which are involved in ligand 
binding and one of which is involved in homodimerisation and heterodimerisation1,2 
(for review, see Ref. 3). EGFR integrates extracellular signals from a variety of ligands to 
yield diverse intracellular responses4,5. The major signal transduction pathway activated 
by EGFR is composed of the Ras-mitogen-activated protein kinase (MAPK) mitogenic 
signalling cascade. Activation of this pathway is initiated by the recruitment of Grb2 to 
tyrosine-phosphorylated EGFR6,7. This leads to activation of Ras through the Grb2-bound 
Ras-guanine nucleotide exchange factor Son Of Sevenless. In addition, the PI3-kinase-Akt 
signal transduction pathway is also activated by EGFR, although this activation is much 
stronger in case there is co-expression of Her38, 9.
The EGFR is implicated in several human epithelial malignancies, notably cancers 
of the breast, lung, colon, head and neck and brain10. Activating mutations in the gene 
have been found, as well as over-expression of the receptor and of its ligands, giving rise to 
autocrine activation loops (for review, see Ref 11). This RTK has therefore been extensively 
used as target for cancer therapy. Both small molecule inhibitors targeting the RTK and 
monoclonal antibodies (mAbs) directed to the extracellular ligand-binding domains have 
been developed and have shown hitherto several clinical successes, albeit mostly for a 
select group of patients12.
From the crystal structures of the Fab fragments of several therapeutic mAbs 
in complex with the ECD of EGFR13-15, much knowledge about the working mechanisms 
of these antibodies has been gathered over the years (for review, see Ref. 16). Most 
therapeutic antibodies target the ligand-binding domain III of the EGFR.  One antibody 
(mAb806) has been reported to recognise an unfolded region of the EGFR that is only 
exposed when cells either over-express EGFR or express a deletion mutant (de2-7 or 
variant (v) III) of the receptor17,18. The domain III-specific, therapeutically used antibodies, 
either occupy EGF contact residues directly (shown for cetuximab and panitumumab13, 
14), or bind outside the EGF contact area and sterically inhibit the conformational change 
necessary for receptor activation (as was shown for matuzumab15). The effects of the 
combined use of the chimeric mAb cetuximab (derived from murine mAb 225) and 
humanised mAb matuzumab (derived from the murine mAb 425) on EGFR signalling has 
recently been investigated and this combination was indeed shown to work well in EGFR 
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inhibition19.
We have previously reported the generation and use of camelid-derived single- 
domain antibody fragments (termed variable domain of the heavy chain of heavy chain 
antibodies (VHH) or Nanobody1) directed to EGFR in therapy of non-established tumours.20 
The single-domain nature of these fragments allows for the combination of different 
nanobodies with different specificities in one molecule: a biparatopic nanobody20,21 (for 
review, see Ref. 22). The aim of the current study was to obtain anti-EGFR nanobodies with 
improved therapeutic efficacy by synthesising biparatopic molecules that would combine 
the specificities of the two domain III-specific anti-EGFR antibodies, i.e., cetuximab and 
matuzumab. We obtained antagonistic nanobodies that competed for the binding of either 
cetuximab or matuzumab to the receptor. When combined into one single nanobody 
format, together with an albumin-binding nanobody for in vivo half-life extension,20,23,24, 
this nanobody CONAN-1 was shown to be a potent receptor antagonist. Importantly, 
our results show that in a mouse model of established A431 xenografts, this biparatopic 
nanobody format was very potent in inhibiting tumour outgrowth.
Materials and Methods
E.coli strain and cell lines
The bacterial strain used was TG1.25 The epidermoid squamous carcinoma cell line A43126 
carrying an amplification of the EGFR gene27, was purchased from the American Type 
Culture Collection (ATCC, cat. no. CRL-1555). Her14 cells are derived from National Institutes 
of Health (NIH) 3T3 fibroblasts and stably express roughly 105 copies of the human EGFR 
on their cell surface28. The human head and neck squamous cell carcinoma (HNSCC) cell 
line UM-SCC-14C (14C) was a kind gift of Dr. T.E. Carey (Ann Arbor, MI, USA). All cells were 
cultured in Dulbecco’s modification of Eagle medium (DMEM; Gibco, Invitrogen, Paisley, 
UK) containing 7.5% (v/v) foetal calf serum (FCS) and 2 mM L-glutamine in a humidified 
atmosphere without antibiotics at 37°C under 5% CO
2
.
Plasmids and constructs
The complementary DNA (cDNA)- encoding scFv 42529, cloned as bispecific single-chain 
Fv antibody fragment in pSecTag,30 was a kind gift of Dr. Van Beusechem (Department of 
Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands). The cDNA 
was re-cloned from pSecTag in a bacterial expression vector identical to pUR585031, except 
lacking the C-terminal biotinylation sequence (LRSIFEAQKMEW). Induction of protein 
1	  The term Nanobody® is a registered trademark of Ablynx and is used with permission.
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expression in E.coli and purification of scFv from the periplasmic space using Immobilise 
Metal ion Affinity Chromatography (IMAC) were performed as has been described.25 The 
construct encoding the EGFR-ECD (amino acides 1-614) fused to a human IgG1 Fc gene 
was a kind gift of Prof. Dr. E.J.J. van Zoelen (Centre for Molecular Life Sciences, Radboud 
University, Nijmegen, the Netherlands). The construct was used to express EGFR-ECD-Fc 
fusion protein from an in-house developed expression vector using Hek293E cells. After 
3 days of culture, cellular supernatant was collected and fusion protein was purified by 
means of protein G affinity chromatography.
Selection of high affinity- and of cetuximab cross-reactive anti-EGFR nanobodies
EGFR “immune” phage nanobody repertoires used for selections had been synthesised 
as previously described20 and were a kind gift of Dr. E.G. Hofman (Cell Biology, Utrecht 
University, the Netherlands)32. Selections were performed on recombinant, purified 
and biotinylated EGFR–ECD (amino acids 1-614; Ref. 33). The protein was biotinylated 
using biotin amido hexanoic acid 3-sulfo-N-hydroxy succinimide ester (Sigma-Aldrich, 
Zwijndrecht, the Netherlands). For affinity selections, antigen concentrations used were 
100, 50, 20, 10 and 1 pM. Phage (roughly 1010 colony-forming units) and antigen were 
mixed in a total volume of 100 µl phosphate buffered saline (PBS) containing 1% (w/v) 
casein and incubated for 3 hrs at room temperature while shaking. For off-rate selection34, 
a 100-fold molar excess of non-biotinylated antigen (EGFR-ECD-Fc fusion) was added and 
incubated for another 3 hours at room temperature. Phage bound to biotinylated antigen 
were then captured in an extravidin-coated well (5 µg/ml in PBS) of a Maxisorp plate (Nunc, 
Rochester, NY) for 15 minutes at room tepmerature. Non-bound phage were removed 
by extensive washing with PBS containing 0.1% (v/v) Tween-20,  and bound phage were 
eluted with trypsin (1 mg/ml in PBS) for 10 minutes at room temperature. Trypsin was 
finally inhibited by the addition of 2,2’-azino-bis(3-ethyl-benzthiazoline-6-sulphonic acid 
(ABTS) (1 mM), and selected phage were used to infect TG1 as described previously35.
For the selection of cetuximab-competitive nanobodies, the method of competitive 
elution36 was used. Briefly, biotinylated EGFR-ECD (4 µg/ml) was captured in a neutravidin-
coated (5 µg/ml overnight in PBS at 4°C) Maxisorp plate for 1 hr at room temperature. 
Phage were allowed to bind for 2 hrs in PBS/0.5% (w/v) casein, and subsequently, plates 
were thoroughly washed (as described previousy). Phage bound to overlapping epitopes 
on EGFR as the one recognised by cetuximab were then eluted by incubation with 200 µg/
ml cetuximab in PBS for four hours at room temperature.
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Competition ELISA
Maxisorp plates were coated with a rabbit polyclonal anti-human IgG serum (1:2000 in 
PBS; Dako, Glostrup, Sweden) overnight at 4°C. Next day, wells were washed with PBS, 
blocked with 2% (w/v) bovine serum albumin (BSA) in PBS (PBS/BSA; 30 min at room 
temperature), and purified EGFR-ECD-Fc was captured at 0.75 µg/ml in PBS/BSA for 1 hr 
at room temperature. All further incubations were performed in PBS/BSA.
For EGF competition, wells were washed with PBS and a mix of nanobody [either 
crude periplasmic extract (50% (v/v) in PBS/BSA) or varying concentrations of purified 
Nanobody] in 800 pM of biotinylated EGF (Molecular probes/Invitrogen, Carlsbad, CA) 
was added. After incubation for 1 hr at room tempeature, wells were washed again, 
and bound EGF was detected with peroxidase-coupled streptavidin (1 in 5000 in PBS/
BSA; Jackson ImmunoResearch Laboratories, Suffolk, England) and staining with ortho-
phenylene diamine (OPD)/H
2
O
2
.
For cetuximab, mab 425 or nanobody competition, monoclonal phage were 
prepared as described.35 Roughly 1010 phage were mixed with a 100-fold molar excess of 
either cetuximab, the 425 scFv or nanobody in 2% (w/v) Marvel (skimmed milk powder) in 
PBS (MPBS), and the mix was added to coated wells containing the EGFR ECD-Fc in triplicate. 
Bound phage was detected with a peroxidase-coupled antibody to M13 (1:10000 in MPBS; 
Amersham/GE Healthcare, Uppsala, Sweden) and staining with OPD/H
2
O
2
. Optical density 
was read at 490nm.
Re-cloning and expression of selected Nanobody-genes
The cDNA-encoding nanobody Alb1 was made synthetically37 using the sequence 
information published in patent WO2006/122786. For the synthesis of bivalent and 
trivalent nanobodies, nanobody-encoding genes were PCR-amplified using the Expand 
High Fidelity PCR System (Roche, Mannheim, Germany) with an appropriate primer set, 
purified, cut with restriction enzymes and cloned into Sfi1-BstEII cut pUR 585031. Linker 
sequences [composed of Gly4-Ser (G
4
S) repeats] were encoded in the primers, making it 
possible to vary the length of the linker separating two nanobody genes. Constructs were 
sequenced38 to verify that no mutations were introduced by PCR. Protein expression in 
E.coli TG1 and purification were performed as described25.
Inhibition of EGFR signalling by selected nanobodies and test for EGFR agonism
The assays measuring the inhibition of EGF-induced EGFR activation by nanobodies and 
detecting possible agonistic effects of nanobodies on the receptor were performed as 
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described previously.20 To demonstrate that equal amounts of cell lysate were loaded in 
each lane, blots were stained for either for β-actin, or for tubulin.
Inhibition of cell proliferation by nanobodies
Measurement of inhibition of cell proliferation by nanobodies or cetuximab using the 
sulpho-rhodamine B (SRB) assay39 was performed as described previously20.
Affinity measurements and pharmacokinetics
Nanobodies were 125I-labelled according to the IODO-GEN method,40 as described by 
Visser et al.41.
For affinity measurements, UM-SCC-14C cells were seeded a day before the assay 
in 24-well tissue culture plates (Corning, Amsterdam, The Netherlands) at 100000 cells 
per well. 125I-labelled nanobodies were diluted in binding medium [DMEM, containing 7.5 
% (v/v) FCS, 25 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) and 2 
% (w/v) Marvel] and added to cells in triplicate. After 2 hrs of incubation at 4°C, non-
bound nanobody was removed by washing twice with ice-cold PBS. Bound nanobody was 
then quantified by lysis of the cells in 1 M NaOH and quantification of the radio-activity 
using a gamma counter (Wallac, Turku, Finland). Results were analysed with the Graph 
Pad software.
Measurement of in vivo pharmacokinetics with 131I-7D12-9G8-Alb1 was performed 
in tumour-bearing mice essentially as described24. Next to a therapeutic dose of trivalent 
nanobody (in Group 2 in the “Therapy study” section), each mouse was injected intra-
peritoneally (i.p.) with 0.33 MBq of radiolabelled nanobody (7.5 µg), and blood was drawn 
at 2, 6, 24, 48, and 72 hrs post injection (p.i.) to determine detailed pharmacokinetics.
Therapy study
The therapy study was performed essentially as described before20. However, therapy 
was started when tumours were established, and the average size of the tumours was 
approximately 100mm3. Group 1 received PBS twice a week during 5 weeks, Group 2 
received nanobody and Group 3 received cetuximab. Together with the second and seventh 
dose of nanobody administration, pharmacokinetics were determined in the nanobody-
treated group. Anti-tumour effects were expressed by a growth delay factor (GDF), which 
was defined as the difference in the median time tumours needed to quadruple in the 
treated group and in the control group, divided by the median quadrupling time of the 
control group.
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Results
Our study set out to improve the inhibitory capacity of anti-EGFR nanobodies by generating 
bi-paratopic molecules that are specific for different epitopes on domain III of the EGFR. 
Therefore, phage nanobody selections were performed using the purified ecto-domain 
of EGFR as target antigen and “immune” phage nanobody repertoires.20,32 To obtain the 
different nanobody specificities, we made use of the mAbs cetuximab and matuzumab 
that were shown to bind to different and non-overlapping epitopes on domain III of the 
EGFR13,15,16. We first set out to obtain antagonistic nanobodies with the highest affinity 
possible, by performing phage selections on very low amounts of biotinylated antigen 
in solution, combined with “off-rate selections”34. When selected nanobody clones were 
tested for EGF competition, six clones (out of 180 clones screened) were found to inhibit 
the binding of EGF to the EGFR (data not shown). These were subsequently screened for 
their kinetic dissociation rate constant (k
off
). Dissociation rate constants were found to vary 
between 2 and 150 x 10-4 s-1 (Table 1). Because of their low dissociation rate constants, 
clones 9G8 and 38G7 were then selected for further characterisation (the amino acid 
sequences of these selected nanobodies can be found in the Supporting Information).
Table 1.  Kinetic dissociation rate constants of selected antagonistic anti-  
 EGFR nanobodies as measured by SPR using BIAcore
After protein production and purification, the IC
50 
for EGF binding to EGFR for 
both nanobodies was measured in enzyme-linked immuno-sorbent assay (ELISA) and 
found to be 6-7 nM for the 9G8 nanobody and 10 nM for the 38G7 nanobody (Fig. 1a). 
As the 9G8 nanobody showed a lower IC
50
 for EGF binding, expressed to a much higher 
level in E.coli and because the 38G7 amino acid sequence contained some very unusual 
Nanobody	   koff	  (10
-­‐4	  s-­‐1)	  
	   	  
27H7	   31.2	  
27E5	   20.4	  
27C7	   12.4	  
27E8	   17.3	  
9G8	   4.0	  
38G7	   2.0	  
7C12	   150	  
7D12	   25	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amino acids at several key positi ons (data not shown), the 9G8 nanobody was selected for 
further engineering. To gain insight into the epitope specifi city of the selected anti -EGFR 
antagonists, selected nanobodies were tested for their competi ti on for binding to the 
EGFR with the whole anti body cetuximab or the scFv of the 425 anti body (matuzumab). 
Surprisingly, all the selected nanobodies competed with the 425 scFv for binding, but not 
with cetuximab (shown for 9G8 in Fig. 1b).
Figure 1. In vitro characterisati on of selected monovalent anti -EGFR nanobodies
(a) The binding of bioti nylated EGF (800 pM) to an EGFR-ECD-Fc fusion was tested in the presence of increasing amounts of 
the 9G8, 7D12, 7C12 or 38G7 nanobodies, or without nanobody. Receptor-bound EGF was then detected via peroxidase-
coupled streptavidin and staining with OPD/H
2
O
2
. (b-d) The binding to EGFR of the 9G8, 7D12 and 9G8 nanobody, expressed 
on phage, was detected in a 100-fold molar excess of the indicated anti body (cetuximab) or anti body fragments.
A B
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We then specifi cally sought to select nanobodies that would recognise an epitope 
that overlapped with that of cetuximab by using the method of competi ti ve eluti on36 
with the anti body cetuximab. Selected nanobodies were subsequently tested for EGF 
antagonism, as well as for competi ti on with cetuximab for binding to EGFR in ELISA. Two 
nanobodies were selected (called 7C12 and 7D12) that blocked the binding of EGF to the 
EGFR (Fig. 1a) and indeed competed for the binding of cetuximab and not for that of the 
scFv of matuzumab (shown for the 7D12 nanobody in Fig. 1c). Based on its lower IC
50 
for 
EGF binding (8 vs 30 nM: Fig. 1a) and lower off -rate (2.5 x 10-3 vs 1.5 x 10-2 s-1; Table 1), 
the 7D12 nanobody was then selected for further engineering. However, the fact that 
the 7D12 and 9G8 nanobodies competed for binding to EGFR with two mAbs that do not 
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Table 2. Affinity values of anti-EGFR nanobodies as meausred by binding of 125I-labelled nanobody to live cells.
Nanobody KD (nM) 
on 14C cells
KD (nM) 
on A431 cells
9G8 14.4 13.8
7D12 10.4 25.7
7D12-7D12 2.1 4.6
9G8-9G8 2.8 10.7
9G8-7D12 7.1 7.5
7D12-9G8 3.1 5.4
block each others’ binding13,15 does not necessarily mean that they did not compete for 
each others’ binding. To confirm that the 7D12 and 9G8 nanobodies indeed had different 
epitope specificities, they were tested for competitive binding to immobilised EGFR. 
Indeed, and as expected, 7D12 and 9G8 did not compete for each others’ binding to EGFR 
(Fig. 1d).
The linking of two nanobody “heads” into bivalent molecules has already been 
shown to increase the potency of such molecules20,42. To find the optimal bivalent anti-
EGFR nanobody combination, the 7D12 and 9G8 nanobody-encoding genes were re-
formatted into bivalent molecules21 in all possible combinations, bivalent, mono-specific, 
or dual-specific/bi-paratopic, using a standard flexible linker of 10 amino acids (in G
4
S 
repeats). The affinities of the monovalent nanobodies, as well as that of the bivalent and 
biparatopic nanobodies were then determined by binding of 125I-labelled nanobody to 
live cells. As expected, bivalent molecules had higher affinities than the corresponding 
monovalent counterparts (Table 2). The mono-specific 7D12-7D12 had the highest affinity, 
followed by the 7D12-9G8 biparatopic molecule.
Subsequently, all constructs were tested for their capacity to inhibit EGF-induced 
EGFR phosphorylation and EGF-dependent cell proliferation. All nanobodies dose-
dependently inhibited the EGF-induced phosphorylation of tyrosine (Y) 1068 of the EGFR 
(Fig. 2). As phosphorylation of Y1068 of the EGFR has been reported to be the initiation 
of signalling towards Ras6, this phosphorylation site of EGFR was measured. The best 
inhibition was achieved with the bivalent 7D12 nanobody and biparatopic molecules 
9G8-7D12 and 7D12-9G8. However, the first two showed a slight increase in receptor 
phosphorylation at the highest nanobody dose used (Fig. 2), a phenomenon that was 
not observed for the 7D12-9G8 biparatopic molecule. These results clearly show that the 
biparatopic anti-EGFR nanobody 7D12-9G8 performed best in inhibiting EGFR signalling.
When tested for their capacity to inhibit tumour cell proliferation, all nanobodies 
inhibited the growth of A431 cells (Fig. 3). For comparison, the whole mAb cetuximab 
was used as reference in all experiments. The biparatopic nanobody 7D12-9G8 proved 
as effective as cetuximab in reducing the growth of A431 cells (Fig. 3d). Both bivalent, 
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monospecific nanobodies 7D12-7D12 and 9G8-9G8 proved less effective in inhibiting the 
proliferation of A431 cells (Fig. 3a and b) than cetuximab or the 7D12-9G8 nanobody. 
For both bivalent, monospecific molecules increased cell proliferation was observed at 
higher nanobody concentrations, consistent with the observed increased level of EGFR 
phosphorylation (Fig. 2). Also, mixtures of monovalent 7D12 and 9G8 or of bivalent 7D12 
and bivalent 9G8 were not as potent as the biparatopic 7D12-9G8 molecule in inhibiting 
A431 cell proliferation (Fig. 3). The biparatopic 9G8-7D12 molecule also slightly stimulated 
the growth of A431 cells at low nanobody concentrations, again in agreement with the 
increased levels of phosphorylated EGFR observed on blot (Fig. 2). These data provide 
strong support for the choice of the 7D12-9G8 as the most effective biparatopic nanobody 
combination. In addition, they show that the order of the two heads was critically 
important for the activity of this biparatopic nanobody. Based on these results, the 7D12-
9G8 molecule was selected for further optimisation and in vivo testing.
An important characteristic of the 7D12-9G8 molecule is the linker length and 
linker composition connecting the two heads. This linker is supposed to provide sufficient 
Figure 2. Inhibition of EGF-induced EGFR 
phosphorylation by monovalent and bivalent 
nanobodies EGF (8 nM) was mixed with 
increasing amounts of nanobody (monovalent 
7D12 and 9G8; bivalent 7D12 and 9G8 and 
bi-paratopic nanobodies 7D12-9G8 and 9G8-
7D12) and the resulting mixtures were added 
to Her14 cells. After stimulation for 15 min, 
cell lysates were prepared, and proteins 
were size separated and blotted to PVDF 
membranes. Membranes were then stained 
for phosphorylated EGFR (Y1068) and for the 
total amount of tubulin as loading control.
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Figure 3. Inhibition of A431 tumour cell proliferation by monovalent and bivalent nanobodies (a-d) The proliferation of A431 
cells in the presence of increasing amounts of nanobody [(a) monovalent and bivalent 9G8; (b) monovalent and bivalent 
7D12; (c) mixtures of monovalent and bivalent 7D12 and 9G8 and (d) biparatopic molecules 7D12-9G8 and 9G8-7D12] was 
measured using a sulphorhodamine-based stain of total cellular protein after TCA precipitation. Proliferation is plotted 
as percentage of maximal growth (cells left without treatment). The whole antibody cetuximab was used as ‘standard’ in 
every test. Data points where the value of the control is statistically different from that of the nanobody-treated group are 
indicated by an asterix. (c) Only different between 7D12+9G8 and control; (d) only different between 9G8-7D12 and control.
space/length and freedom to allow the two nanobodies to bind (chelate43) simultaneously 
to the same EGFR molecule. We therefore analysed the effect of flexible linkers consisting 
of G
4
S repeats varying in length from 5 to 30 amino acids. The resulting bivalent constructs 
were then tested for their ability to inhibit A431 cell proliferation. Surprisingly, the length 
of the linker used between the two nanobody heads turned out to be almost inversely 
correlated with the efficacy of the molecule in inhibiting A431 cell proliferation, with 5- 
and 10- amino acids linkers being optimal (Fig. 4a). Therefore, a linker of 10 amino acids 
was chosen as the optimal format for the anti-EGFR 7D12-9G8 bi-paratopic nanobody.
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Since the 7D12-9G8 nanobody has a molecular weight of roughly 30 kDa, it would 
be cleared very rapidly in vivo via the kidneys once injected into the blood stream of 
mice44. To prolong the in vivo half-life of small proteins, binding to albumin has been 
reported to be an excellent option.20,23,24 Therefore, the gene encoding the anti-mouse 
serum albumin (MSA)/human serum albumin (HSA) nanobody Alb1 (this nanobody 
recognises both MSA as well as HSA with a equilibrium dissociation constant (KD) of 6.5 
nM for MSA and 0.57 nM for HSA) was made synthetically37 and fused C-terminally to 
the biparatopic 7D12-9G8 nanobody using two different linker lengths (15 or 30 amino 
acids in repeats of Gly
4
-Ser) between the anti-EGFR nanobodies and Alb1. First, trivalent 
nanobodies were tested for their functionality in ELISA: the binding of biotinylated MSA 
to EGFR-bound 7D12-9G8 and 7D12-9G8-Alb1 was assessed and shown to depend on 
the presence of the Alb1 nanobody (Fig. 4b). These results show that at least one of the 
anti-EGFR heads together with the Alb1 nanobody present in the same trivalent molecule 
could simultaneously bind antigen. Since in an in vivo (therapy) situation, albumin will be 
abundantly present, both trivalent nanobodies (containing either a 15- or 30-amino acid 
linker before the Alb1 nanobody) were then tested for their capacity to inhibit A431 cell 
proliferation in the presence of 1 % (w/v) HSA. The construct containing a 15-amino acid 
linker before the Alb1 nanobody significantly lost potency in the presence of HSA (data 
not shown). However, for the construct containing a 30-residue linker between the anti-
EGFR units and Alb1 unit, efficacy in inhibition of cell proliferation was not affected by the 
presence of HSA (Fig 4c). Therefore, this version was selected for further in vivo testing 
and was named COoperative NANobody-1 (CONAN-1).
To check whether the CONAN-1 nanobody by itself did not induce activation of 
the EGFR, the nanobody was given as ligand at high concentration to EGFR overexpressing 
cells (Her14 cells). Figure 4d shows that CONAN-1 did not cause receptor activation in the 
absence of EGF, whereas cells readily responded to EGF stimulation. Finally, the CONAN-1 
nanobody was shown to strongly inhibit EGF induced signalling (Fig. 4e): not only receptor 
phosphorylation was inhibited (Fig. 2), but also the phosphorylation of MAPK reduced to 
background levels. These results show that the CONAN-1 nanobody functioned as a true 
receptor antagonist and it was therefore tested in an in vivo therapy study.
To measure blood pharmacokinetics of the CONAN-1 molecule, a trace amount 
of radiolabelled nanobody was injected intravenously in the tail vein of tumour-bearing 
mice, together with a therapeutic dose of nanobody. Blood sampling revealed an in vivo 
half-life of approximately 48 hrs (Fig. 5a), when fitted to a monoexponential decay. In a 
murine model of established A431 human xenografts in athymic mice, the administration 
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Figure 4. In vitro opti malisati on and characterisati on of trivalent biparatopic nanobody CONAN-1 (a) The proliferati on 
of A431 cells in the presence of increasing amounts of biparatopic nanobody 7D12-9G8 (with linkers varying in length 
between the two nanobody units) was measured using a sulphorhodamine-based stain of total cellular protein aft er TCA 
precipitati on. Proliferati on is plott ed as percentage of maximal growth (cells left  without treatment). Error bars have been 
omitt ed to increase the clarity of the fi gure. The diff erent linker lengths between the two nanobodies are indicated. (b) 
Purifi ed EGFR-ECD-Fc fusion protein was immobilised via a coated anti -human Fc anti -serum, and a concentrati on range of 
either bivalent (7D12-9G8) or trivalent (CONAN-1) nanobody was bound. The binding of bioti nylated mouse serum albumin 
(MSA) was subsequently detected with peroxidase-conjugated streptavidin and staining with OPD/H
2
O
2
. (c) The proliferati on 
of A431 cells in the presence of increasing amounts of nanobody was measured using the sulphorhodamine B assay. The 
eff ect of the presence of human serum albumin (HSA: 1%) in the medium was assessed. (d) EGF (8 nM) or nanobody (1 
µM) was added to serum-starved Her14 cells (-). Aft er sti mulati on for 15 min, cell lysates were prepared, and proteins were 
size separated and blott ed to PVDF membranes. Membranes were then stained for phosphorylated EGFR (Y1068) and for 
the total amount of tubulin as loading control. (e) EGF (8 nM) was mixed with increasing amounts of Nanobody, and the 
resulti ng mixture was added to Her14 cells. Aft er sti mulati on for 15 minutes, cell lysates were prepared, and proteins were 
size separated and blott ed to PVDF membranes. Membranes were then stained for phosphorylated EGFR (Y1068) and for 
the total amount of tubulin as loading control.
of CONAN-1 i.p. as therapy was compared to therapy using cetuximab. Based on the 
measured pharmacokineti cs of CONAN-1 (Fig. 5a), therapy was given twice weekly. 
CONAN-1 had an effi  cacy in inhibiti ng the growth of established A431 tumours that was 
largely comparable to that of cetuximab during treatment (Fig. 5b). The mean tumour 
volume in the cetuximab-treated group diminished slightly aft er 4 days, up to 2 weeks 
of treatment (a phenomenon not observed in the nanobody-treated group), but then 
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increased at approximately the same speed as that of the nanobody-treated group. After 
treatment was stopped, tumours of mice in the nanobody-treated group did not regrow 
significantly faster than tumours of mice in the cetuximab-treated group. During therapy, 
CONAN-1 induced a significantly stronger effect than cetuximab during the first 6 days, 
but cetuximab caused a significantly stronger antitumour effect after Day 8 (p < 0.05; 
independent sample T-test). A comparison of the growth-delay factors for quadrupling 
of the tumour volume revealed that CONAN-1 induced a strong response in tumour 
growth inhibition (GDF = 1.52) but that this response was slightly stronger in the group 
treated with cetuximab (GDF = 2.19; Table 3). In a separate, equal experimental setup, 
therapy using the trivalent anti-EGFR nanobody 7D12-7D12-Alb1 was also compared to 
that using cetuximab. A comparison of the GDFs calculated for both nanobody treatments 
revealed that CONAN-1 (GDF = 1.52) induced a much stronger antitumour response than 
the 7D12-7D12-Alb1 nanobody (GDF = 1; Table 3). Importantly, this proves again that the 
combination of different paratopes and thereby different modes of EGFR inhibition into 
a single molecule was superior to the use of monospecific targeting for EGFR inhibition.
Discussion
Our study set out to combine nanobodies into a biparatopic format in order to improve 
their efficacy in tumour growth inhibition. The results show the efficacy of the optimised 
CONAN-1 nanobody in therapy to be better than that of monospecific 7D12-7D12-Alb1 
and almost equal to that of the well-characterised anti-EGFR mAb cetuximab, although 
the former is devoid of immune effector functions.
To obtain anti-EGFR nanobodies that recognize non-overlapping epitopes on 
the ligand-binding domain 2 of EGFR (domain III), we made use of two mAbs of which 
the binding sites were previously shown to be different by crystallography13,15. First, we 
selected nanobodies for high affinity binding34. Surprisingly, these selections only resulted 
in clones that cross-reacted with the scFv of matuzumab (shown for the 9G8 nanobody in 
Fig. 1). The nanobodies Ia1, L2-3.40 and IIIa3, previously found using EGF elution,20 were 
also found to compete for binding to EGFR with the 9G8 nanobody and the 425 scFv (data 
not shown). The high prevalence of nanobodies recognising the part of domain III also 
bound by matuzumab is probably a reflection of the immunogenicity of that particular part 
of the receptor. However, by carefully designed phage nanobody selections, cetuximab 
cross-reactive nanobodies were readily obtained. These results underline the power of 
the combination of active immunisation of Llama, nanobody repertoire cloning and phage 
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nanobody selections to obtain nanobodies that recognise defined epitopes on a given 
antigen (for review, see Ref. 22).
 Second, phage nanobody selections were performed in combination with specific 
elution using cetuximab. Only two nanobodies were found that blocked binding of EGF 
to EGFR and that of cetuximab to EGFR: clones 7D12 and 7C12. These nanobodies have 
previously been described by Gainkam et al45. The reported affinity of the 7D12 nanobody 
(2.3 nM; Ref. 45) differs from the affinity value we obtained (10 nM; Table 2). This 
discrepancy might well be due to the different methods used to measure the affinity. 
We deliberately chose for cell-binding experiments, as the affinity values obtained by 
this method are probably more representative for the in vivo situation. The EGFR makes 
numerous contacts with other receptors, integrins and lipids32, which may shield particular 
epitopes on the ecto-domain that are accessible in an in vitro Surface Plasmon Resonance 
(SPR) setup. However, the 125I-labelling of the nanobodies may have influenced their 
affinity, as tyrosines in the antigen binding sites may have been altered, thereby lowering 
the affinity.
The order in which the two nanobodies were linked together in a bivalent or 
biparatopic molecule was shown to be an important parameter for the efficacy of the anti-
Figure 5. In vivo pharmacokinetics and therapy 
using CONAN-1 nanobody in athymic (nu/nu) 
mice bearing subcutaneous A431 xenografts
(a) Together with a therapeutic dose of 
trivalent nanobody (1 mg), 131I-labeled 
CONAN-1 (7.5  µg, corresponding to 0.33 MBq) 
was injected intraperitoneally (i.p.) in tumour-
bearing athymic (nu/nu) mice to measure 
detailed blood pharmacokinetics. Blood pool 
radioactivity was measured in time and plotted 
as percentage of injected dose per gram of 
tissue as a function of time. (b) Athymic (nude) 
mice bearing subcutaneously implanted A431 
xenografts were treated with phosphate-
buffered saline (PBS; diamonds), cetuximab; 
barbed rounds or trivalent nanobody CONAN-1 
(crosses). Treatment consisted of biweekly 
injections (i.p.) of 1 mg of protein (arrows).
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EGFR biparatopic molecule (Figs. 2 and 3). In addition, the linker composition also strongly 
influenced the characteristics of the nanobody, as a hinge-derived sequence between 
9G8 and 7D12 caused this biparatopic molecule to act as a receptor agonist (results not 
shown). The same phenomenon can slightly be observed for the 9G8-7D12 biparatopic 
nanobody containing a flexible linker and the 7D12-7D12 monospecific molecule (Fig. 4). 
The engineering and thorough testing of this type of therapeutic molecules is therefore 
critically important to avoid artificial receptor activation.
Table 3. Growth delay factors (GDF) for quadrupling of tumour volume after different treatment
Surprisingly, the 7D12-7D12 bivalent nanobody had the highest affinity, yet 
was not the most potent in inhibiting tumour cell proliferation (Table 2 and Fig. 3). This 
may be explained by artificial activation of the EGFR caused by crosslinking of receptors 
through intermolecular binding of the nanobody. The 7D12-9G8 nanobody did not 
cause receptor activation (Figs. 2, 3d and 4d) and therefore functioned as true receptor 
antagonist. However, simultaneous binding of the two heads in the biparatopic nanobody 
7D12-9G8 to one and the same EGFR molecule (“chelating” binding43) could not be 
demonstrated. Size exclusion chromatography and crosslinking experiments did not give 
conclusive results (data not shown). Preliminary X-ray crystallographic data confirm the 
predicted location of the epitopes of 7D12 and 9G8 (details of cocrystal structures of EGFR 
fragments with 7D12 and 9G8 will be published separately, Ferguson et al., manuscript in 
preparation).  These structures also suggest that simultaneous binding of both heads of 
7D12-9G8 may be possible with a 10-amino acids linker. However, chelating binding will 
be highly dependent on the linker composition. Based on the estimated locations of the 
C-terminus of 7D12 and N-terminus of 9G8 in these crystal structures, a linker of only 10 
amino acids would have to pass very closely to the surface of EGFR. It is conceivable that 
such a linker does not permit the biparatopic nanobody to chelate43 the EGFR, but that the 
7D12-9G8 nanobody binds the receptor with only one head at any given time. However, 
the presence of the second specificity within the same molecule probably results in fast 
rebinding once the first nanobody unit dissociates from its epitope, thereby resulting in 
Treatment	   GDF	  
	   	  
cetuximab	   2.19	  
CONAN-­‐1	   1.52	  
7D12-­‐7D12-­‐Alb1	   1	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increased apparent affinity (compare 7D12 and 9G8 with 7D12-9G8; Table 2) and increased 
potency in EGFR inhibition (Fig. 3). Also, binding of the biparatopic 7D12-9G8 to EGFR 
may induce some conformational change and thus an “induced fit,” thereby permitting 
both heads to bind simultaneously. For the monospecific, bivalent 7D12-7D12 molecule, 
simultaneous binding of both heads would require a cluster of receptors, where domain 
III is available in two adjacent EGFR molecules. Predimers of EGFR in the absence of EGF 
have been demonstrated46,47. However, the EGFR in such complex will probably not be 
bound bivalently by 7D12-7D12, as the ligand binding domains 2 (domain III) are located 
on either side of the “back-to-back” dimer2, pointing away from each other.
The in vivo half-life of the CONAN-1 nanobody was very comparable to that of a 
similar nanobody construct described by Tijink et al24 and to that of directly radiolabelled 
MSA (data not shown). As the affinity of the Alb1 nanobody for HSA is even higher than 
that for MSA [6.5 nM (MSA) vs 0.57 nM (HSA)], it is expected that the CONAN-1 nanobody 
would circulate in humans with the same kinetics as that of HSA (its half-life being 10-14 
days). The pharmacokinetics would then be very comparable to that of a whole IgG.
Treatment with cetuximab resulted in tumour regression after 4 days, which 
lasted until approximately day 14 (when tumour started to re-grow). This is indicative of 
activation of immune effector cells. Despite the fact that the CONAN-1 nanobody cannot 
interact with the immune system, its efficacy was largely comparable to that of cetuximab. 
This could be partially due to better tumour penetration24 in combination with similar 
(or even better) pharmacokinetics (see Ref. 24;Fig. 5). The modular nature of nanobodies 
permits the addition of “effector” heads (e.g., a nanobody to recruit effector cells); it 
would be interesting to test such constructs in comparison with cetuximab.
The modularity of nanobodies in combination with the power and possibilities of 
phage display also permit the synthesis of combinations of nanobodies recognising well-
defined epitopes on other receptors (e.g., the combination of nanobodies recognising the 
pertuzumab and trastuzumab epitopes on Her2/Neu). Additionally, it permits the synthesis 
of multi-specific molecules capable of inhibiting two (or even more) signal transduction 
pathways simultaneously, which may well lead to a higher efficacy of nanobody-mediated 
therapy. In conclusion, our results show that the rational design and synthesis of multivalent 
nanobody molecules are promising options to develop new cancer therapeutics.
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Supplemental data
Amino acid sequences of selected nanobodies; CDR regions are indicated in italic and 
underlined.
7D12*:   QVKLEESGGGSVQTGGSLRLTCAASGRTSR SYGMG WFRQAPGKEREFVS GISWRGDSTGYADSVKG 
RFTISRDNAKNTVDLQMNSLKPEDTAIYYCAA AAGSAWYGTLYEYDY      WGQGTQVTVSS
9G8:   EVQLVESGGGLVQAGGSLRLSCAASGRTFS SYAMG WFRQAPGKEREFVV AINWSSGSTYYADSVKG 
RFTISRDNAKNTMYLQMNSLKPEDTAVYYCAA GYQINSGNYNFKDYEYDY   WGQGTQVTVSS
38G7:   EVQLVESGGGLVQAGGSLRLSCAASGRTFS SYVMG WFRQATGKEREFVA TIAWDSGSTYYADSVKG 
RFTISRDNAKNTVHLQMNSLKPEDTAVYYCAA SYNVYYNNYYYPISRDEYDY WGQGTQVTVSS
*The amino acid sequence of 7D12 can already be found in the paper by Gainkam et al. 
(J Nucl Med. 2008 May;49(5):788-795).
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Abstract
Hepatocyte Growth Factor (HGF) and its receptor c-Met are associated with increased 
aggressiveness of tumors and poor prognostic outcome of patients with cancer. Here, 
we report the development and characterization of therapeutic anti-HGF (αHGF)-
Nanobodies and their potential for positron emission tomographic (PET) imaging to 
assess HGF expression in vivo. 
Two αHGF-Nanobodies designated 1E2 and 6E10 were identified, characterized, 
and molecularly fused to an albumin-binding Nanobody unit (Alb8) to obtain serum 
half-life extension. The resulting Nanobody formats were radiolabeled with the positron 
emitter zirconium-89 (89Zr, t
½
=78 hours), administered to nude mice bearing U87 MG 
glioblastoma xenografts, and their biodistribution was assessed. In addition, their 
therapeutic effect was evaluated in the same animal model at doses of 10, 30 or 100 μg 
per mouse. 
The 89Zr-Nanobodies showed similar biodistribution with selective tumor 
targeting. For example, 1E2-Alb8 showed decreased blood levels of 12.6%ID/g±0.6%ID/g, 
7.2%ID/g±1.0%ID/g, 3.4%ID/g±0.3%ID/g and 0.3%ID/g±0.1%ID/g at 1, 2, 3, and 7 days after 
injection, whereas tumor uptake levels remained relatively stable at these time points: 
7.8%ID/g±1.1%ID/g, 8.9%ID/g±1.0%ID/g, 8.7%ID/g±1.5%ID/g and 7.2%ID/g±1.6%ID/g. 
Uptake in normal tissues was lower than in tumor, except for kidneys.
In a therapy study, all Nanobody-treated mice showed tumor growth delay 
compared with the control saline group. In the 100-μg group, four of six mice were cured 
after treatment with 1E2-Alb8 and 73 days follow-up, and three of six mice when treated 
with 6E10-Alb8. 
These results provide evidence that Nanobodies 1E2-Alb8 and 6E10-Alb8 have 
potential for therapy and PET imaging of HGF-expressing tumors. 
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Introduction
Hepatocycte growth factor (HGF), also known as scatter factor, is secreted as a single-chain, 
inactive polypeptide by mesenchymal cells, and is cleaved by serine proteases into a 69-
kDa α-chain and 34-kDa β-chain (1-3). HGF is the only known ligand for the c-Met receptor. 
The c-Met receptor is expressed during embryogenesis and adulthood in the epithelial 
cells of many organs like liver, prostate, pancreas, muscle, kidney, and bone marrow. In 
tumor cells, c-Met activation triggers diverse series of signaling cascades resulting in cell 
growth, proliferation, invasion, metastasis formation, and escape from apoptosis (3). 
Overexpression of HGF and c-Met is associated with increased aggressiveness of tumors 
and poor prognostic outcome of patients with cancer (www.vai.org/vari/metandcancer 
and ref. 4). HGF and c-Met expression have been observed in most solid tumors. Blocking 
the soluble factor might be a beneficial strategy over blocking the c-Met receptor, as HGF is 
expected to be highly expressed in the tumor only, is easily accessible for Nanobodies, and 
is the only know ligand for the c-Met receptor. The possibility for success with targeting 
soluble factors has been illustrated with the anti-VEGF antibody bevacizumab (5). 
 The last decades several pharmaceutical companies have been actively involved 
in the development of therapeutic tyrosine kinase inhibitors and monoclonal antibodies 
(mAbs) that antagonize c-Met activation. At least 16 agents have been or are being 
evaluated in the clinic at the moment, as reviewed by Liu and colleagues (6). To their and 
our knowledge, 3 anti-HGF (αHGF) mAbs are under clinical development at the moment, 
including AMG102 (rilotumumab), a humanized anti-human HGF IgG2 from Amgen, AV-
299 from Schering/Aveo, and TAK-701 from Millennium. 
 In the present study, we introduce αHGF-Nanobodies. Nanobodies are derived 
from a unique antibody format that is present in species from the family of Camelidae, 
including llama, camel, and dromedary. These animals contain, besides their conventional 
antibody repertoire, an antibody class consisting of heavy chain-only antibodies (7-9). 
The variable region of the heavy chain-only antibodies (VHH) represents the complete 
binding unit of the antibody and is also termed Nanobody®. Unique features of the 
Nanobody technology platform in comparison to conventional mAb technology are rapid 
drug development, biophysical and chemical robustness, and the potential to target 
intractable targets for antibodies including G-protein-coupled receptors (GPCR) and ion 
channels (9). Particularly attractive is the ability to design modular drugs based on 15-
kDa Nanobody building blocks combined with each other, with other protein domains 
or with other molecules or drugs. Nanobodies have been combined in a wide range of 
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formats, including multivalent (multiple Nanobodies with identical-binding sites for the 
same antigen; refs. 10,11), biparatopic (2 Nanobodies binding to 2 different epitopes on 
the same antigen; refs. 12,13), and bispecific (Nanobodies binding to 2 different antigens; 
refs. 13,14) molecules. These formats are easy to construct and the modular proteins 
can often be expressed at high levels in bacteria or yeast. As a result of this formatting 
flexibility, the range of therapeutic applications for Nanobodies appears to be beyond 
that possible for conventional antibodies and antibody fragments. Nanobodies can also 
be tailored for a half-life varying from less than 2 hours up to a few weeks, by choosing 
from a wide range of half-life extension technologies. This versatility increases the number 
of therapeutic options available to Nanobodies ranging from acute to chronic indications 
where a monthly or bimonthly dosing regimen may be desirable.
Initial biodistribution studies with monospecific anti-EGFR (αEGFR)-Nanobodies in 
tumor-bearing mice showed, as expected, rapid blood clearance with a serum half-life time 
of less than an hour and low tumor uptake (15-17). Therefore, monospecific Nanobodies 
do not seem to be qualified for long-term blockage of growth factors and their receptors. 
Improvement of the pharmacokinetic and dynamic properties of otherwise short-live 
molecules can be achieved by fusing an anti-albumin unit (αAlb) to the Nanobody, as 
described by Tijink and colleagues (18). They compared the biodistribution of a bivalent 
αEGFR-Nanobody (αEGFR-αEGFR) with a trivalent Nanobody construct containing the 
αAlb-unit (αEGFR-αEGFR-αAlb) in nude mice bearing A431 tumors. Tumor uptake of 
αEGFR-αEGFR-αAlb was significantly higher than of αEGFR-αEGFR: 35.2%ID/g ± 7.5 %ID/g 
vs 5.0%ID/g ± 1.4 %ID/g. What is more, biodistribution of αEGFR-αEGFR-αAlb (50 kDa) was 
comparable to cetuximab (150 kDa), while it showed faster and deeper tumor penetration. 
The therapeutic potential of αEGFR-Nanobodies in comparison with conventional αEGFR 
mAbs was demonstrated by Roovers and colleagues (13). 
 In the present study, we developed and characterized two αHGF-Nanobodies 1E2-
Alb8 and 6E10-Alb8 for their capacity to inhibit binding of HGF to the c-Met receptor and 
for their potential in diagnosis and therapy of cancer. After labeling with the positron 
emitter zirconium-89 the Nanobodies were evaluated in biodistribution studies in nude 
mice bearing U87 MG glioblastoma xenografts. Besides that, αHGF-Nanobodies were 
tested as therapeutic agents in the same animal model. 
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Materials and Methods
Details of production and selection of αHGF-Nanobodies are presented in the 
Supplementary Materials.
Selective binding of Nanobodies to human HGF in ELISA
Nanobody-containing periplasmic extracts were analyzed for their ability to bind HGF. HGF 
(294-HG/CF, R&D systems) was coated on ELISA plates at 2 μg/mL. Plates were washed and 
subsequently blocked using PBS with 1% casein. Periplasmic extracts of individual clones, 
prediluted 1:10 in PBS/1% casein/0.05% Tween, were added and plates were incubated 
at room temperature for 2 hours. Binding to immobilized HGF was detected using mouse 
anti-c-myc monoclonal antibody, followed by a horseradish peroxidase-conjugated rabbit-
anti-mouse (human and bovine serum protein pre-absorbed) monoclonal antibody for 
detection. Individual clones were scored as putative HGF binders if the clones showed 
high optical densities in the assay. Overall, more than 90% of the clones were able to bind 
HGF. 
Kinetic measurement Nanobody-antigen K
d
 values
Kinetic (k
a
 and k
d
) and affinity constants (K
d
) of individual purified Nanobodies were 
determined by surface plasmon resonance on a Biacore T100 instrument. Human HGF 
(R&D systems) was amine-coupled to a CM5 sensor chip at a density of 2,500 relative 
units. Remaining reactive groups were inactivated with ethanolamine. Nanobody binding 
was assessed at varying concentrations ranging from 500 to 15 nmol/L. Each sample was 
injected for 2 minutes at a flow rate of 45 μL/min to allow binding to chip-bound antigen. 
Next, binding buffer without Nanobody was sent over the chip at the same flow rate to 
allow dissociation of bound Nanobody. After 10 minutes, remaining bound analyte was 
removed by injecting regeneration solution (1 mol/L NaCl, 50 mmol/L NaOH). Binding-
dissociation curves were used to calculate k
off
 values. 
Receptor-ligand binding assay
Serial dilutions of purified Nanobodies were analyzed for their ability to block the interaction 
of human HGF with c-Met-Fc using the AlphaScreenTM assay (PerkinElmer). In brief, 5 µL 
of prediluted individual Nanobody clones were incubated with 3 nmol/L biotinylated HGF, 
2 nmol/L c-Met-Fc, streptavidin-coated donor beads, and antihuman IgG1 Fc Nanobody 
covalently coupled Alphascreen acceptor beads. mAb clone 24612 (R&D systems) known 
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to inhibit the HGF/c-Met-Fc interaction was used as a positive control. Assays were read in 
an Envision AlphaScreen option fitted multimode reader (PerkinElmer).
Cells and culture
U87 MG (human glioblastoma), Bx-PC3 (human prostate carcinoma) and A549 (human 
alveolar basal epithelial cell carcinoma) cells were all obtained from the American Type 
Culture Collection (www.ATCC.com) and cultured according to their recommendations. 
Cell lines were not authenticated by the authors.
Functional cell assays: c-Met phosphorylation assay
A549 cells were plated in growth medium and after 24 hours the cells were starved for 
18 to 20 hours. c-Met phosphorylation was stimulated with 5 nmol/L human HGF for 15 
minutes. Each of the half-life extended Nanobodies 1E2-Alb8 and 6E10-Alb8 was prepared 
as a 3-point serial dilution series in the stimulation medium before adding to the cells. 
Following the 15-minute incubation, cells were immediately placed on ice and lysed in 
RIPA buffer (Cell Signaling Technology). Quantification of phosphorylated (Tyr1349) and 
total c-Met was performed using MSD 96-Well MULTI-SPOT® Phospho (Tyr1349)/Total 
c-Met Assay according to the manufacturer’s instructions. IC
50
 values were calculated 
using the 4 Parameter Logistic equation (GraphPad Prism).
Functional cell assays: proliferation assay
BxPc3 cells were seeded in cell culture E-plates at a cell density of 10,000 cells per well 
and incubated overnight in culture medium at 37°C and 5% CO
2
. Cells were then starved 
with medium containing 1% ITS (insulin, transferrin, selenium) for 4 hours after which 0.6 
nmol/L HGF was added together with serial dilutions of Nanobodies 1E2-Alb8 and 6E10-
Alb8. The cell growth curves were automatically recorded on the xCELLigence System 
(Roche Applied Sciences) in real-time. The cell index was followed for 3 days.
 
Preparation of 89Zr-1E2-Alb8 and 89Zr-6E10-Alb8
For preparation of the 89Zr conjugates, the 89Zr was coupled to the Nanobody by use of the 
bifunctional chelate p-isothiocyanatobenzyl desferrioxamine (Df-Bz-NCS, catalog # B705, 
Macrocyclics), essentially as described by Vosjan and colleagues (19). 
Quality control of 89Zr-1E2-Alb8 and 89Zr-6E10-Alb8
All radioactive conjugates were analyzed by instant thin-layer chromatography (ITLC) 
to determine the labeling efficiency and radiochemical purity. The integrity of the 
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Nanobody was analyzed via size exclusion chromatography by high-performance liquid 
chromatography (HPLC), and sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) followed by phosphor imager analysis (Storm820; GE Healthcare). 
Immunoreactivity was determined by a HGF-coated enzyme-linked immunosorbent assay 
essentially as described by Collingridge and colleagues (20). 
Biodistribution study
The distribution of 89Zr-labeled αHGF-Nanobodies was examined in nude mice (HSD: 
Athymic Nude-Foxn1nu, 20-30 g; Harlan Laboratories) inoculated subcutaneously with 2 x 
106 U87 MG cells at 2 lateral sides. These animal experiments were done according to NIH 
Principles of Laboratory Animal Care and Dutch national law (Wet op de dierproeven, Stb 
1985, 336). 
Mice bearing U87 MG xenografts (size ~100 mm3) were injected with 0.37 MBq 
89Zr-Df-Bz-NCS-1E2-Alb8 or 0.37 MBq 89Zr-Df-Bz-NCS-6E10-Alb8 via the retro-orbital plexus. 
Unlabeled Nanobody was added to the injection mixture to obtain a final dose of 30 µg per 
mouse. At 1, 2, 3 or 7 days post injection (p.i.) 5 mice per group were anesthetized, bled, 
killed and dissected. Blood, tumor, and normal tissues were weighed and radioactivity 
was measured in a gamma counter (Wallac). Radioactivity uptake for each sample was 
calculated as the percentage of the injected dose per gram of tissue (%ID/g). 
In addition, a Nanobody dose-diminishing study was conducted. To this end, 5, 10, 
20 and 30 µg of 89Zr-labeled 1E2-Alb8 (0.23-0.83 MBq) was injected in mice bearing U87 
MG xenografts, and at 3 days p.i. 5 mice per group were examined as described above.
Blood kinetics
Blood concentrations of αHGF-Nanobodies were examined in 2 groups of 2 mice. One 
group of tumor-bearing mice received 0.37 MBq 89Zr-1E2-Alb8 (30 µg) whearas the other 
group received 0.37 MBq 89Zr-6E10-Alb8 (30 µg). Blood was collected at 1 and 3 hours, 
and at 1, 2, 3 and 7 days p.i. by tail laceration and radioactivity was measured in a gamma 
counter. Radioactivity for each sample was calculated as %ID/g. 
Therapy study
The therapeutic effectiveness of the αHGF-Nanobodies was studied in the same nude 
mice model as described for the biodistribution study. For this purpose, 7 groups of 6 
mice with established U87 MG xenografts were used. The mean tumor size at the start 
of the study was ~100 mm3, and was similar for the different treatment groups. All mice 
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received i.p. treatment 3 times a week for 5 weeks. Group 1 was the control group and 
received 200 µl of saline solution per treatment. Group 2, 3 and 4, received 10, 30 and 
100 µg of Nanobody 1E2-Alb8, respectively. Group 5, 6 and 7 received 10, 30 and 100 µg 
of Nanobody 6E10-Alb8, respectively. Body weight and tumor volume were measured 3 
times a week up to 73 days after end of treatment. 
Statistical analysis
Biodistribution and therapy experiments were statistically analyzed with SPSS 15.0 
software. using Student t test for unpaired data. Two-sided significance levels were 
calculated and P <0.01 was considered statistically significant. Survival was calculated 
using Kaplan-Meier curves. 
Figure 1. αHGF-Nanobodies neutralize HGF-mediated cellular functions. (A) αHGF-Nanobodies neutralize HGF-mediated 
c-Met phosphorylation. The percentage inhibition of c-Met phosphorylation was measured over an 8-point dose-response 
of each Nanobody by an enhanced chemiluminescence assay. (B) αHGF-Nanobodies inhibit HGF-dependent growth of PC3 
cells. The viability of PC3 cells cultured more 3 days in the presence of 0.6 nmol/L HGF was measured over an 8-point dose-
response of each Nanobody via impedance measurement. Anti-c-Met 5D5 Fab was used as a positive control.
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Results
Generation and characterization of αHGF-Nanobodies 1E2 and 6E10
To obtain antagonistic Nanobodies specific for HGF, phage Nanobody repertoires were 
synthesized from peripheral blood lymphocytes from llamas immunized with HGF. After 
panning to immobilized HGF, single clones were screened as periplasmic extracts for HGF 
reactivity by ELISA. Approximately 90% of the clones tested were found to bind HGF. In a 
next step, their potential to inhibit HGF/c-Met interaction was assessed in an AlphaScreen 
and resulted in a final panel of 12 clones, which showed good inhibition of the HGF/c-
Met interaction. Using a Biacore T100, we analyzed the affinity of the Nanobodies to 
HGF. On the basis of these analyses, Nanobodies 1E2 and 6E10 were selected from this 
panel for further characterization. These selected Nanobodies inhibited binding of HGF 
to c-Met with IC
50
 values in the low nanomolar range (1.8 nmol/L for 1E2 and 3 nmol/L 
for 6E10 Nanobody) though 100% inhibition was not achieved. The kinetic parameters of 
Nanobody-antigen showed that both Nanobodies displayed low nmol/L affinity constants 
(1.36 nmol/L for 1E2 and 1.14 nmol/L for 6E10 Nanobody).
Re-formatting of Nanobodies for in vivo use and in vitro characterization of these formats
To increase the in vivo half-life of the αHGF Nanobodies, bispecific formats were generated 
whereby the αHGF-Nanobodies were genetically linked to a Nanobody with specificity to 
serum albumin (Alb8). These bispecific Nanobodies were produced as myc-His6 tagged 
proteins in E. coli and analyzed for their potential to neutralize HGF-mediated c-Met 
phosphorylation. A549 cells do not express HGF; thus, this assay mimicked a paracrine 
model of ligand-mediated receptor activation. When Nanobody 1E2-Alb8 or 6E10-
Alb8 was introduced into HGF-containing medium before addition to the cells, c-Met 
phosphorylation was inhibited in a dose-dependent manner though less efficient than 
control anti-c-Met 5D5 Fab (Fig. 1A). 
We next measured inhibition of HGF-induced proliferation of Bx-PC3 cells. Also 
here, a dose-dependent inhibition was observed when the Nanobodies were added to 
the Bx-PC3 cells in culture, but also here inhibition was less efficient as compared to the 
anti-c-Met 5D5 Fab control (Fig. 1B).
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Radiolabeling and quality control of 89Zr-1E2-Alb8 and 89Zr-6E10-Alb8
Labeling of both Nanobodies with 89Zr resulted in overall labeling yields of 75 to 90%, after 
PD-10 column purification. Radiochemical purity was always more than 97%. Integrity of 
the Nanobodies was optimal as determined by HPLC and SDS-PAGE. Immunoreactivity of 
89Zr-1E2-Alb8 and 89Zr-6E10-Alb8 was similar to that of the reference 131I-labeled αHGF-
Nanobodies (~50%).
Biodistribution study
For biodistribution studies nude mice bearing U87 MG xenografts were injected with either 
89Zr-1E2-Alb8 or 89Zr-6E10-Alb8. Biodistributions at 1, 2, 3, or 7 days p.i. are shown in Fig. 2. 
Both αHGF-Nanobodies showed similar biodistributions with selective tumor uptake, no 
significant differences were observed (P>0.01). Whereas blood levels gradually decreased 
over time, tumor uptake remained relatively stable. Blood levels were 12.6%ID/g ± 
0.7%ID/g, 7.2%ID/g ± 1.0%ID/g, 3.4%ID/g ± 0.3%ID/g and 0.3%ID/g ± 0.1%ID/g for 89Zr-
1E2-Alb8 and 13.1±0.6, 7.4±0.6, 3.5±0.5, and 0.5±0.1 %ID/g for 89Zr-6E10-Alb8 at 1, 2, 3, 
and 7 days p.i., respectively. Tumor uptake at these time points was 7.8%ID/g ± 1.1%ID/g, 
8.9%ID/g ± 1.0%ID/g, 8.7%ID/g ± 1.5%ID/g, and 7.2%ID/g ± 1.6%ID/g for 89Zr-1E2-Alb8, and 
7.5%ID/g ± 0.8%ID/g, 8.8%ID/g ± 1.3%ID/g, 6.5%ID/g ± 2.5%ID/g, and 6.3%ID/g ± 4.0%ID/g 
at 1, 2, 3, and 7 days p.i., respectively, for 89Zr-6E10-Alb8. Tumor uptake was higher than in 
normal organs, except for kidneys. The latter is typical for small proteins, which are rapidly 
cleared via the kidneys.
Figure 2. Biodistribution of αHGF-Nanobodies 89Zr-1E2-Alb8 (A) and 89Zr-6E10-Alb8 (B) in nude mice bearing U87 MG 
xenografts at 1, 2, 3 and 7 days p.i. Data are presented as average of 5 animals and SDs. No significant differences in uptake 
between both Nanobodies were observed (P<0.01).
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Dose-diminishing study
A dose-diminishing study was conducted with 89Zr-1E2-Alb8 to determine the optimal 
Nanobody dose for in vivo imaging. Nude mice bearing U87 MG xenografts were injected 
with 0.32 ± 0.01, 0.47 ± 0.01, 0.47 ± 0.01, or 0.83 ± 0.01 MBq 89Zr-1E2-Alb8, containing 5, 
10, 20 or 30 µg 1E2-Alb8, respectively. Three days p.i., similar biodistribution was seen for 
all dose groups (Fig. 3). No significant differences were observed in tumor uptake, being 
8.2%ID/g ± 1.2%ID/g, 8.1%ID/g ± 1.3%ID/g, 6.3%ID/g ± 1.7%ID/g, and 6.9%ID/g ± 1.1%ID/g 
for the 5, 10, 20, and 30 µg dose groups, respectively. High uptake in kidneys was observed 
for all dose groups. Also no significant differences were observed between the different 
dose groups (P > 0.01).
 
Blood kinetics in mice
Blood kinetics of 89Zr-1E2-Alb8 (30 µg) and 89Zr-6E10-Alb8 (30 µg) appeared to be similar 
(Fig. 4). Blood levels of Nanobody constructs were 41.7%ID/g ± 0.6%ID/g and 35.1%ID/g 
± 1.48%ID/g 1 hour after injection for 89Zr-1E2-Alb8 and 89Zr-6E10-Alb8, respectively, and 
slowly decreased from 4.3%ID/g ± 0.1%ID/g to 0.3%ID/g ± 0.1%ID/g between 72 and 168 
Figure 3. Biodistribution of αHGF-Nanobody 89Zr-1E2-Alb8 in nude mice bearing U87 MG xenografts at 3 days p.i. with 
different amounts of Nanobody. Data are presented as average of 5 animals and SD. No significant differences were 
observed between the dose groups (P<0.01).
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Figure 4. Blood kineti cs of 89Zr labeled 1E2-Alb8 and 6E10-Alb8 in nude mice bearing U87 MG xenograft s (n=2 per group) up 
to 7 days aft er injecti on. Total administered dose, 30 µg.
hours p.i. for 89Zr-1E2-Alb8 and from 4.2%ID/g ± 0.1%ID/g to 0.5%ID/g ± 0.1%ID/g for 89Zr-
6E10-Alb8. 
Therapy study
Mice receiving Nanobodies showed tumor growth delay in comparison to the control PBS-
group, while no toxicity was observed (Fig. 5A). Within the treatment period of 35 days all 
control mice were sacrifi ced because of the large volumes of the tumors. Mice receiving 
the lowest dose (10 µg) had minimal benefi t whereas the intermediate and highest dose 
groups (30 µg and 100 µg) showed extensive tumor growth delay.   
At the end of treatment (day 35) only mice in the intermediate and highest dose 
groups were alive, and followed ti ll day 108 aft er start of treatment. At the end of the 
study 4 of 6 mice (7 of 11 tumors) were cured in the group receiving 100 µg 1E2-Alb8, and 
3 of 6 mice (6 of 11 tumors) in the group receiving 100 µg 6E10-Alb8, while 3 of 6 mice (5 
of 11 tumors) were cured in the group receiving 30 µg 1E2-Alb8. In contrast, all mice in 
the group receiving 30 µg 6E10-Alb8 faced regrowth of tumors during follow up (Fig. 5B 
and 5C).
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Discussion
Targeting of the HGF/c-Met pathway is considered to be a promising approach for treatment 
of cancer. Activation of c-Met by its ligand HGF can lead to multiple cellular responses, 
including invasion, proliferation, and motility. In this study, we described the development 
of 2 Nanobodies designated 1E2 and 6E10, with low nanomolar affinity for HGF, that 
have the capacity to inhibit binding of HGF to the c-Met receptor. By genetically linking 
these αHGF-Nanobodies to a Nanobody unit with specificity for serum albumin (Alb8; 
refs.13,18,21), 1E2-Alb8 and 6E10-Alb8 were obtained. Nanobodies were radiolabeled 
Figure 5. Therapy study with αHGF-Nanobodies 1E2-Alb8 and 6E10-Alb8 in nude mice bearing U87 MG glioblastoma 
xenografts (A). Treatment was 3 times a week for 5 weeks. Kaplan-Meier survival curves of nude mice treated with different 
amounts of 1E2-Alb8 (B) or 6E10-Alb8 (C). Treatment with all Nanobody concentrations caused significant tumor growth 
delay of the established tumors after day 6 (P< 0.01), and curative responses after treatment with 30 or 100 µg 1E2-Alb8, 
or 100 µg 6E10-Alb8.
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with 89Zr to enable accurate assessment of in vivo biodistribution either by taking biopsies 
as carried out herein or alternatively by noninvasive PET imaging as is foreseen in future 
clinical trials. 89Zr-1E2-Alb8 and 89Zr-6E10-Alb8 showed a similar extended serum half-
life as has been previously described for αEGFR-Nanobodies (18), with blood levels of 
10%ID/g to 15%ID/g at 24 hours after injection. Biodistribution studies also showed 
selective accumulation of 89Zr-1E2-Alb8 and 89Zr-6E10-Alb8 in HGF-producing U87 MG 
xenografts. Besides this, both αHGF-Nanobodies were able to inhibit tumor growth in U87 
MG tumor-bearing nude mice, and upon treatment by 100 μg i.p. injections, 3 times a 
week for 5 weeks, cures were observed in 4 of 6 mice with 1E2-Alb8 and in 3 of 6 mice 
with 6E10-Alb8. 
 Several therapy studies with αHGF mAbs have been performed in U87 MG tumor-
bearing mice in the past, and this allows ranking of the potency of the αHGF-Nanobodies 
described herein. In 2001, Cao and colleagues (22) reported for the first time on HGF-
neutralizing mAbs capable for exerting antitumor activity. A mixture of 3 antibodies (200 
µg per mouse every day until day 20; i.p. or intratumoral injection) was used for therapy 
in mice that had been injected one day earlier with C-127 or U118 cells. C-127 are mouse 
breast tumor cells transformed with human HGF and mouse Met, whereas U118 are human 
glioblastoma cells showing autocrine HGF production. Inhibition of tumor outgrowth was 
observed for both cell lines. The same mAb mixture (200 µg per mouse every 2 days until 
day 10; i.p. or intratumoral injection) also caused tumor growth inhibition in mice bearing 
established U118 xenografts (average size of 100 mm3), however, no tumor regression or 
cures were observed. In these studies a mixture of 3 mAbs was used for therapy, because 
in vitro studies had shown that no single mAb appeared capable of neutralizing the activity 
of HGF. The authors, therefore, postulated that a minimum of 3 HGF epitopes have to be 
blocked to prevent c-Met tyrosine kinase activation and to exert anti-tumor activity. 
In 2006, Burgess and colleagues (23) introduced fully human mAbs directed to 
an epitope in the β-chain of HGF, mAb AMG102 included, which showed inhibition of 
HGF-driven c-Met phopshorylation and of tumor growth as single agents. For their in vivo 
experiments they used established xenografts with an average size of 180 mm3 derived 
from the glioblastoma cell lines U87 MG and U118, both expressing human HGF and 
c-Met. The most potent mAb showed significant growth inhibition and tumor regression 
when administered at a dose of 10 or 30 μg twice a week, and 7 of 10 animals in the 30-μg 
dose group had no measurable tumor mass at the end of the experiment. Because of the 
very short follow-up time of 17 days after start of therapy, and the lack of withdrawal from 
therapy, it did not become clear from these studies whether cures could be obtained like 
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in our studies with the same Nanobody dose in the same xenograft model. 
In later studies, the group of Burgess showed the potential of using αHGF therapy 
in combination approaches for treatment of glioblastoma (24). In the above described 
U87 MG xenograft model, low doses of AMG102 (3 µg twice a week) enhanced the efficacy 
of temozolomide or docetaxel. What is more, a first in human phase I trial in patients 
with advanced solid tumors showed that AMG102 is safe and well tolerated, with a linear 
pharmacokinetic profile within the investigated dose range (up to 20 mg/kg i.v. every 2 
weeks) (25). Despite the fact that the maximum-tolerated dose was not reached, 16 of 23 
evaluable patients had a best response of stable disease with a progression-free survival 
ranging from 7.9 to 40 weeks. Above data indicate that αHGF-based therapy has clinical 
potential. Recently, indication was made that the HGF/c-Met pathway is also a therapeutic 
target in metastatic renal cell carcinoma. Nevertheless, Schöffski and colleagues showed 
that no significant growth inhibition occurred with AMG102 (26). Similarly, HGF and its 
receptor c-Met have been implicated in the pathogenesis of glioblastoma, but Wen (27) 
and colleagues showed in a phase II study that AMG102 monotherapy treatment at doses 
up to 20 mg/kg was not associated with significant antitumor activity in the selected 
patient groups.
Besides these mAbs, studies were conducted with the murine mAb L2G7 in 3 
different established tumor models among which U87 MG (28,29).  Treatment with 50 or 
100 µg L2G7, i.p. twice weekly, was started when tumor volume reached approximately 
50 mm3 and resulted in inhibited tumor growth and regressions. Because of the short 
follow-up period (till day 40 after injection of cells) and the continuation of therapy during 
that time period, it is impossible to draw conclusions about cure rates in these studies. 
L2G7 efficacy was also examined in mice bearing pre-established intracranial U87 MG 
glioma xenografts. L2G7 (100 µg, i.p., twice weekly) given from days 5 to 52, significantly 
prolonged animal survival. In control mice, median survival was 39 days and all mice died 
from progressive tumors by day 41. In contrast, all mice treated with L2G7 survived to 
day 70 and 80% survived to day 90. At day 91 animals remaining alive were sacrificed 
and examined for tumor burden. All mice were found to have brain tumors left, which 
appeared to be consistent with tumor regrowth after withdrawal of L2G7 therapy.
Despite the fact that the αHGF-Nanobodies evaluated in this study did not fully 
inhibit c-Met-mediated phosphorylation and cell growth in vitro, in vivo these Nanobodies 
were found capable to give cures. These data indicate that in vitro functional assays are 
not fully predictive for assessment of the in vivo therapeutic potential of αHGF-targeting 
ligands. One aspect in favor of Nanobodies in comparison to traditional full-lengths mAbs 
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is their faster and deeper tumor penetration as was previously observed for the αEGFR-
Nanobody formats (18). 
On the basis of the achievements described herein we think clinical evaluation 
of either 1E2-Alb8 or 6E10-Alb8 is justified. In such studies, the use of 89Zr-immuno-PET 
might be of added value. Taking the complexity of signal transduction routes into account, 
it is uncertain whether a relationship between imaging uptake and response will be seen 
in patients. What might be seen, however, is a good negative predictive value of imaging, 
which means that there will most probably be no response when there is no Nanobody 
uptake in the tumor. In such way imaging might be of value to enrich the patient population 
that might benefit from αHGF treatment. In addition, imaging might be of value to assess 
the Nanobody dosage for optimal tumor targeting, the optimal schedule of Nanobody 
administration and cross reactivity with normal tissues to anticipate toxicity.
The potential of 89Zr-immuno-PET in mAb development and applications has been 
shown for several mAbs directed against membrane receptors (30-33), the c-Met receptor 
included (34), but also for a mAb directed against a growth factor, that is, bevacizumab 
directed against VEGF. Like the 89Zr-αHGF Nanobodies, 89Zr-bevacizumab showed selective 
uptake in VEGF-producing xenografts in mice (35), whereas uptake decreased when 
VEGF expression was inhibited by treatment with HSP90 inhibitors (36,37), indicating 
a relationship between 89Zr-bevacizumab tumor uptake and VEGF expression. What is 
more, 89Zr-bevacizumab biodistribution could be imaged quantitatively and at excellent 
resolution, and in the mean time clinical trials have been started with 89Zr-bevacizumab, 
as a follow up of single-photon emission computed tomography (SPECT) studies with 111In-
bevacizumab in patients with melanoma (38). Although the performance of immuno-
SPECT is less optimal than of immuno-PET, in these latter studies all known melanoma 
lesions were detected with VEGF-SPECT. In analogy, 89Zr-immuno-PET might be supportive 
in the clinical development of the αHGF-Nanobodies. 
To further improve the therapeutic potential of αHGF-Nanobodies, formatting 
into multi-targeting Nanobodies might be an appealing option. Among others, linking 
αHGF-Nanobodies to our recently described αEGFR-Nanobody 7D12 might be promising 
(17). Like other researchers postulated; combination therapies are needed to overcome 
acquired resistance to inhibitors of signal transduction pathways. For instance, as recently 
described in lung tumors, resistance to the small-molecule EGFR inhibitors gefitinib and 
erlotinib might be achieved through amplification of the c-Met gene (39). By combining 
αHGF and αEGFR units within one Nanobody construct, simultaneous blockage of both the 
EGFR and c-Met/HGF signal transduction pathways might result in improved therapeutic 
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effects.  
In summary, the results presented in this study showed that the Nanobodies 1E2-
Alb8 and 6E10-Alb8 are capable of selective targeting HGF-producing tumors. Furthermore, 
treatment of U87 MG-bearing mice with these Nanobodies resulted in inhibition of 
tumor growth and ultimately caused cures, indicating the therapeutic potential of αHGF-
Nanobodies as cancer therapeutics in humans.  
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Supplementary materials
Production and selection of αHGF-Nanobodies
Anti-HGF Nanobodies were generated at Ablynx NV (Ghent, Belgium). Two Llama glama 
were immunized with 100 and 50 µg human HGF (Peprotech, cat# 100-39) in Stimmune 
adjuvant (Cedi Diagnostics) and blood was collected. These animal experiments were 
conducted with the approval of the Ethical Committee of the Faculty of Veterinary 
Medicine, University of Ghent, Belgium. 
Anti-HGF Nanobodies were isolated using phage display. To this end, 2 libraries 
were constructed and panned on human HGF. Principles in short; peripheral blood 
mononuclear cells were prepared from blood samples using Ficoll-Hypaque according to 
the manufacturer’s instructions. Next, total RNA was extracted from these cells and used 
as starting material for RT-PCR to amplify Nanobody encoding gene fragments. These 
fragments were cloned into phagemid vector pAX50. Phage was prepared according to 
standard methods and stored after filter sterilization at 4oC for further use. Phage library 
size from both animals was 0.7 x 108 and 2.1 x 108, and percentages of insert 100 and 
91.3%, respectively. Phage libraries were used for selection on immobilized human HGF, 
and the best selections, with the highest enrichment factor, were chosen for further 
analysis. Bound phage was eluted by addition of trypsin and rescued via infection of E. 
coli. Individual colonies were picked and grown in 96 deep well plates (1 mL). 
Nanobody expression was induced by addition of IPTG and periplasmic extracts 
(80 μL) were prepared according to standard methods. Alternatively, selected Nanobodies 
were expressed in the periplasmic space of E. coli as c-myc and His6 tagged proteins in 
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a culture volume of 50 mL and purified via immobilized metal affinity chromatography 
(IMAC). Nanobodies were eluted from the column with 250 mM imidazole followed by gel 
filtration and buffer exchange to PBS.
Selected human HGF–specific Nanobodies were converted into a bispecific 
format by genetic fusion to the albumin-binding Nanobody Alb8 using a flexible Gly-Ser 
linker (Gly4-Ser-Gly3-Ser).
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Summary, discussion, and future perspectives
Currently, therapeutic monoclonal antibodies (mAbs) gain attention, due to their 
excellent potential for diagnosis and systemic treatment of cancer. Hundreds of mAbs 
and mAb fragments are under clinical development. To date, the U.S. Food and Drug 
Administration (FDA) has approved 30 mAbs, mostly for systemic treatment of cancer1-3. 
Despite the economic recession the annual mAb sales have grown till $48 billion in 20104. 
The top 5 mAbs had sales over $5 billion each in 20101.
 Unfortunately, efficacy of current mAbs is still limited, with clinical benefit for 
only a small group of patients. Ideally, the best drug candidates should be identified early 
in drug development, whereas patient populations most likely to benefit from treatment 
should be well defined. Molecular imaging can be of great help in fulfilling these tasks. 
One of the upcoming techniques is positron emission tomography (PET), which is suitable 
for quantitative whole body imaging with high resolution. PET can be of use in selecting 
patient populations, assessing target expression, and determining optimal mAb dosages 
(to minimize the side effects). The last decade PET imaging with use of mAbs (immuno-
PET) showed valuable improvement at several stages of mAb development and clinical 
applications. Besides full-sized intact mAbs also mAb-fragments (e.g. Nanobodies) and 
third generation, non-traditional mAb-like scaffolds are gaining more attention. Immuno-
PET can play a crucial role in early development of each of these targeting drugs.
For immuno-PET guided therapy with intact mAbs two approaches exist. The first 
approach is based on the same-day imaging with fast kinetic mAb-based PET probes. 
This results in a quick procedure to assess target expression in patients and a low 
radiation burden, especially when radionuclides with half-lives between 1-15 h are used 
e.g., gallium-68 (68Ga,  t
½ 
= 1.13 h)5,6. In a second approach, the therapeutic intact mAbs 
themselves are radiolabeled and imaged in a pre-therapy scouting setting or early during 
the course of therapeutic treatment. This gives a better insight in the in vivo behavior and 
efficacy of the particular mAbs in individual patients. In the latter approach, therapeutic 
intact mAbs are radiolabeled with long-lived PET isotopes like zirconium-89 (89Zr, t
½ 
= 78.4 
h) or iodine-124 (124I, t
½ 
= 100.3 h) and imaged prior or during the course of mAb therapy. 
Very recent insights showed that selective targeting of just one single tumor 
target might be insufficient for optimal therapeutic efficacy. Cancer cells appear to have 
the inherent ability to use several growth factor (receptor) systems for growth advantage 
and survival. This means that other receptor systems can take over the signaling and 
therefore tumors are still able to survive after blockade of just one growth factor 
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(receptor) system. The potential of dual-specificity antibody therapy has already been 
demonstrated in several studies in which mAbs or tyrosine kinase inhibitors affecting 
different anti-cancer targets, e.g., EGFR, HER2, IGF-IR, VEGF or VEGF-R2 were combined7-14. 
Nanobody technology might be better suited for blockade of growth factor (receptor) 
systems. Nanobodies are smaller than intact traditional IgG mAbs and can therefore better 
penetrate in a tumor. Furthermore, Nanobody technology enables easy construction of 
so-called “dual specific” or “multi-specific” Nanobodies (targeting several tumor targets 
simultaneously). For preclinical and clinical evaluation of the targeting potential of such 
new antibody fragments immuno-PET can be of great help.
Chapter 1 described the current role and future potential of immuno-PET, and 
introduced a novel class of antibody-fragments: Nanobodies. With the introduction of 
Nanobodies, a new dimension might possibly be added to development of new anti-
cancer drugs as well as improved assessment of target expression in tumors. In this 
chapter also commonly upregulated, overexpressed and/or activated tumor targets which 
play a crucial role in malignant growth were described. 
In chapter 2, the novel p-isothiocyanatobenzyl-desferal (Df-Bz-NCS) was 
introduced. This novel bifunctional Df-Bz-NCS chelator allows a labeling procedure 
that consists of two steps. In comparison, in the old procedure the synthesis of the 
tetrafluorophenyl ester of succinylated Fe-desferrioxamine B (N-suc-Df-Fe-TFP) takes 
three steps, and the labeling procedure another three steps15. In both methods the Df-
chelate is conjugated to the lysines of a mAb in about 50 min. An important difference 
in the new conjugation procedure compared to the old one is the absence of a second 
step at a low pH (pH 4.5) to remove Fe from the Df-chelate. Avoiding this low pH step is a 
major improvement when pH-sensitive proteins are used, as has been recently shown for 
89Zr-Nanocolloidal albumin16. By omitting this step the whole procedure is speeded up by 
approximately 40 min. In the new procedure as described in this thesis, conjugation was 
carried out with a 3-fold molar excess of Df-Bz-NCS chelator, resulting in a chelate:mAb-
ratio of 1.5:1. With this conjugate, 89Zr-labeling was almost quantitative after 30 minutes 
of labeling at room temperature at pH 6.8-7.2. After PD-10 column purification the 89Zr-
Df-Bz-NCS-mAb conjugates appeared to be optimal with respect to radiochemical purity, 
integrity, and immunoreactivity. A point of serious attention is the way of addition of the 
Df-Bz-NCS to the mAb-solution. When the Df-Bz-NCS, which is dissolved in DMSO, is added 
in one time without shaking or proper mixing, mAb-aggregates are easily formed. For that 
reason it was stated that the Df-Bz-NCS should be added stepwise to the mAb-solution. 
A second point of attention concerns the stability of the radiolabeled mAb upon storage. 
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Buffers containing Cl- should be avoided, since those buffers cause detachment of 89Zr 
from the mAb, due to radiation-induced formation of hypochlorite. The latter component 
very effectively reacts with the bis-thiourea unit of the new linker. Therefore, the use of a 
0.25 M sodium acetate buffer is strongly recommended. The novel Df-Bz-NCS chelate was 
extensively compared with the reference N-suc-Df chelate. Biodistribution and imaging 
studies in different tumor bearing mouse models showed high and selective accumulation 
in tumors. Furthermore, no significant in vivo differences were observed between 89Zr-Df-
Bz-NCS-mAb and 89Zr-N-suc-Df-mAb conjugates. 
In chapter 3 a protocol was written to provide other research groups and 
pharmaceutical companies with a straightforward and convenient method for the labeling 
of 89Zr to mAbs or mAb fragments via this new Df-Bz-NCS chelate. This protocol not only 
can be used as a standard operating procedure, but also makes aware of critical steps.
 For radiolabeling of mAb fragments (e.g. Nanobodies) 89Zr is not strictly necessary, 
since the biological half-life of a Nanobody (t
½
= 1-3 h) does not really require the 78.4 
hour half-life of 89Zr. An alternative PET isotope might be 68Ga, with a half-life of 1.16 h. 
In chapter 4 a labeling method with 68Ga via the novel Df-Bz-NCS chelate was described. 
Crucial in optimal 68Ga radiolabeling is the use of ultra pure HCl, to keep the natGa 
concentrations as low as possible and also to minimize the amounts of Al, Fe and Zr, being 
strong competitors for complexation with Df. Also the purification and reduction of the 
68Ga-generator eluate volume is important. With the use of an anion exchange column 
removal of contaminating metals as well as minimizing the volume of the 68Ga-solution was 
achieved. Radiolabeling with 68Ga was performed at room temperature within a relatively 
broad pH range of 5.0-6.5 for only 5 min. Once the labeling method was established the 
first objective was to test whether the novel Df-Bz-NCS chelate is also the appropriate 
chelator for stable incorporation of 68Ga and for conjugation to mAbs or Nanobodies. The 
second objective in this study was to evaluate Nanobody 7D12, by use of immuno-PET 
and biodistribution experiments. When a 3-fold molar excess of Df-Bz-NCS was added to 2 
mg 7D12, 0.2 Df-groups per Nanobody molecule were coupled. Subsequent labeling with 
freshly eluted and purified 68Ga resulted in a radioactivity yield of 55-70% (not corrected 
for decay). Comparable results were shown with the reference compound 89Zr-Df-Bz-NCS-
7D12. Stability of both compounds was compared in a sodium acetate buffer, without 
Cl- -ions. The 68/67Ga-labeled Nanobody showed minimal release after 5 h (1.5 - 2.0%) in 
sodium acetate buffer at 4°C, but 6-7% of the 67Ga was released after 24 h, whereas the 
89Zr-labeled Nanobody showed only 1% release after 24 h at 4°C. In human serum the 
radiochemical purity of both compounds was equal after 5 h incubation; however, the 
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percentage of dissociation of the radioisotope after 24 h in serum was more for the 67Ga 
compound than for the 89Zr compound (7-8% and 1-2 % respectively). In a mouse model 
both the 68Ga radiolabeled and the 89Zr radiolabeled Nanobody 7D12 were studied. High 
and selective tumor uptake was seen for both compounds. Significant higher uptake was 
seen in catabolic organs like, liver and spleen for the 68Ga labeled 7D12. These data most 
probably reflect the slightly lower stability observed in the in vitro stability experiments. 
When outlining the second objective of this study, examining the anti-EGFR Nanobody 
7D12 as imaging probe for immuno-PET, tumors were clearly visible with radiolabeled 
7D12, and tumor-to-blood ratios were high (e.g., 25.7 for 68Ga-7D12 and 42.4 for 89Zr-
7D12 at 3 h post injection) indicating that the anti-EGFR Nanobody might be a good 
imaging compound.
On the basis of aforementioned biodistribution data, there is no clear preference 
in the use of either 68Ga or 89Zr for clinical imaging with Nanobodies. Both radionuclides 
are nowadays commercially readily available. An advantage of using 89Zr is that logistics 
of labeling, transportation and clinical handling are easier, due to its longer half-life. A 
disadvantage of 89Zr might be the higher radiation burden to the patient, although this 
burden is expected to be lower than for 89Zr-labeled intact mAbs as have extensively 
been used in clinical immuno-PET studies.
 From the results obtained in chapter 2, 3 and 4 concerning the novel Df-Bz-NCS 
chelator, it can be concluded that this chelator is well suited for labeling of intact mAbs 
with 89Zr, and for labeling of antibody fragments, like Nanobodies, with 89Zr or 68Ga for 
immuno-PET applications. The novel chelate is commercially available at Macrocyclics 
(www.macrocyclics.com) and can be produced in a GMP compliant way, on request. Also, 
in March 2012, the Fe-N-suc-Df-TFP-ester was added to the portfolio of ABX (www.ABX.
de). With this recent input from ABX, a second chelator company showed their interest 
in 89Zr chemistry. Furthermore, it also allows other laboratories or research groups to 
choose their desired labeling method. Till now the use of the procedure as described by 
Verel15 was only reserved to research groups who synthesized this Fe-N-suc-Df-TFP ester 
themselves or when the ester was provided by our group. 89Zr-immuno-PET imaging has 
now reached a matured stage, and allows global exploration.
 Nanobodies are a promising novel class of antibody-based fragments for imaging. 
With their small molecular size, Nanobodies are fast penetrating agents allowing imaging 
within a few hours post injection. Therefore, Nanobodies can have great potential in 
tumor detection, confirmation of target expression, and selection of patients who have 
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the highest chance to benefit from mAb-therapy. Besides as a diagnostic tracer, another 
potnet application is the construction of multi-specific Nabododies by  combining multiple 
Nanobody units within one molecule. In this way, Nanobodies targeting different receptors 
can be developed, and improvement in therapeutic effectiveness might be acchieved.  
In chapter 5 therapeutic applications of anti-EGFR Nanobodies were examined. 
To be more precise, a bi-paratopic (directed to two different epitopes on EGFR) 
Nanobody, called CONAN-1, was developed and characterized. In earlier studies, bi-
valent Nanobodies directed against EGFR had showed their potency in a mouse model17. 
Hereto mice subcutaneously injected with 107 A431 cells one day before treatment, were 
treated twice weekly with three different bi-valent anti-EGFR Nanobody constructs for 
4 weeks. Significant delay of A431 xenograft outgrowth was observed during treatment 
for all three Nanobody constructs compared to a control group. However, in this study 
no established xenografts were used and no comparison with cetuximab was made. 
In our study, as described in chapter 5, we hoped to improve the inhibitory effects of 
Nanobodies via the construction of bi-paratopic Nanobodies. To this end, we selected and 
constructed Nanobodies that could recognize domain III of EGFR, competing with EGF, and 
Nanobodies that could bind to another epitope on domain III inhibiting the dimerization 
of the receptor. Nanobody 7D12, the same Nanobody as described in chapter 4, was 
selected as the most potent Nanobody competing with EGF with an IC
50
 of 8 nM. The 
second selected Nanobody was 9G8 with an IC50 of 6-7 nM. After engineering these two 
Nanobodies in vitro tests were performed to select the most optimal construct. In these 
tests different linker lengths as well as the sequential order of the Nanobody units were 
examined. It turned out that 7D12-9G8 with a linker length of 10 amino acids was the 
optimal bi-paratopic Nanobody construct. 7D12-9G8 was more effective than 9G8-7D12 
in inhibiting the phosphorylation of EGFR, and also in causing tumor cell growth inhibition 
in the proliferation assay. With respect to the different linker lengths for 7D12-9G8, linker 
lengths >10 amino acids showed less growth inhibition in the proliferation assay.
Because Nanobody 7D12-9G8 has a molecular weight of about 35 kDa, it is 
excreted very rapidly via the kidneys in vivo. To extend the half-life of the Nanobodies in 
vivo, binding to albumin has been reported as an excellent option17-19. Therefore, an anti-
albumin Nanobody (called Alb1) was C-terminally fused to the bi-paratopic Nanobody. The 
thus constructed Nanobody, 7D12-9G8-Alb1 was studied in a mouse study and compared 
with the monoclonal antibody cetuximab (Erbitux®). Treatment of mice bearing A431 
tumors with cetuximab resulted in tumor regression after 4 days till approximately day 
14. Despite the fact that 7D12-9G8-Alb1 cannot interact with the immune system (like 
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intact mAbs can via their Fc part) its efficacy was largely similar to that of cetuximab. This 
is most probably due to the better tumor penetration of Nanobodies amidst the similar 
pharmacokinetics.
 These data demonstrate the flexibility of Nanobody technology for the formation 
of constructs that show optimal binding characteristics even when several units are 
coupled to each other, like a bead chain. These findings encourage further exploration 
of the Nanobody toolbox, for the development of bi- and multi-specific Nanobodies, 
targeting two or more critical tumor targets. With respect to head and neck squamous 
cell carcinomas (HNSCC) overexpression of both EGFR and HGF/c-Met has been observed, 
while expression was correlated to bad prognosis20. Possible new Nanobody constructs 
may be bi-specific Nanobodies consisting of a unit targeting EGFR and another unit 
targeting c-Met or HGF (e.g., αEGFR-αc-Met-αAlb1 or αHGF-αEGFR-αAlb1). 
In chapter 6, we described two monospecific Nanobodies (1E2 and 6E10) targeting 
HGF. Targeting the HGF/c-Met pathway is considered to be a promising approach for 
treatment of cancer. HGF is the only known ligand for c-Met. c-Met is overexpressed in 
various tumor types. Also in this study the earlier described method was used to elongate 
the half-life of these Nanobodies in vivo: genetic fusion of an anti-albumin Nanobody to 
the anti-HGF unit. Both anti-HGF Nanobodies were radiolabeled with 89Zr via the novel 
method as developed and described in chapter 2 and 3, to enable accurate assessment 
of in vivo biodistribution. This can be achieved by taking biopsies as performed in this 
study, or alternatively by non-invasive PET imaging, as might been foreseen in future 
clinical trials. Biodistributions showed selective accumulation of both 89Zr-labeled anti-
HGF Nanobodies in mice bearing U87 MG xenografts. In addition, both αHGF-Nanobodies 
were able to inhibit tumor growth in the same mouse model, and upon treatment with 
100 µg, three times a week up to 5 weeks, cures were observed in 4 of 6 mice with 1E2-
Alb8 and in 3 of 6 mice with 6E10-Alb8.
On the basis of the achievements described above, we decided to use the 
remaining time to explore the potential of bi- and multi-specific Nanobodies for therapy. 
Blocking two or more critical tumor targets e.g., EGFR, HGF/c-Met, VEGF, IGF-1R, HER2, by 
one single Nanobody construct might give better therapeutic results. Our first attempt to 
test this hypothesis was with a bi-specific Nanobody targeting EGFR as well as IGF-1R. To 
this end, we developed and tested several Nanobody constructs. After in vitro evaluation, 
Nanobody 7D12 targeting EGFR and Nanobody 11C6 targeting IGF-1R were selected, and 
Nanobodies 7D12-11C6-Alb1, 7D12-7D12-Alb1 and 11C6-11C6-Alb1 were constructed. In 
a preclinical therapy study in nude mice bearing the head and neck xenograft FaDu the 
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bi-specifi c Nanobody 7D12-11C6-Alb1 was found to show a bett er effi  cacy than the mono-
specifi c Nanobodies 7D12-7D12-Alb1, and 11C6-11C6-Alb1, see fi gure 1. 
Figure 1. Therapy study with bi-specifi c Nanobody 7D12-11C6-Alb1, mono-specifi c Nanobodies 7D12-7D12-Alb1 and 11C6-
11C6-Alb1 and cetuximab (αEGFR mAb) in nude mice bearing FaDu HNSCC xenograft s. 7D12 is targeti ng EGFR, whereas 
11C6 is targeti ng IGFR. Treatment was given 2 ti mes a week: 330 µg Nanobody or 1000 µg mAb for 5 weeks. Treatment with 
bi-specifi c Nanobody 7D12-11C6-Alb1 caused signifi cant tumor growth delay of the established tumors aft er day 5 (P< 0.05) 
that lasted ti ll day 25 compared to the mono-specifi c Nanobodies and the control saline group. N=6 mice per group, SD bars 
are omitt ed for clarity.
 Besides this, during the fi rst 25 days aft er start of treatment 7D12-11C6-Alb1 
caused the same tumor growth delay as cetuximab. Ulti mately, aft er 25 days, tumors in 
the Nanobody treated mice group started to grow more rapidly than the tumors in the 
cetuximab group. This is most probably due to the fact that Nanobodies lack the Fc-region, 
and immune responses are absent. These fi rst promising in vivo results, however, could 
not be confi rmed in another tumor model. In nude mice bearing the human lung cancer 
xenograft  line A549 no tumor growth delay was observed upon treatment with 7D12-
11C6-Alb1. So, it can be concluded that the constructi on of multi -specifi c Nanobodies 
directed at diff erent tumor targets is possible, though the fi rst results are somewhat 
variable. EGFR is known to be a promising tumor target, but in several studies IGF-1R was 
reported not to be a promising target for therapy21. This might explain the observed poor 
tumor growth delay in our studies.
Notwithstanding the preliminary results with these bi-specifi c Nanobodies our 
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findings might very well be a prelude to further development of more promising bi-specific 
and multi-specific Nanobodies. As EGFR and HGF/c-Met are frequently overexpressed 
in tumors, HNSCC included, a promising candidate might be a Nanobody that targets 
both receptors, e.g., 7D12-1E2-Alb8. Furthermore, it is also known that VEGF is an 
important target in many carcinomas. VEGF is involved in angiogenesis, and blocking of 
this ligand causes tumor growth inhibition. It is already known that inhibition of EGFR 
with cetuximab results in anti-angiogenic effects like a decrease in VEGF synthesis22. VEGF 
expression was elevated in αEGFR-resistant colon cancer22. Therefore, bi-specific αEGFR-
αVEGF Nanobodies might be an interesting combination. A potential advantage of using 
bi-specific Nanobodies for simultaneous blockade of a receptor and neutralization of a 
growth factor is that sterical aspects and therefore also Nanobody linker length might be 
less critical for optimal efficacy.
In conclusion: With the new Df-Bz-NCS chelate a less laborious procedure is available for 
assessment of tumor targeting using immuno-PET. Nanobodies showed their potential 
as fast and convenient diagnostic tools for assessment of target expression. In addition, 
Nanobodies might become successful agents in cancer therapy. Further improvement of 
multi-specific Nanobodies allows for multi-targeted therapies by targeting several tumor 
targets, blocking different critical signaling routes and improving therapy results.
References
 1  Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol. 2008; 9: 423-30.
 2  Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug 
Discov. 2007; 6: 349-56.
 3  Scolnik PA. mAbs: a business perspective. MAbs. 2009; 1: 179-84.
 4  Maggon K. Top Ten Monoclonal Antibodies. Knol 2012.
 5  Olafsen T, Wu AM. Antibody vectors for imaging. Semin. Nucl. Med. 2010; 40: 167-81.
 6  McCabe K, Wu AM. Positive progress in immunoPET - Not just a coincidence. Cancer Biother. Radiopharm. 2010; 
25:253-81.
 7  Tonra JR, Deevi DS, Corcoran E et al. Synergistic antitumor effects of combined epidermal growth factor receptor 
and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. 2006; 12: 2197-207.
 8  Goetsch L, Gonzalez A, Leger O et al. A recombinant humanized anti-insulin-like growth factor receptor type I 
antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy 
against human cancer xenografts. Int. J. Cancer 2005; 113: 316-28.
142
 9  Jung YD, Mansfield PF, Akagi M et al. Effects of combination anti-vascular endothelial growth factor receptor and 
anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur. J. 
Cancer 2002; 38: 1133-40.
 10  Shaheen RM, Ahmad SA, Liu W et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular 
endothelial and epidermal growth factor receptors. Br. J. Cancer 2001; 85: 584-9.
 11  Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur. J. Cancer 2007; 
43: 481-9.
 12  Larbouret C, Robert B, Navarro-Teulon I et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor 
and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin. Cancer Res. 2007; 13: 3356-62.
 13  van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PMP, Roovers RC. Crosstalk 
between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for 
cancer therapy. Curr. Cancer Drug Targets. 2009; 9: 748-60.
 14  Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates 
redundant signaling and proliferation in head and neck carcinoma cells. Clin. Cancer Res. 2011;17:4425-38.
 15  Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: 
comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 2003; 44: 1271-
81.
 16  Heuveling DA, Visser GWM, Baclayon M et al. 89Zr-nanocolloidal albumin-based PET/CT lymphoscintigraphy for 
sentinel node detection in head and neck cancer: preclinical results. J. Nucl. Med. 2011; 52: 1580-4.
 17  Roovers RC, Laeremans T, Huang L et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic 
anti-EGFR Nanobodies. Cancer Immunol. Immunother. 2007; 56: 303-17.
 18  Dennis MS, Zhang M, Meng YG et al. Albumin binding as a general strategy for improving the pharmacokinetics of 
proteins. J. Biol. Chem. 2002; 277: 35035-43.
 19  Tijink BM, Laeremans T, Budde M et al. Improved tumor targeting of anti-epidermal growth factor receptor 
Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol. Cancer Ther. 2008; 
7: 2288-97.
 20  Knowles LM, Stabile LP, Egloff AM et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and 
neck squamous cell cancer. Clin. Cancer Res. 2009; 15: 3740-50.
 21  Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 2012; 
12: 159-69.
 22  Bianco R, Rosa R, Damiano V et al. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-
epidermal growth factor receptor drugs in human cancer cells. Clin. Cancer Res. 2008; 14: 5069-80.
143
8
Hoofdstuk 8:
Nanobody constructen, voor het blokkeren van groeifactoren 
en hun receptoren: mogelijke toepassing in PET imaging en 
kankertherapie
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Therapeutische monoklonale antilichamen (mAbs) staan op dit moment erg in de 
belangstelling. Zo wordt er veel onderzoek gedaan naar hun mogelijke toepassingen 
zowel in de diagnostiek als bij de behandeling van kanker. Meer dan 100 mAbs en mAb-
fragmenten worden er op dit moment klinisch getest. Tot op heden zijn er 30 mAbs 
goedgekeurd door de “US Food and Drugs Administration” (FDA), waarvan de meeste 
voor de systemische behandeling van kanker1-3. Ondanks de economische crisis groeide 
de jaarlijkse verkoop van mAbs in 2010 tot 48 miljard dollar4. De omzet van de mAbs die 
in 2010 in de top 5 stonden bedroeg meer dan 5 miljard dollar1. 
 Helaas is de effectiviteit van de huidige mAbs vaak nogal beperkt en heeft slechts 
een klein gedeelte van de patiënten die mAbs krijgen baat bij deze behandeling. Idealiter 
zouden al tijdens een vroege fase van ontwikkeling de beste medicijnen geselecteerd 
moeten worden en snel duidelijk zou moeten zijn welke patiëntengroepen waarschijnlijk 
het meeste baat zullen hebben van de behandeling met het medicijn. Moleculaire 
beeldvorming kan hieraan een bijdrage leveren. Een veelbelovende techniek is positron 
emissie tomografie (PET) waarbij kwantitatieve moleculaire beeldvorming van het gehele 
lichaam mogelijk is. PET kan een bijdrage leveren bij de selectie van patiëntengroepen, 
het bepalen van de targetexpressie in de tumor, en het bepalen van de optimale dosis 
(om bijwerkingen beperkt te houden). De laatste jaren is gebleken dat PET scans met 
behulp van mAbs (immuno-PET) een toegevoegde waarde hebben tijdens verschillende 
fasen van mAb-ontwikkeling en klinische toepassingen. Naast intacte mAbs staan ook 
mAb-fragmenten (zoals Nanobodies) en derde generatie mAb-achtige verbindingen in 
de belangstelling. Immuno-PET kan een cruciale rol spelen tijdens de vroege fase van 
ontwikkeling van deze medicijnen.
 Er bestaan twee manieren om de ontwikkeling van therapie met intacte mAbs 
met behulp van immuno-PET te ondersteunen. Bij de eerste methode wordt er een 
snelklarend radioactief gelabeld mAb-fragment toegediend en een PET scan gemaakt op 
dezelfde dag. Op deze manier wordt het snel duidelijk of het mAb kan binden aan de tumor 
en is de stralingsbelasting voor de patiënt gering, zeker als het gebruikte radionuclide een 
korte halveringstijd heeft (tussen 1-5 uur) zoals bijvoorbeeld het geval is bij gallium-68 
(68Ga, halveringstijd (t
½
)= 1.13 uur)5,6. Bij de tweede methode wordt het therapeutische 
mAb zelf radioactief gelabeld en wordt er een PET scan gemaakt voor aanvang van de 
therapie (scouting procedure) of kort nadat de behandeling gestart is. Op deze manier 
kan er beter gekeken worden hoe het mAb zich gedraagt en hoe de biodistributie is bij 
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de individuele patiënt. Bij deze laatste toepassing wordt het therapeutische mAb gelabeld 
met een langlevend PET isotoop zoals zirconium-89 (89Zr, t
½
=78.4 uur) of jodium-124 (124I, 
t
½
=100.3 uur) en worden de patiënten gescand net voor of tijdens hun behandeling met 
het therapeutische mAb.
 Recent is vastgesteld dat het selectief blokkeren/uitschakelen van één 
tumortarget waarschijnlijk niet voldoende is om een optimaal therapeutisch effect 
te bereiken. Tumorcellen kunnen namelijk voor hun snelle groei en overleving gebruik 
maken van meerdere groeifactoren of groeireceptor-systemen. Dit betekent dat als er één 
systeem wordt uitgeschakeld een ander groeireceptor-systeem de groei en overleving kan 
overnemen. Daarom wordt er op dit moment ook veel onderzoek gedaan naar mAb-therapie 
waarbij zgn. bispecifieke mAbs en tyrosine kinase remmers worden gebruikt die twee 
tumortargets gelijktijdig kunnen blokkeren, bijv. EGFR, HER2, IGF-1R, VEGF of VEGF-R27-14. 
Nanobody technologie kan nog geschikter blijken voor het blokkeren/uitschakelen van 
groeifactor (receptor) systemen. Nanobodies zijn namelijk kleiner dan traditionele intacte 
mAbs en kunnen daarom beter in de tumor doordringen. Daarnaast is het met behulp van 
de Nanobody technologie relatief eenvoudig om bispecifieke of multispecifieke Nanobody 
constructen te maken die meerdere tumortargets tegelijk kunnen blokkeren. Immuno-PET 
kan een grote bijdrage leveren bij de preklinische en klinische evaluatie van deze nieuwe 
mAb-fragmenten.
 In hoofdstuk 1 werd de huidige en de toekomstige rol van immuno-PET beschreven. 
Ook werd er een nieuwe klasse mAb-fragmenten geïntroduceerd: Nanobodies. Met 
het introduceren van Nanobodies wordt er wellicht een nieuwe wereld geopend in de 
ontwikkeling van nieuwe antikanker medicijnen en voor het vaststellen van tumortarget-
expressie. Er werden tevens in dit hoofdstuk verschillende tumortargets beschreven 
waarvan bekend is dat ze veelal opgereguleerd en/of geactiveerd zijn bij kanker.
 In hoofdstuk 2 werd het nieuwe p-isothiocyanatobenzyl-desferal (Df-Bz-NCS) 
geïntroduceerd. Met behulp van dit nieuwe bifunctionele Df-Bz-NCS chelaat kan de 
positron emitter 89Zr in twee stappen aan een mAb gekoppeld worden. Ter vergelijking, 
in de oude procedure vergt de synthese van de tetrafluorfenyl ester van gesuccinyleerd 
Fe-desferrioxamine B (N-suc-Df-Fe-TFP) drie stappen, waarna nog drie stappen nodig zijn 
om 89Zr aan een mAb te koppelen15. In beide methoden wordt het Df-chelaat in ongeveer 
50 min geconjugeerd aan de lysines van een mAb. Een belangrijk verschil is echter dat met 
de nieuwe conjugatieprocedure geen tweede stap nodig is waarin bij een lage pH (pH 4.5) 
het Fe verwijderd wordt. Door het vermijden van deze stap bij lage pH kunnen ook pH-
gevoelige eiwitten succesvol geconjugeerd worden zoals recent is beschreven voor 89Zr-
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Nanocolloidaal albumine16. Door het weglaten van deze stap wordt de totale procedure 
ook nog versneld met zo’n 40 minuten. In de nieuwe procedure zoals in dit proefschrift 
beschreven werd de conjugatie uitgevoerd met een drievoudige molaire overmaat van 
Df-Dz-NCS chelaat wat resulteerde in een chelaat:mAb ratio van 1.5:1. Met dit conjugaat 
was de 89Zr-koppeling na 30 minuten bij kamertemperatuur met een pH tussen 6-8 en 
7.2 bijna kwantitatief. Na zuivering over een PD-10 kolom bleek het geproduceerde 89Zr-
Df-Bz-NCS-mAb conjugaat optimaal, het was radiochemisch zuiver, en de integriteit en 
immunoreactiviteit van het mAb waren behouden gebleven. Een punt van aandacht was 
het toevoegen van het Df-Bz-NCS aan de mAb-oplossing. Het Df-Bz-NCS was opgelost 
in DMSO en als dit in één keer zonder mengen toegevoegd werd aan de mAb-oplossing 
ontstonden er precipitaties en aggregaten. Daarom wordt dringend aangeraden het Df-
Bz-NCS stapsgewijs toe te voegen aan de mAb-oplossing. Het tweede punt dat aandacht 
vraagt is de stabiliteit van het radioactief gelabelde mAb tijdens het bewaren. Het gebruik 
van Cl¯ bevattende buffers moet vermeden worden omdat deze er voor zorgen dat het 89Zr 
kan loslaten van het mAb. Dit komt omdat er t.g.v. stralingsschade hypochloriet gevormd 
wordt. Dit hypochloriet reageert specifiek met het bis-thiourea gedeelte van het nieuwe 
chelaat. Daarom wordt er aangeraden om een 0.25 M natrium acetaat buffer te gebruiken 
bij het bewaren van het radioactief gelabelde mAb. Het nieuwe Df-Bz-NCS chelaat werd 
uitgebreid vergeleken met het oude N-suc-Df chelaat. In diverse biodistributie- en PET-
studies werden hoge en selectieve tumoropnames met beide mAb conjugaten gevonden. 
Er werden geen significante verschillen gemeten tussen beide mAb conjugaten.
 In hoofdstuk 3 werd een protocol geschreven om andere onderzoeksgroepen en 
farmaceutische bedrijven een eenvoudige en gemakkelijke methode te geven voor de 
koppeling van 89Zr aan mAbs of mAb-fragmenten via het nieuwe Df-Bz-NCS chelaat. In dit 
protocol wordt ook gewezen op de kritische stappen in deze methode.
 Voor het imagen van mAb-fragmenten (zoals Nanobodies) is 89Zr niet strikt 
noodzakelijk omdat de biologische halveringstijd van een Nanobody (t
½ 
= 1-3 uur) niet 
echt een langlevend isotoop als 89Zr nodig heeft (t
½ 
= 78.4 uur). Een mogelijk alternatief 
PET isotoop zou 68Ga kunnen zijn, dat een t
½
 van 1.16 uur heeft. In hoofdstuk 4 werd een 
koppelingsmethode van 68Ga via het nieuwe Df-Bz-NCS chelaat beschreven. Heel belangrijk 
bij deze koppeling is het gebruik van ultra zuivere HCl om het natuurlijke Ga (natGa) en 
de hoeveelheden Al, Fe en Zr zo laag mogelijk te houden. Deze metalen competeren 
namelijk sterk voor de complexatie met het Df-chelaat. Verder zijn ook de zuivering en 
het verkleinen van het 68Ga-generator eluaatvolume van belang. Door gebruik te maken 
van een anion-uitwisselingskolom werden de ongewenste metalen verwijderd en werd 
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het volume van de 68Ga-oplossing geminimaliseerd. Het koppelen van 68Ga vond plaats bij 
kamertemperatuur gedurende 5 minuten met een pH die lag tussen 5.0-6.5. Toen deze 
koppelingsreactie eenmaal opgezet was, werd eerst onderzocht of het nieuwe Df-Bz-NCS 
chelaat het meest geschikte chelaat is voor het stabiel koppelen van 68Ga aan mAbs en 
Nanobodies. Vervolgens werd het in vivo gedrag van het volgens deze methode gelabelde 
68Ga-Nanobody 7D12 geëvalueerd door middel van immuno-PET en biodistributie studies. 
Door het toevoegen van een drievoudige molaire hoeveelheid Df-Bz-NCS aan 2 mg 7D12 
konden 0.2 Df-groepen per Nanobody molecuul gekoppeld worden. De daarop volgende 
koppeling met vers geëlueerd en gezuiverd 68Ga leverde 50-70% radioactiviteitopbrengst 
op (niet gecorrigeerd voor verval). Vergelijkbare resultaten werden verkregen met de 
referentieverbinding 89Zr-Df-Bz-NCS-7D12. De stabiliteit van beide verbindingen werd 
vergeleken in een natrium acetaat buffer, zonder Cl¯-ionen. Het 68/67Ga gekoppelde product 
bleef 5 uur stabiel na productie (1.5-2.0% vrij 68/67Ga) in natrium acetaat bij 4˚C, maar na 
24 uur was 6-7% van het 67Ga vrij. De referentieverbinding met 89Zr bleek maar 1% vrij 89Zr 
te bevatten na 24 uur bij 4˚C. Na 5 uur incubatie in humaan serum was de radiochemische 
zuiverheid nagenoeg gelijk voor beide producten, maar ook hier was na 24 uur het 89Zr-
gelabelde Nanobody stabieler dan het 67Ga-gelabelde Nanobody (1-2% vrij 89Zr en 7-8% 
vrij 67Ga). Bij evaluatie van het 68Ga-gelabelde en het 89Zr-gelabelde Nanobody 7D12 in 
een muizenmodel werd een hoge en selectieve tumoropname waargenomen voor beide 
producten. Significant hogere opname van het 68Ga-Nanobody werd gezien in de katabole 
organen zoals de lever en milt. Deze data weerspiegelen de stabiliteitsverschillen die 
waren gevonden bij de in vitro experimenten. Met betrekking tot het onderzoeken of het 
anti-EGFR Nanobody 7D12 gebruikt kan worden voor immuno-PET, kunnen we zeggen dat 
alle tumoren duidelijk zichtbaar werden gemaakt door het radioactief gelabelde 7D12. 
Daarnaast waren de tumor tot bloed ratio’s hoog (bijv. 25.7 voor 68Ga-7D12 en 42.4 voor 
89Zr-7D12 op 3 uur na injectie). Dit geeft aan dat het anti-EGFR Nanobody mogelijkerwijs 
goed gebruikt kan worden voor immuno-PET.
 Op basis van de hiervoor beschreven biodistributiegegevens kan niet gezegd 
worden welk radioisotoop het meest geschikt is voor klinische immuno-PET met 
Nanobodies. Beide radionucliden zijn tegenwoordig commercieel verkrijgbaar. Een 
voordeel bij het gebruik van het langlevende 89Zr is de gemakkelijkere logistiek bij het 
transport en bij klinische handelingen. Het kan echter zijn dat de stralingsbelasting voor 
de patiënt iets hoger is in het geval van 89Zr en dit zou een nadeel betekenen. Toch zal deze 
stralingsbelasting naar verwachting beduidend lager zijn dan de stralingsbelasting met 89Zr 
gelabelde intacte mAbs, die nu al veelvuldig in de kliniek gebruikt worden. 
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 De in hoofdstuk 2, 3 en 4 beschreven resultaten geven aan dat het nieuwe 
chelaat zeer geschikt is voor het koppelen van 89Zr aan intacte mAbs en voor het 
koppelen van 89Zr of 68Ga aan mAb-fragmenten zoals Nanobodies voor immuno-PET 
toepassingen. Het nieuwe chelaat is commercieel verkrijgbaar bij Macrocyclics (www.
macrocyclics.com) en kan op verzoek geproduceerd worden onder GMP condities. Door 
eerder genoemde ontwikkelingen toonde een tweede chelaatbedrijf interesse in de 
89Zr chemie. In maart 2012 werd de Fe-N-suc-Df-TFP-ester toegevoegd aan het portfolio 
van ABX (www.ABX.de). Hierdoor kunnen andere laboratoria of researchgroepen kiezen 
van welke koppelingsmethode zij gebruik willen maken. Tot op heden was voor andere 
researchgroepen alleen de procedure Verel15 toepasbaar, als ze zelf de Fe-N-suc-Df-TFP 
ester synthetiseerden of als de ester door ons verstrekt werd. 89Zr-immuno-PET is nu klaar 
voor wereldwijde toepassingen.
 Nanobodies zijn een interessante nieuwe klasse van mAb-fragmenten voor 
imaging. Omdat Nanobodies tamelijk klein zijn, kunnen ze zich snel in het lichaam 
verplaatsen waardoor er al binnen enkele uren na injectie een scan gemaakt kan worden. 
Daarom lijken Nanobodies zeer geschikt voor snelle tumordetectie, het bevestigen 
van target expressie en voor de selectie van patienten die mogelijk baat hebben bij 
een bepaalde mAb-therapie. Naast toepassing als diagnostische tracer, bestaat ook de 
mogelijkheid meerdere Nanobody-units te combineren tot één nieuw molecuul. Aldus 
zouden Nanobodies geconstrueerd worden die in staat zouden zijn om meer dan één 
receptor pathway te blokkeren en zodoende therapeutische effecten kunnen verbeteren. 
 In hoofdstuk 5 werden de therapeutische toepassingen van anti-EGFR Nanobodies 
onderzocht. Een biparatopisch (gericht tegen twee verschillende epitopen op EGFR) 
Nanobody, genaamd CONAN-1, werd ontwikkeld en gekarakteriseerd. In eerdere studies 
hadden bivalente Nanobodies gericht tegen EGFR in een muizenmodel hun effectiviteit 
laten zien17. Hierbij werden muizen, die kort daarvoor subcutaan waren ingespoten met 
107 A431 cellen, twee keer per week behandeld met drie verschillende bivalente anti-EGFR 
Nanobody-constructen gedurende 4 weken. Hierbij gaven de drie Nanobody-constructen 
een significante vertraging van xenograft groei, dit in vergelijking met de controle groep. 
In deze studie werd echter geen gebruik gemaakt van reeds uitgegroeide tumoren 
(xenografts) en ook werden de geteste Nanobodies niet vergeleken met cetuximab. In onze 
studie, zoals beschreven in hoofdstuk 5, hoopten we het remmende effect op tumorgroei 
te verbeteren door gebruik te maken van biparatopische Nanobodies. We selecteerden en 
construeerden Nanobodies die kunnen binden aan domein III van EGFR en competeren 
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met EGF, en Nanobodies die kunnen binden aan een ander epitoop op domein III om 
dimerisatie van de receptor te blokkeren. Nanobody 7D12, ook al gebruikt in hoofdstuk 4, 
werd geselecteerd als het meest potente Nanobody dat kan competeren met EGF met een 
IC
50
-waarde van 8 nM. 9G8 was het andere Nanobody dat geselecteerd werd met een IC
50
-
waarde van 6-7 nM. Na de productie van deze twee Nanobodies werden diverse in vitro 
testen uitgevoerd om het optimale construct te selecteren. Zo werden er verschillende 
linkerlengtes getest alsmede de volgorde van de Nanobody-units. 7D12-9G8 met een 
linkerlengte van 10 aminozuren bleek het meest optimale biparatopische Nanobody-
construct. 7D12-9G8 was effectiever dan 9G8-7D12 in het remmen van de fosforylering 
van EGFR en ook in tumorcelgroeiremming. Bij een linkerlengte >10 aminozuren werd 
minder groeiremming waargenomen.
 Omdat Nanobody 7D12-9G8 slechts een moleculair gewicht van 35 kDa heeft 
wordt het in vivo snel via de nieren uitgescheiden. Er is in de literatuur beschreven 
dat door binding aan albumine de in vivo verblijftijd van de Nanobodies verlengd kan 
worden17-19. Om die reden werd een anti-albumine Nanobody (genaamd Alb1) C-terminaal 
gefuseerd aan het biparatopische Nanobody. Het verkregen construct, 7D12-9G8-
Alb1, werd vervolgens bestudeerd in een muizenstudie en vergeleken met het mAb 
cetuximab (Erbitux®). De behandeling van A431 tumordragende muizen met cetuximab 
gaf tumorregressie van dag 4 tot ongeveer dag 14 na de start van behandeling. Ondanks 
het feit dat 7D12-9G8-Alb1 niet het immuunsysteem kan activeren (zoals intacte mAbs 
dat wel kunnen via hun Fc gedeelte) was de effectiviteit gelijk aan cetuximab. Dit komt 
waarschijnlijk omdat Nanobodies beter in de tumor kunnen binnendringen, ondanks hun 
vergelijkbare farmacokinetiek.
 Deze gegevens demonstreren de grote flexibiliteit van de Nanobody-technologie 
bij het maken van constructen met optimale bindingskarakteristieken, zelfs als er meerdere 
units aan elkaar gekoppeld worden. Deze bevindingen zijn bemoedigend voor verder 
onderzoek naar de mogelijkheden van Nanobodies, bijvoorbeeld voor het ontwikkelen 
van bi- en multispecifieke Nanobodies die twee of meerdere kritische targets kunnen 
blokkeren. Zo zouden voor de behandeling van plaveiselcelcarcinoom in het hoofd-
halsgebied nieuwe bispecifieke Nanobodies interessant kunnen zijn, die zowel EGFR als 
c-Met of HGF kunnen blokkeren (bijv. aEGFR-ac-Met-aAlb1 of aHGF-aEGFR-aAlb1). Het is 
namelijk bekend dat zowel EGFR als HGF/c-Met tot overexpressie komen in dit tumortype, 
en dat overexpressie gecorreleerd is aan een slechte prognose20.
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 In hoofdstuk 6 beschreven we twee monospecifieke Nanobodies (1E2 en 
6E10) die aan HGF kunnen binden. Het blokkeren van de HGF/c-Met signaleringsroute 
wordt als een belangrijke veelbelovende benadering beschouwd voor de behandeling 
van kanker. HGF is het enige bekende ligand voor c-Met. c-Met komt tot overexpressie 
in veel verschillende tumortypes. Ook in deze studie hebben we gebruik gemaakt van 
eerder genoemde methodes om de in vivo verblijftijd van de Nanobodies te verlengen: 
het genetisch fuseren van een anti-albumine Nanobody aan het anti-HGF Nanobody. Aan 
beide anti-HGF Nanobodies werd 89Zr gekoppeld met behulp van de nieuwe methode 
zoals ontwikkeld en beschreven in hoofdstuk 2 en 3, om accurate biodistributiegegevens 
te verkrijgen. In deze studie werd dat gedaan door middel van het nemen van biopten, 
maar een goed alternatief zou non-invasieve immuno-PET kunnen zijn, wat eventueel 
gebruikt zou kunnen worden in toekomstige klinische studies. De biodistributiestudie liet 
selectieve ophoping van beide 89Zr-gelabelde anti-HGF Nanobodies zien in muizen met 
U87 MG tumoren. Ook bleken beide anti-HGF Nanobodies in staat om tumorgroei te 
remmen in hetzelfde muizenmodel. Bij de behandeling met 100 µg, drie keer per week 
gedurende vijf weken, werden curaties waargenomen in 4 van de 6 muizen die behandeld 
waren met 1E2-Alb8 en in 3 van de 6 muizen die behandeld waren met 6E10-Alb8.
Op basis van bovengenoemde resultaten besloten we de resterende promotieperiode 
extra inzicht te verwerven in de mogelijkheden van bi- en multispecieke Nanobodies 
voor therapie. Het blokkeren van twee of meerdere kritische tumortargets zoals EGFR, 
HGF/c-Met, VEGF, IGF-1R en HER2 door één Nanobody-construct zou wellicht veel betere 
therapeutische resultaten kunnen opleveren. Onze eerste poging om deze hypothese te 
testen was met een bispecifiek Nanobody dat zowel EGFR als IGF-1R kan blokkeren. Na in 
vitro evaluatie werden Nanobody 7D12 (gericht tegen EGFR) en Nanobody 11C6 (gericht 
tegen IGF-1R) geselecteerd en de Nanobodies 7D12-11C6-Alb1, 7D12-7D12-Alb1 en 11C6-
11C6-Alb1 geproduceerd. Een preklinische therapie studie in muizen met de hoofd-hals 
plaveiselcelcarcinoom xenograft FaDu liet zien dat het bispecifieke Nanobody 7D12-11C6-
Alb1 beter in staat is tumorgroei te remmen dan de monospecifieke Nanobodies 7D12-
7D12-Alb1 en 11C6-11C6-Alb1, zie Figuur 1.
 Ook was de tumorgroei gedurende de eerste 25 dagen na de start van de 
behandeling gelijk voor 7D12-11C6-Alb1 en cetuximab. Uiteindelijk groeiden de tumoren 
in de met Nanobody behandelde muizen na 25 dagen sneller dan de tumoren in de 
cetuximab groep. Dit kan worden verklaard door de afwezigheid van een Fc-gedeelte bij 
de Nanobodies waardoor immuunresponses afwezig blijven. Deze eerste veelbelovende in 
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vivo resultaten konden helaas niet bevesti gd worden in een tweede tumormodel. In muizen 
met de longkanker xenograft lijn A549 werd geen tumorgroeiremming waargenomen met 
7D12-11C6-Alb1. Er kan dus geconcludeerd worden dat we in staat zijn om multi specifi eke 
Nanobodies, gericht tegen verschillende tumortargets te construeren, maar dat de eerste 
resultaten nog variabel zijn. Een verklaring voor de tegenvallende tumorgroeiremming zou 
kunnen zijn dat de gekozen combinati e (anti -EGFR x anti -IGF-1R) niet de meest opti male 
was. EGFR is gebleken een goed tumortarget te zijn, maar een recente andere studie21 
toonde aan dat IGF-1R wellicht niet het meest veelbelovende target is.
 Wij zijn van mening dat bovenvermelde eerste resultaten met nieuwe bispecifi eke 
Nanobodies een gerede aanleiding vormen om andere veelbelovende bispecifi eke en 
multi specifi eke Nanobodies te gaan ontwikkelen. Het is bijvoorbeeld bekend dat zowel 
EGFR als HGF/c-Met vaak tot overexpressie komen in tumoren, waaronder hoofd-hals 
plaveiselcelcarcinoom. Bispecifi eke Nanobodies die beide receptoren blokkeren zouden 
zeer waardevol kunnen zijn, bijvoorbeeld 7D12-1E2-Alb8. Verder is het ook bekend 
Figuur 1. Therapiestudie met het bispecifi eke Nanobody 7D12-11C6-Alb1, monospecifi eke Nanobodies 7D12-7D12-Alb1 en 
11C6-11C6-Alb1 en cetuximab (aEGFR mAb) in muizen met de hoofd-hals plaveiselcelcarcinoom xenograft  FaDu. 7D12 is 
gericht tegen EGFR en 11C6 tegen IGF-1R. Behandeling werd twee keer per week gegeven: 330 µg Nanobody of 1000 µg mAb 
gedurende 5 weken. Behandeling met het bispecifi eke Nanobody 7D12-11C6-Alb1 gaf signifi cant betere tumorgroeiremming 
(p<0.05) tussen dag 5 en dag 25 na de start van behandeling, dit ten opzichte van de monospecifi eke Nanobodies en de 
controle groep. N=6 muizen per groep, standaarddeviati es zijn voor de duidelijkheid uit de grafi ek weggelaten.
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dat VEGF een belangrijk target is voor verschillende carcinomen. VEGF is betrokken bij 
de bloedvatvorming (angiogenese) van tumoren, en door dit ligand te blokkeren kan 
tumorgroeiremming optreden. Het is al bekend dat door het blokkeren van EGFR met 
cetuximab er anti-angiogenese effecten optreden, zoals het verlagen van de VEGF 
expressie22. Daarom zou een bispecifiek aEGFR-aVEGF Nanobody een interessante 
combinatie kunnen zijn. Een potentieel voordeel bij het gebruik van bispecifieke 
Nanobodies voor het gelijktijdig blokkeren van een receptor en het neutraliseren van een 
groeifactor is dat sterische hindering minder kritisch wordt voor effectiviteit, en daarmee 
ook de linkerlengte tussen de Nanobody-units.
Concluderend:  met het nieuwe Df-Bz-NCS chelaat is er een procedure ontwikkeld die 
minder bewerkelijk is waardoor het bepalen van tumortargeting met behulp van immuno-
PET eenvoudiger wordt. Nanobodies hebben zich bewezen als snelle en gemakkelijke 
diagnostische moleculen om targetexpressie te bepalen. Daarnaast zouden Nanobodies 
ook succesvol kunnen worden in kankertherapie. Verdere verbetering van multispecifieke 
Nanobodies kan leiden tot het blokkeren van meerdere tumortargets, het blokkeren van 
verschillende kritische routes en het effectiever maken van therapieën.
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